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Background: Magnetic Resonance Imaging (MRI) provides images with excellent structural 
detail, but imparts limited information about the characteristics of paediatric tumours. MRI 
based functional imaging probes tissue properties to provide clinically important information 
about metabolites, structure and cellularity. 
Aim: To determine the added value of advanced MRI, particularly diffusion-weighted 
imaging (DWI) and magnetic resonance spectroscopy (MRS), in non-invasive diagnosis and 
management of paediatric tumours, and facilitate integration into clinical practice. 
Methods: Children with newly diagnosed body and brain tumours were imaged using multi 
b-value DWI and MRS respectively. Imaging data was used to develop a clinical decision 
support system for presentation to clinicians. Added diagnostic and clinical value of 
additional information was ascertained through retrospective and prospective evaluation. 
Results: Quantitative DWI confers added diagnostic accuracy beyond conventional MRI, 
allowing discrimination of benign from malignant body tumours through morphological and 
quantifiably significant differences in Apparent Diffusion Coefficient (ADC) histograms. 
Chemotherapeutic response is reflected through visually apparent and quantifiably significant 
histogram changes. Review of MRS improves diagnostic accuracy of paediatric brain 
tumours, adding therapeutic value through avoiding biopsy of indolent lesions, aiding tumour 
characterisation, and allowing earlier treatment planning and clinical decision-making.  
Conclusion: Advanced MRI adds value to non-invasive diagnosis and management of 
paediatric tumours in a real-time clinical setting. Presentation of complex information 
through a decision support system makes it accessible and comprehensible for clinicians, 
overcoming barriers precluding clinical use. Multicentre assessment is needed to promote 
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Imaging is central to the diagnosis and management of solid tumours in children. Although 
conventional Magnetic Resonance Imaging (MRI) can accurately define the size and location 
of tumours and provide images with excellent structural detail, it often cannot answer other 
important questions influencing clinical management decisions. Tumour type, 
aggressiveness, metastatic potential or early treatment response cannot be determined 
accurately using conventional imaging techniques (Peet et al., 2012).  
 
Functional imaging examines specific tissue properties relevant to the underlying biology of 
tumours. Techniques include diffusion and perfusion weighted imaging (DWI and PWI), 
assessing tissue structure and blood flow, and 1H-magnetic resonance spectroscopy (MRS), 
measuring metabolite profiles. These complimentary modalities provide important 
information about tumour characteristics, allowing derivation of a more complete biological 
picture (Panigrahy and Bluml, 2009; Panigrahy et al., 2010). As conventional imaging cannot 
reliably discriminate between different types of tumours, biopsy and histopathology is usually 
necessary to determine a definitive diagnosis and treatment plan (Louis et al., 2007). Novel 
imaging methods can give improved information on tumour type and prognosis and allow 
treatment response to be monitored through providing data about the composition of imaged 
tissue (Peet et al., 2012). 
 
Significant advances have been made in developing advanced imaging techniques and 
considering their implementation. This thesis evaluates the added value of novel functional 
imaging methods in paediatric oncology and investigates the optimum way of integrating 
these techniques into clinical practice to guide clinical decision-making and improve patient 
care. 
Diffusion weighted imaging (DWI) provides qualitative and quantitative information that 
may be used to improve tumour detection, characterization and monitoring of treatment 
response (Koh et al., 2007). DWI is based on microscopic water diffusion in tissue. Images 
acquired with high- and low-diffusion weighting (b-values) are used to develop Apparent 
Diffusion Coefficient (ADC) maps (Poretti et al., 2012). ADC values are a quantitative 
measure of diffusion with an inverse relationship with cellularity (Humphries et al., 2007) 
that may be useful for tumour characterisation. 
 
Solid malignant tumours have high tissue cellularity, a high nuclear-to-cytoplasm ratio and a 
large number of cell membranes per unit volume. Densely packed and randomly organized 
cells inhibit motion of extracellular water protons and restrict diffusion, reflected 
quantitatively by a reduction in ADC. Highly cellular malignant tumours have low ADC 
(Humphries et al., 2007), as do abscesses and inflammation which restrict diffusion due to 
their cellular inflammatory exudate and high protein levels (Gawande et al., 2013). Benign 
solid tumours, cystic lesions and necrosis display less restricted diffusion and have a higher 
ADC due to their high water content, low tissue cellularity and low number of cell 
membranes.  
 
MRS is a non-invasive technique that is most commonly used to aid discrimination between 
different types and grades of brain tumour. 1H-MRS uses the property that each hydrogen 
containing molecule resonates at a slightly different frequency in the MRI scanner to measure 
the chemical composition of tissue. Information is provided about intermediary metabolites 
such as choline (involved in membrane synthesis) N-acetyl aspartate (neuronal marker) and 
mobile lipids (apoptosis and necrosis) (Orphanidou-Vlachou et al., 2018) The frequencies 
and intensities of resonances are presented graphically in a magnetic resonance spectrum 
(Figure 1.1).  
Figure 1.1. Mean magnetic resonance spectrum (MRS) of normal brain (white matter). mIns – myo-
Inositol; tCho – total choline; Cr – creatine; NAA –  N-acetyl aspartate ; LMM – lipids and 
macromolecules 
 
Single voxel spectroscopy (SVS) acquires MRS data from a single region of interest (ROI) 
and has been used successfully in multicentre paediatric studies (Davies et al., 2010a). 
Mulitvoxel spectroscopy (also called chemical shift imaging, CSI, or magnetic resonance 
spectroscopic imaging, MRSI) provides information on tissue heterogeneity but is more 
complex to acquire and analyse.  
 
MRS is widely available clinically and could be incorporated into a standard MRI protocol 
during diagnostic imaging and at follow-up. Although magnetic resonance spectra may be 
used for clinical decision-making, routine implementation and interpretation has presented 
challenges in clinical practice. 
 
Perfusion MRI evaluates blood flow and volume to impart information about 
microvasculature and angiogenesis. Techniques include dynamic contrast enhanced (DCE) 
and dynamic susceptibility contrast (DSC) MRI, arterial spin-labelling (ASL) and intavoxel 
incoherent motion (IVIM). Increased perfusion may reflect increased vascular growth 
associated with higher grade tumours (Laigle-Donadey et al., 2008). 
 
DCE and DSC-MRI are performed using rapid sequence MRI following contrast injection via 
a mechanical pump that is often incompatible with central venous lines. Arterial spin-
labelling (ASL) is a promising alternative in children (Hirai et al., 2011; White et al., 2014; 
Knutsson et al., 2010), allowing non-invasive quantitative measurement of cerebral perfusion 
without contrast injection and the associated requirement for IV access (Proisy et al., 2015). 
IVIM is a relatively new and largely experimental technique that uses an adaptation of DWI 
to detect the bulk motion of water molecules in the capillaries as a measure of perfusion (Le 
Bihan et al., 1988). 
 
Functional imaging provides information to facilitate clinical decision-making in paediatric 
oncology that is not available with conventional imaging techniques. Additional information 
could be used for diagnosis, to provide prognostic biomarkers, to guide biopsy and to monitor 
treatment response. Although there is considerable evidence in the adult oncology literature 
for the role of functional imaging, this cannot be extrapolated directly to the paediatric 
population in view of age and tumour specific differences (Peet et al., 2012). Evaluation of 
paediatric tumours is complex due to their diverse histological presentation and biological 
behaviours, confounded by technical challenges in performing complex imaging in young 
children.   
 
This thesis focuses on the clinical use of DWI in solid paediatric body tumours and MRS in 
brain tumours. In view of this, this introductory chapter will focus primarily on these imaging  
techniques and applications. 
 
Pre-operative diagnosis can be difficult using conventional MRI alone (Orphanidou-Vlachou 
et al., 2013; Panigrahy et al., 2006). Radiologists use information about tumour site and size 
in combination with other imaging features such as enhancement, diffusion characteristics 
and clinical factors to form a differential diagnosis. Intraoperative histopathology is often 
inaccurate and does not permit pre-operative planning, and definitive histopathology is 
generally unavailable until several days after surgery (Ng et al., 2008). Functional imaging 
has potential to improve patient care through early diagnosis. Improved diagnostic 
information could guide surgical decision-making and provide information at an early stage 
to enable treatment planning to optimise outcome and minimise morbidity. 
 
Although there is evidence in the literature that quantitative DWI and ADC provide useful 
information for diagnosis of body tumours in adult oncology, there is a paucity of prospective 
data from paediatric patients. Studies in adults have shown DWI to be sensitive and specific 
for detecting colorectal tumours (Ichikawa et al., 2006), pancreatico-biliary tumours 
(Ichikawa et al., 2007), liver metastases (Koh et al., 2008), and differentiating malignant liver 
tumours from abscesses (Chan et al., 2001). The limited number of studies in children 
suggest DWI has potential value in paediatric oncology (Kocaoglu et al., 2010; Humphries et 
al., 2007; Alibek et al., 2009; Abdel Razek et al., 2009; Battal et al., 2012; Gawande et al., 
2013; McDonald et al., 2011). 
 
Paediatric studies have demonstrated ADC of malignant body lesions to be lower than benign 
lesions (Kocaoglu et al., 2010; Humphries et al., 2007; Alibek et al., 2009; Abdel Razek et 
al., 2009; Battal et al., 2012; Gawande et al., 2013; McDonald et al., 2011). Although an 
early small prospective study reported lower mean ADC in malignant than benign abdominal 
masses without reaching significance (Humphries et al., 2007), more recent studies suggest 
ADC can reliably characterise tumours (Kocaoglu et al., 2010; Abdel Razek et al., 2009; 
Lope et al., 2010; Neubauer et al., 2012). Evaluation of head and neck masses found mean 
ADC values of malignant, benign solid and benign cystic lesions of 0.93, 1.57 and 2.01 x 10-3 
respectively, with significant difference between malignant and benign masses (Abdel Razek 
et al., 2009). Average ADC values of benign and malignant abdominal (2.28 and 0.84 x 10-3 
respectively) (Kocaoglu et al., 2010), musculoskeletal (1.71 and 0.78  x 10-3 respectively) 
(Neubauer et al., 2012) and orbital tumours (Lope et al., 2010) were also significantly 
different. Most studies compare solid malignant with cystic benign lesions, possibly leading 
to an artificially elevated comparator mean ADC in benign masses. A retrospective analysis 
did, however, demonstrate a significant difference between mean ADC in benign and 
malignant solid abdominal tumours (1.6 and 1.07 x 10-3 respectively) (Gawande et al., 2013).  
 
Cut-off ADC values have been proposed for diagnosing malignant body tumours and are 
similar across studies. Evaluation of abdominal masses suggested ADC cut-offs of 1.1 
(Kocaoglu et al., 2010) or 1.29 x 10-3 (sensitivity 77%, specificity 82%) (Gawande et al., 
2013). A value of 1.25 x 10-3 differentiated malignant from benign head and neck masses 
(sensitivity 94.4%, specificity 91.2%) (Abdel Razek et al., 2009) and < 1.03 x 10-3 was 
proposed for musculoskeletal tumours (sensitivity 90%, specificity 91%) (Neubauer et al., 
2012). Sensitivity may be higher for solid, homogeneous tumours compared to necrotic 
tumours (Gawande et al., 2013).  
 
Further research is needed into quantitative DWI in paediatric oncology. Direct comparison 
of results is difficult as evidence consists of small heterogeneous retrospective case series 
with variations in study design, ADC parameters, region of interest (ROI) measurement 
(Rumboldt et al., 2006; Gauvain et al., 2001; Yamashita et al., 2009; Yeom et al., 2013), b-
values (Neubauer et al., 2012) and inclusion criteria (Yamasaki et al., 2005; Gauvain et al., 
2001). 
 
MRS may be used in combination with conventional imaging to support non-invasive 
diagnosis of childhood brain tumours (Panigrahy et al., 2006; Davies et al., 2008; 2010b). 
Brain tumours in children are histologically diverse entities with overlapping and 
heterogeneous imaging features. Chemical profiles are a useful diagnostic aid, with different 
tumour types displaying characteristic patterns of metabolite levels (Panigrahy et al., 2006; 
Davies et al., 2008; 2010b). Studies in adults have found MRS in conjunction with MRI 
improves accuracy of non-invasive diagnosis of brain tumours (Julia-Sape et al., 2012) and 
combining MRS with pattern recognition gives diagnostic precision comparable to 
histopathology in a multi-centre setting (Garcia-Gomez et al., 2009).  Pattern recognition of 
MRS profiles has been a useful aid to diagnosis in children (Panigrahy et al., 2006; Davies et 
al., 2008). 
 
Quantitative interpretation of metabolites measured by MRS can facilitate non-invasive 
tumour categorisation. Brain tumours in general have high levels of choline and lactate and 
reduced N-acetyl aspartate (Arle et al., 1997; Davies et al., 2008), and individual metabolites 
may be used quantitatively to determine tumour type. High grade tumours have high levels of 
choline, lipids (Astrakas et al., 2004) and glycine (Davies et al., 2010b), while taurine has a 
strong association with primitive neuroectodermal tumours (Kovanlikaya et al., 2005) and 
medulloblastomas (Panigrahy et al., 2006; Davies et al., 2008). Creatine is significantly lower 
in pilocytic astrocytomas than in other paediatric brain tumours (p<0.000001) (Panigrahy et 
al., 2006). The differences between the mean spectra of the three most common paediatric 
posterior fossa tumours is illustrated in Figure 1.2. 
Figure 1.2. Comparison of MRS profiles and MR images of posterior fossa tumours, demonstrating 
(A) ependymoma, (B) medulloblastoma and (C) pilocytic astrocytoma.  
 
Paediatric pilocytic astrocytomas, medulloblastomas and ependymomas have been accurately 
classified using MRS (Wang et al., 1995; Arle et al., 1997; Davies et al., 2008; Vicente et al., 
2013). Metabolite ratios of NAA:Cho and Cr:Cho differentiated these tumours with accuracy 
of 0.85 (Wang et al., 1995), as did a neural network, using ratios of N-acetyl aspartate, 
choline and creatine (accuracy 0.88) (Arle et al., 1997) and Linear Discriminant Analysis 
(LDA) (accuracy 0.93) (Davies et al., 2008). Diagnostic classifiers, as illustrated in Figure 
1.3., have been assessed in a multinational setting (accuracy 0.98) (Vicente et al., 2013). 
 
Figure 1.3.   Decision Support System (DSS) output showing normalised metabolite profiles (left), 
linear discriminant function (D.F.) scores (centre) and MR spectra (right) for a case (red) compared 
with mean values for pilocytic astrocytoma (green), ependymoma (blue) and medulloblastoma (cyan). 
(Davies et al., 2016) 
 
MRS can facilitate diagnosis of paediatric low-grade glioma subgroups. Significantly 
different choline and myo-inositol concentrations have been found in glioneuronal and glial 
tumours compared to other histological subtypes (Orphanidou-Vlachou et al., 2013). 
Metabolite profiles of pilocytic astrocytomas and unbiopsied optic pathway gliomas differ 
significantly depending on neurofibromatosis type I status and location (Orphanidou-Vlachou 
et al., 2013). As these tumours are often unbiopsied and treatment response differs between 
subtypes, accurate non-invasive diagnosis could improve outcome. 
 
Although MRS can add value in diagnosing adult brain tumours in clinical practice (Murphy 
et al., 2002; Moller-Hartmann et al., 2002; Galanaud et al., 2006; Panigrahy et al., 2006; 
Julia-Sape et al., 2012), there is a paucity of evidence in children. A retrospective study found 
MRS significantly improved accuracy of radiological diagnosis of paediatric brain tumours 
over MRI alone (Shiroishi et al., 2015), with 63% correctly diagnosed using MRI compared 
with 87% with MRI and MRS (Shiroishi et al., 2015). Added value for MRS compared with 
conventional radiology was found in a further retrospective study of paediatric brain tumour 
patients (Davies et al). Prospective studies are needed to validate these promising results in a 
clinical setting. 
 
Biopsy plays an important role in establishing histological diagnosis in paediatric 
malignancy, often with considerable morbidity and risk of sampling error. While 
conventional MRI cannot always determine optimal biopsy site of heterogeneous tumours 
(Martin et al., 2001), functional imaging can help target biopsy in tumours containing cystic 
or necrotic elements. DWI can identify densely packed tumour cells (Humphries et al., 2007), 
potentially guiding biopsy to areas likely to give a diagnostic yield. MRS with MRSI may 
guide biopsy in diffuse or large complex brain tumours in which heterogeneity poses a risk of 
sampling unrepresentative tissue.  
 
Prognosis of histopathologically similar paediatric tumours varies considerably, with 
differences in clinical behaviour related to underlying biology. There is little evidence that 
volume of a primary tumour at diagnosis is a useful prognostic factor for most malignancies 
(Olsen, 2015). Functional imaging provides novel non-invasive biomarkers to facilitate 
tumour characterization (Peet et al., 2007) and on-going risk stratification. This additional 
information has potential to be clinically useful through allowing individualization of 
treatment, with intensification in high-risk patients and reduction in those found to be low-
risk. 
 
DWI could aid risk stratification in paediatric oncology through identification of high-grade 
tumours.  Water diffusion is restricted by molecular and macromolecular barriers within the 
matrix of high-grade tumours due to the dense structure of tumour tissue. It has been 
hypothesized that restriction in diffusion increases with tumour grade, corresponding to 
reduction in ADC values in higher grade tumours in adult studies (Wang et al., 2011). Further 
research is needed to determine if this is applicable to tumours in children.  
 
MRS has identified several non-invasive prognostic biomarkers in CNS tumours. Lipids and 
scyllo-inositol are predictive of poor survival, whereas glutamine and N-acetyl aspartate 
suggest improved survival (Wilson et al., 2013). Mobile lipids correlate negatively with 
intracellular glutamine (essential to lipogenesis in hypoxic tumour cells), implying a 
functional link (Wilson et al., 2013).  
 
High intracellular macromolecules and lipids are associated with aggressive brain tumours 
(Vicente et al., 2013) with correlation between grade and mobile lipids (Astrakas et al., 
2004). Medulloblastoma and ependymoma have greater lipid concentrations than pilocytic 
astrocytoma (Vicente et al., 2013). Choline is higher in medulloblastoma (grade IV) and 
ependymoma (grade II) than pilocytic astrocytoma (grade I) (Vicente et al., 2013), predicting 
poor survival in other non-metastatic CNS tumours (Marcus et al., 2007). An increased pre-
treatment ratio of choline to N-acetyl aspartate predicts shorter survival in DIPG (Hipp et al., 
2011). High citrate suggests poor survival in grade II astrocytoma (Bluml et al., 2011) and 
glutamate signifies poor prognosis in medulloblastoma (Wilson et al., 2014).   
 
Low choline to N-acetyl aspartate ratio is predictive of good prognosis (Warren et al., 2000) 
and high myo-inositol levels are a biomarker of long progression-free survival in 
supratentorial pilocytic astrocytoma (Harris et al., 2008). Low creatine, common in grade I 
pilocytic astrocytoma (Harris et al., 2008), indicates good prognosis in grade II and III glioma 
(Hattingen et al., 2010). A multivariate model of survival across all CNS tumours based on 3 
MRS biomarkers at diagnosis (lipids, glutamine and scyllo-inositol) had similar accuracy to 
histopathological grade in predicting survival (Wilson et al., 2013).  
  
Metabolite profiles of metastatic and localised brain tumours differ, reflecting disparities in 
underlying biology and suggesting the possibility of identifying tumours at risk of metastatic 
relapse. Metastatic medulloblastomas have lower mobile lipids and higher total choline than 
localised tumours, suggesting decreased cell death and increased cell growth (Peet et al., 
2007).  
 
Clinicians rely on changes in tumour size to assess treatment response. This can take weeks 
or months to become apparent and does not always reflect the degree of histological 
response, particularly in lesions undergoing significant necrosis. A tumour may undergo 
tissue differentiation despite increasing in volume or conversely decrease in size but remain 
predominantly composed of malignant cells. Non-invasive biomarkers of response would be 
particularly helpful in monitoring tumours that are un- or incompletely resected, slow to 
respond to chemotherapy, or those that appear to progress through treatment.    
ADC is a potential biomarker of response in body tumours not treated by upfront resection 
(Humphries et al., 2007). DWI could detect early therapeutic success at a cellular level as cell 
death, loss of membrane integrity and reduced cellular density are reflected by increased 
ADC (Oka et al., 2010). Serial ADC measurements may allow quantitative response 
monitoring and continuous risk stratification. Measurable changes in ADC distribution have 
been reported, with tumours with histopathologically good response demonstrating greater 
increase in median ADC (McDonald et al., 2011). Minimum ADC has reflected response in 
osteosarcoma, with higher values post-chemotherapy correlating significantly with improved 
histological response (Oka et al., 2010). A small retrospective study of abdomino-pelvic 
neuroblastoma revealed significantly higher post-chemotherapy ADC (Demir et al., 2015). 
 
Monitoring treatment response of brain tumours enables continuing risk stratification and 
treatment planning.  The conventional method of measuring change in size on structural MRI 
is confounded by difficulties differentiating tumour from post-treatment changes. MRS 
provides information about characteristic changes in metabolites such as mobile lipids, myo-
inositol and total choline that are potential early markers of response (Harris et al., 2008). 
Myo-inositol is a potential biomarker for monitoring supratentorial pilocytic astrocytomas, 
with future progression predicted by decreasing levels of this metabolite (Harris et al., 2008). 
Developing “real time” non-invasive biomarkers would be of clinical benefit through 
allowing adaptation of treatment as disease evolves (Peet et al., 2007).  
 
Differentiating tumour progression from pseudoprogression and diagnosing relapse and 
metastatic disease can be difficult using conventional MR imaging alone. Emerging evidence 
suggests functional imaging may add value in this area. Comparing MRS profiles of 
paediatric brain tumours at diagnosis and relapse may distinguish relapse from 
pseudoprogression and radiation necrosis, as no significant difference has been observed in 
any metabolite, lipid or macromolecule measured at diagnosis and first local or distant 
relapse (Gill et al., 2013).  
 
Tumours are heterogeneous masses consisting of a mixture of histological cell types, 
interspersed with necrosis and chemotherapy-induced changes. Mean or median ADC may be 
unrepresentative as high ADC in non-viable regions counteracts low values in cellular 
regions. Calculating ADC histograms using a multi-Gaussian model (Hales et al., 2015) 
provides information about distinct cellular subpopulations. Histogram peaks correspond to 
different tissue types and reflect chemotherapy-induced changes as differentiation occurs. 
Histograms could guide biopsy to target malignant regions avoiding cysts and necrosis. 
 
Constructing a whole-tumour ROI allows histogram analysis of an entire tumour (Woo et al., 
2014a), allowing reflection of heterogeneity. This technique has shown promise in 
differentiation and grading of paediatric CNS lesions (Bull et al., 2012) and differentiating 
tumour type and grade in adults (Pereira et al., 2015; Mimura et al., 2016; Hao et al., 2016). 
ADC parameters decrease as grade increases (Pereira et al., 2015), with higher grade 
histograms having left shift, more positive skew and higher kurtosis (Pereira et al., 2015). 
 
ADC histograms have been used in Wilms tumours to determine predominant histological 
cell type and predict subtype after chemotherapy (Hales et al., 2015). Comparing pre- and 
post- treatment histograms show an increase in mean ADC, with a shift to the right reflecting 
transformation to less cellular stromal tissue (Hales et al., 2015) (Figure 1.4.).  
Figure 1.4.  Diffusion Weighted Imaging (DWI) used to assess chemotherapeutic response in a 
Wilms tumour.  A) ADC Histogram demonstrating shift to the right following response to neo-
adjuvant chemotherapy. B) Region of Interest (ROI) drawn around the tumour. (Hales et al., 2015)  
More sophisticated methods of DWI analysis are emerging as understanding of ADC 
parameters improves. DWI is influenced by both structural components and perfusion in 
biological tissues, leading to variation in ADC depending on choice of b-values (Mazaheri et 
al., 2012). This variability can limit identification of threshold ADC values to differentiate 
benign from malignant lesions and makes study comparison difficult.  
 
The intravoxel incoherent motion (IVIM) model allows extraction of additional information 
about perfusion from multi b-value DW-MRI to further characterise tumour tissue (Le Bihan 
et al., 1988). IVIM separates pure diffusion (D) from the pseudodiffusion component (D*) 
arising from microcirculatory perfusion and allows calculation of a perfusion fraction (f) 
corresponding to signal from the vasculature (Le Bihan et al., 1988). IVIM-D has performed 
better than ADC in discriminating low- from high-grade hepatocellular carcinoma (Woo et 
al., 2014b). Although IVIM is a very new technique and not in routine clinical use at present, 
it has successfully differentiated benign from malignant lesions in adults (Kang et al., 2014; 
Klauss et al., 2016). IVIM-f has differentiated high- from low-grade brain gliomas (Federau 
et al., 2012).  
 
The techniques described in this thesis are largely complimentary and there is an increasing 
recognition that a multi-modal approach to data acquisition should be followed (Peet et al., 
2012). The International Society of Pediatric Oncology Europe (SIOPE) Brain Imaging 
Group has agreed a protocol for brain tumours which includes single voxel MRS, Diffusion 
Tensor Imaging (DTI) and DSC-MRI. In the UK, the Children’s Cancer and Leukaemia 
Group’s Functional Imaging Group have advocated a protocol for abdominal tumours 
including multi b-value DWI. The main parameter sets for these protocols are given in the 
supplementary material (Appendix 1 and 2). Specific clinical situations may make other 
protocols optimal but adaptations require significant local experience in using the technique. 
 
A number of issues must be addressed when considering clinical use of functional imaging in 
paediatric oncology. There are several challenges to routine implementation of these 
techniques into clinical practice, including developing standardised acquisition protocols with 
appropriate quality control measures, processing and presenting information, and handling 
complex quantitative data that requires presentation in a format comprehensible to clinicians.  
 
DWI is suitable for paediatric use as it requires no IV access, contrast injection or compliance 
with breath-hold techniques. Routine clinical integration is feasible as multi b-value DWI can 
be performed on all modern MR scanners as part of a standardised protocol. Acquisition 
times are short, with additional scanning time of 2-7 minutes for body protocols. ADC values 
are independent of magnetic field strength (Gawande et al., 2013) which aids translation 
across different scanners.  
 
Although qualitative DWI is used routinely in brain tumours and to some extent in non-CNS 
tumours, there is a need for further research into quantitative applications prior to 
incorporation into routine clinical practice. Most evidence consists of small retrospective case 
series confounded by lack of standardization of DWI techniques. There is no standard method 
for determination of Region of Interest (ROI): some studies have drawn several small ROIs in 
the solid component of a tumour (Gawande et al., 2013; Oka et al., 2010), whereas others 
have included the entire tumour volume with and without cystic (Kocaoglu et al., 2010; 
Abdel Razek et al., 2009; Humphries et al., 2007) and necrotic (Littooij et al., 2015; 
McDonald et al., 2011) areas. Choice of b-values also varies between studies leading to 
inconsistencies in ADC values and making direct comparison of results difficult. Technical 
difficulties could lead to misinterpretation of ADC, with small tumour size, necrosis, 
bleeding and calcification influencing measurements.  
 
Although quantitative ADC measurements may be clinically useful, analysis of quantified 
data represents a departure from traditional working for radiologists, necessitating further 
training and attitudinal shift. Further challenges include ensuring reproducibility of DWI, 
both within and between centres. Inter-observer reliability should be addressed, although 
good inter-observer correlations between ADC measurements have been reported (Gawande 
et al., 2013; Littooij et al., 2015). Standardized protocols and diffusion phantoms are required 
to ensure ADC values before and after treatment accurately reflect changes in diffusion, and 
centres should adhere to set protocols and implement robust quality assurance.  
 
MRS is not widely used in clinical practice and a number of challenges must be overcome to 
allow its implementation as a routine tool in clinical decision-making. Implementation has 
been hampered by lack of agreed quality control measures, acquisition protocols and analysis 
techniques for specific clinical scenarios. Further challenges include processing and 
presenting information, assessing quality of spectra and accurately interpreting data.  
                                                                                         
MRS can be performed during routine MRI scanning without need for additional IV access or 
general anaesthesia. An MRS protocol consisting of acquisition of a single voxel spectrum 
should add no more than 5 minutes to total examination time. Better data can be acquired in a 
shorter time period using MRI scanners with higher field strength (e.g. 3T systems). Single 
voxel MRS could be used in centres without additional spectroscopy support as data is 
relatively easy to acquire, assess and interpret. More complicated techniques such as multi-
voxel MRS are more difficult to integrate into mainstream practice due to delays in reporting 
and the requirement for MR spectroscopist help with interpretation.  
 
There is a paucity of research into how to implement diagnostic information from MRS into 
the clinical diagnostic pathway in routine clinical practice. Biomarkers need to be evaluated 
in well-defined diagnostic groups treated in a standardized manner as part of a clinical trial. 
Prospective studies are needed to evaluate the diagnostic impact of MRS over MRI alone in 
brain tumours in children. The STARD (Standards for Reporting of Diagnostic Accuracy) 
Guidelines for reporting diagnostic accuracy (Bossuyt et al., 2003)  should be adhered to 
ensuring studies of sufficient quality are conducted to provide high quality evidence for the 
added value of this technique. 
 
Advancements in MRI techniques have highlighted the need for analysis tools to extract and 
analyse relevant information to aid clinical decision-making. A major hurdle to incorporating 
multimodal functional imaging into real time radiological diagnosis is the difficulty in timely 
analysis of quantitative data, especially in busy radiology departments and the emergency 
setting. As radiologists are not trained to quantitatively evaluate functional imaging data it is 
important to present comprehensible information and minimise need for complex analysis.  
 
Clinical Decision Support Systems (CDSSs) have potential to make complex advanced MRI 
data available to aid clinical decision-making. CDSSs aim to facilitate optimum human 
performance through harnessing advanced imaging and analysis techniques and allowing 
them to be used in conjunction with the clinical user’s decision-making skills and abilities. 
Availability of a user-friendly and flexible CDSS that encompasses a variety of medical 
image analysis techniques and post-processing methods could facilitate uptake of advanced 
MRI techniques such as DWI and MRS in a real-time clinical setting.   
 
There are, at the time of writing, no CDSSs available to facilitate clinical use of multi b-value 
DWI for the diagnosis, characterisation or treatment monitoring of solid body tumours. 
Although MRS classifiers are being developed for adults brain tumour diagnosis (Tate et al., 
2006), data cannot be extrapolated for paediatric use as childhood tumours are very different 
entities. One challenge in paediatrics is developing robust classifiers from small patient 
numbers given the numerous different types of childhood brain tumours, extensive 
subcategorisation, and need to restrict cases by patient age and tumour location. It is difficult 
to obtain sufficient cases to formulate robust classifiers and impossible to develop and 
implement classifiers to distinguish all types of paediatric brain tumours. 
 
Providing CDSSs that are acceptable to clinicians is challenging. A CDSS should be user-
friendly with an intuitive graphical user interface, adaptable as data sets and diagnostic 
classification schemes are regularly updated, and appropriate for use in a clinical setting. As 
clinicians are reluctant to use systems that do not fit into routine clinical practice, integration 
with other diagnostic tools is essential. A Participatory Design approach may be used in 
developing a CDSS, actively involving clinicians in the design process to ensure the final 
product meets the needs of those intended to use it (Dredger et al., 2007). Once established, 
user acceptance studies should be conducted in the clinical environment to determine the 
value of the CDSS. 
 
Functional imaging provides information on tumour properties unavailable from conventional 
MR imaging. Clinically, functional imaging can improve non-invasive diagnosis and early 
treatment monitoring, as well as providing biomarkers of prognosis. Further research is 
needed to define the optimum use of functional imaging in a clinical setting and integrate 
these promising new techniques into routine practice to improve care of children with cancer. 
 
Overall Aims  
The aims of this work were to determine the added value of functional imaging and its 
derived biomarkers for diagnosis and treatment monitoring in paediatric oncology when 
compared with reporting of conventional imaging used in routine practice. A secondary aim 
was to facilitate the integration of advanced MR imaging techniques into clinical practice. 
 
Objectives  
1. To establish the role of quantitative DWI and ADC histogram analysis in the 
diagnosis of paediatric solid body tumours. 
2. To prospectively evaluate the added value of DWI and ADC histogram analysis in 
non-invasive differentiation of benign from malignant childhood tumours. 
3. To evaluate DWI and quantitative ADC and IVIM histogram analysis as potential 
biomarkers for evaluating the chemotherapeutic response of paediatric solid tumours.  
4. To determine the reproducibility of ADC histogram-derived parameters and formulate 
recommendations for methodology of ROI selection. 
5. To determine the added value of qualitative radiological review of single voxel MRS 
in the non-invasive diagnosis of paediatric brain tumours.  
6. To review clinical use of MRS over a defined time period, explore its added 
therapeutic value over conventional imaging and its role in non-invasive diagnosis 
and clinical decision-making, and investigate its potential impact on patient care. 
7. To contribute to the design, development, and evaluation a clinical decision support 
system for automatic processing, evaluation and representation of advanced magnetic 
resonance imaging data to provide real-time diagnostic support for clinicians. 
 
The theory of advanced MR imaging, including DWI and MR spectroscopy, is summarised in 
chapter 2. Study methodology and a summary of statistical analysis techniques used in this 
work are described in chapter 3. 
 
Chapter 4 focuses on establishing the added value of quantitative DWI and ADC histogram 
analysis in the diagnosis of paediatric solid body tumours to meet objective 1. Development 
of a CDSS through creating a repository of benign and malignant tumours with which new 
cases can be compared, to meet objective 7, is also described. This work has been presented 
orally at the Childhood Cancer and Leukaemia Group (CCLG) Summer Meeting, London, 
2017, and as a poster at the International Society of Magnetic Resonance Imaging Meeting 
(ISMRM), Hawaii, 2017.  
 
To fulfil objectives 2 and 7, chapter 5 is a prospective evaluation of the added value of DWI 
and ADC histogram analysis and the CDSS under development in the differentiation of 
benign from malignant childhood tumours. As ADC histogram analysis has never before 
been evaluated prospectively in paediatric oncology, it is important to do so to validate and 
explore the clinical utility of techniques found to show promise retrospectively. 
 
Chapter 6 explores the role of DWI and quantitative ADC and IVIM histogram analysis as 
potential biomarkers in evaluating the chemotherapeutic response of paediatric solid tumours, 
in accordance with objective 3. This work was presented orally and as a poster at the 
Childhood Cancer and Leukaemia Group (CCLG) Annual Summer Meeting, Newcastle, July 
2016. 
 
To satisfy objective 4, chapter 7 determines the inter-rater reproducibility of ADC histogram-
derived parameters and aims to formulate recommendations for methodology of ROI 
selection. There is as yet no established recommended method for ROI construction, and it is 
important to ensure that any technique proposed for incorporation into clinical practice is 
reproducible, clinically applicable and provides clinically relevant and robust information. 
 
Chapter 8 aims to determine the added value of qualitative radiological review of single voxel 
MRS in the non-invasive diagnosis of paediatric brain tumours, in accordance with objective 
5. This work was presented orally at the International Society of Paediatric Oncology 
(SIOPe), Prague, 2017 and the Sankey Research Regional Meeting, Birmingham, 2016, as a 
poster at the International Society of Paediatric Neuro-Oncology (ISPNO) Meeting, Denver, 
2018, and is currently In Press for publication in Neuro-Oncology Practice. 
 
Chapter 9 is a review of clinical use of MRS and an exploration of its added therapeutic value 
over conventional imaging, its role in non-invasive diagnosis and clinical decision-making 
and its potential impact on patient care. This work was presented orally at the International 
Society of Paediatric Neuro-Oncology (ISPNO) Meeting, Liverpool, 2016, and is published 
in Neuro-Oncology Practice. 
 














It is important to have a basic understanding of the fundamental principles of Nuclear 
Magnetic Resonance (NMR) and Magnetic Resonance Imaging (MRI) to understand 
Magnetic Resonance Spectroscopy (MRS) and Diffusion Weighted Imaging (DWI) and their 
roles in clinical practice. MRI detects protons (1H) present in tissue, of which the majority are 
in water, to generate two-dimensional structural images.1H MRS is designed to detect proton 
signals from metabolites and macromolecules to determine their relative concentrations. DWI 
images reflect the motion of water within tissues on the scale of Brownian motion to provide 
information about cellularity through degrees of diffusion restriction. 
 
MRI, MRS and DWI are based upon nuclear magnetic resonance (NMR), a phenomenon in 
which nuclei absorb and emit electromagnetic radiation when placed in an external magnetic 
field. The hydrogen nucleus is a single, positively charged proton with an intrinsic magnetic 
quality termed nuclear spin that produces a magnetic field. Although other atomic nuclei also 
possess nuclear spin, hydrogen is used in clinical MRI and MRS due to the prevalence of 
hydrogen atoms in human tissue with high water content.  
 
An MRI scanner comprises a primary magnet, gradient magnets, radiofrequency (RF) coils 
and a computer system that generates images. Nuclear spin vectors (dipole moments) are 
randomly oriented in the absence of an applied magnetic field. Application of a primary 
external magnetic field (Bo) by the primary magnet causes hydrogen atoms in tissue to align 
parallel (low energy) or antiparallel (high energy) to it. A greater proportion of nuclei align 
parallel, contributing to a net magnetic vector (Figure 2.1.).  
Figure 2.1. Application of a constant external magnetic field (Bo) leads to polarization of magnetic 
nuclear spins as the dipole moments align with the external field 
Longitudinal magnetisation is when the tissue is magnetised in a direction parallel to the 
direction of the magnetic field. Transverse magnetization is when the direction of 
tissue magnetization is at a 90° angle with respect to that of the magnetic field (Figure 2.2.) 
Figure 2.2. Magnetic gradient fields oriented in the Transverse (x, y) and Longitudinal (z) planes  
 
Protons precess or spin around the long (z) axis of the primary magnetic field at a rate termed 
the Larmor frequency. The Larmor frequency is calculated using the Larmor equation:  
ω = γBο                       (2.1) 
(ω = frequency, γ = gyromagnetic ratio, B = magnetic field strength) 
and is thus proportional to the gyromagnetic ratio of the nucleus and the strength of the 
external magnetic field. Hydrogen has a relatively high gyromagnetic ratio, characterised by a 
large energy difference between spin states. The frequency of precession changes in 
proportion to the magnetic field strength measured in Tesla, with 1.5T commonly used in 
clinical practice. Protons are in phase when they precess together and out of phase when they 
precess separately.  
 
Magnetic gradient fields are generated from gradient coils in an MRI scanner. They are 
oriented in the x, y and z axes (Figure 2.2.) and allow spatial encoding or localisation for 
images. Radiofrequency (RF) coils allow application of a RF pulse (B1) with the same 
precession frequency as the nuclei within the primary magnetic field. This causes some low-
energy parallel protons to flip to a high-energy state, decreasing longitudinal magnetisation. 
As the protons precess in phase the net magnetization vector turns towards the transverse 
plane at 90° to the primary field, resulting in transverse magnetisation.  
 
Relaxation occurs as nuclei return to the equilibrium state and is measured in two directions: 
longitudinal (T1) parallel to Bo (z axis), and transverse (T2) perpendicular to Bo (x-y axis). 
T1, “spin-lattice” or “longitudinal” relaxation time, describes the time taken for an individual 
nucleus to return to its equilibrium state, or recovery of the z-component of the net 
magnetization vector. T2, “spin-spin” or “transverse” relaxation time, is related to the effect 
of nuclear spins on one another and refers to time taken for precessing nuclei to fall out of 
alignment with one another. T2 relaxation is generally shorter than or equal to T1. Different 
types of tissue show different T1 and T2 relaxation, manifest as image contrast: T1 
hyperintensity in tissue usually means a shorter T1, whereas T2 hyperintensity means a 
longer T2. Cerebrospinal fluid, for example, has a long T1 and appears dark on T1 weighted 
images. Pathologies can appear as either hypointense (dark) or hyperintense (bright) on T1 or 
T2 weighted images. 
 
The Free Induction Decay (FID) (Figure 2.3.) is the signal detected by the receiver coil of the 
MR scanner, induced by the RF excitation of nuclear spins that decreases exponentially at a 
time constant T2*. In reality, spins dephase much faster than T2 due to inhomogeneities in 
the external magnetic field (Bo), which means it has different strengths at different locations. 
As this causes destructive interference that shortens the FID, T2* is always shorter than T2.  
 
Figure 2.3. Free Induction Decay  
 
The FID refers to the electric current changes in the receiver coil. The oscillating magnetic 
field generated by the precessing nuclear net magnetisation is detected by the receiver coil 
and used to generate images. When the MR computer detects the RF signal it undergoes 
analogue-to-digital conversion followed by Fourier Transform (a mathematical procedure for 
reconstructing images from raw data) to produce an image. 
 
Diffusion-Weighted Imaging (DWI) is an MR technique that utilises the Brownian motion of 
spins to provide information about the properties of biological tissue. Diffusion represents the 
net displacement of a group of molecules within a pre-determined voxel between two time 
points. In DWI, the thermally driven diffusion of water protons within human tissue is 
exploited to visualize tissue characteristics. The apparent diffusion of water reflects tissue 
cellularity, the composition of the extracellular space, cell membrane integrity and the 
viscosity of tissue fluids.  
 
In order to generate diffusion weighting on an image, applied diffusion gradients are added to 
a conventional MRI sequence (Figure 2.4.). The sequence of choice for DWI is spin echo-
planar imaging (EPI), which has a rapid acquisition time and encounters little motion-induced 
artefact, although it is prone to susceptibility artefacts (e.g. at the base of the skull). 
Diffusion-weighted contrast is produced by a Pulsed Gradient Spin Echo (PGSE) consisting 
of a 90-180° spin-echo pair of RF pulses. The first gradient applies a phase shift to the 
protons, which is reversed by the second gradient. Signal attenuation occurs as the second 
gradient is unable to undo all the changes induced by the first gradient due to the movement 
or diffusion of protons.  
Figure 2.4. Application of diffusion gradients (G) to a conventional spin-echo MRI sequence. Two 
diffusion gradients of magnitude (G) and duration (δ), separated by time interval (Δ), are added 
symmetrical to the 180° RF pulse. 
DWI exploits the different diffusion properties of water molecules in structurally different 
tissues, with image contrast generated as the measured signal is dependent on particle motion. 
Tissues with high water content have mobile molecules that lead to high signal attenuation 
and deliver low signal intensity, whereas more solid and cellular tissues give less attenuation 
and stronger signal intensity. Signal attenuation is described by the Stejskal-Tanner equation:  
                                                                 S(b) = S0 ∙ exp(-bD)         (2.2) 
In which S(b) is the signal received for a certain applied gradient or b-value (measured in 
units of s/mm2), S0 is the signal strength with no diffusion weighting, and D is the diffusion 
constant of the imaged tissue (measured in units of mm2/s-1).  
 
The b-value reflects the strength and timing of gradients used to generate diffusion-weighted 
images. The higher the b-value, the greater the diffusion effect. Multiple DW images can be 
obtained with a range of b-values through altering the strength and magnitude of the applied 
gradient. The effect of diffusion is more prominent in images acquired with higher b-values, 
with values for b of up to 1000 s/mm2 necessary to obtain good image contrast. Images 
obtained at b0 with no applied gradient contain no information about diffusion and are a T2 
weighted structural image.  The b-value is given by the equation: 
                                                             b = γ2G2δ2(Δ−δ3)             (2.3) 
where γ is the gyromagnetic ratio (a constant, 42.58 MHz/T for protons), G the strength of 
the applied gradient, δ the duration of the gradient, and Δ the time between two gradients. It 
can thus be seen that signal loss is dependent on the strength and duration of gradients 
applied and the time between pulses.  
 
If DWI is performed with a minimum of two b-values, the Apparent Diffusion Coefficient 
(ADC) can be calculated as a straight line of the logarithm of the signal values. The term 
“apparent” is used because the parameter comprises information from tissue and capillary 
perfusion in addition to pure diffusion (D). ADC is expressed in units of 10−3 mm2/s and is 
calculated using a monoexponential fit of the b-values 0 and 1000 s/mm2.  Repeating this for 
each voxel within an image creates a parametric ADC map, with the ADC value in any given 
voxel being the slope of the line of the relationship between the logarithm of the signal 
intensity and the b-value (Figure 2.5.). Higher ADC values are reflected in voxels with high 
water diffusivity, which have a steeper slope of signal attenuation with increasing b-values. 
Highly cellular tissues will demonstrate a more gradual attenuation slope with lower ADC 
values.  
Figure 2.5. Apparent diffusion coefficient (ADC) calculation  
Calculation of ADC from multi b-value DWI using a monexponential fit. The logarithm of relative 
signal intensity is plotted against the b-value for each image voxel acquired at same anatomic position 
at increasing gradients (Koh et al., 2011). 
 
The b1000 DW image is often used to identify areas of restricted diffusion as they have high 
intensity. However, since the b0 image is a T2 weighted image, hyper-intense signal on the 
b1000 DW images may be due to inherently high T2 signal of the tissue (“T2 shine-through”) 
rather than restricted diffusion. ADC maps are helpful as they mathematically eliminate T1 
and T2 contrast effects in the images avoiding this pitfall. ADC maps facilitate visualisation 
of diffusion patterns as low areas of tissue diffusion appear hypo-intense, whereas high areas 
of diffusion are hyper-intense, the inverse of high b-value DW images. In addition to this, as 
ADC is dependent on tissue properties but largely independent of other factors which vary 
with acquisition technique (e.g. field strength), ADC maps allow comparison of images 
obtained by different scanners at different centres and even at different field strengths.  
 
DWI measures the attenuation of the signal due to water motion. This has contributions from 
Brownian motion of water but there will also be some movement of water on a similar 
timescale within the capillary bed due to perfusion. Signal attenuation in DWI thus depends 
on the velocity of the flowing blood and the vascular architecture of the imaged tissue in 
addition to the diffusion of water. When DWI is conducted in well-perfused tissue within the 
b-value range 0–1000 s/mm2, some of the signal attenuation at low b-values (0–100 s/mm2) 
arises from microcirculation within the capillary network since this is at a faster timescale 
than pure diffusion (Le Bihan et al., 1988). 
 
Multi b-value DWI has potential to non-invasively assess both diffusion and perfusion in 
tissue through the intravoxel incoherent motion (IVIM) model. The IVIM model uses 
biexponential fitting to describe DWI data given that measured signal attenuation comprises a 
mixture of effects of tissue perfusion and diffusion. IVIM simultaneously assesses the 
diffusion components corresponding to true molecular diffusion in tissue (D) and pseudo-
diffusion (D*) from perfusion in the micro-capillary network. It also allows derivation of the 
perfusion fraction (f) from the micro-vascular network that reflects tissue vascularity (Le 
Bihan et al., 1988).  
 
The biexponential relationship between b-values and the diffusion signal intensities is 
described by the following equation (Le Bihan et al., 1988): 
                                          S(b)/ S0 = f ∙ exp(-bD*) + (1-f) ∙ exp(-bD)        (2.4)    
S0 is the signal intensity at b = 0 and S(b) reflects intensities in s/mm2. The f parameter is the 
perfusion fraction from flowing blood, D is the true water diffusion coefficient and D* the 
pseudo-diffusion coefficient in blood.  
 
The effect of pseudodiffusion (D*) on the signal attenuation in each imaging voxel is 
dependent on the b-value. The relative contribution of pseudodiffusion to the DWI signal is 
significant at lower b-values, but only accounts for a small proportion of signal at higher b-
values.  D* and D can be separated as the rate of signal attenuation from pseudodiffusion is 
normally an order of magnitude greater than tissue diffusion. This is depicted in Figure 2.6. 
Figure 2.6. Effects of diffusion (D) and pseudo-diffusion (D*) on the MRI signal 
At high b-values values (>100 s/mm2) perfusion effects are negligible with D* >> D.  Linear 
fitting of the higher b values can be performed to calculate the D parameter from the gradient 
of fit. The f parameter can be deduced by extrapolating the fit to the y-axis and taking the 
difference to the b0 signal. At low b-values (<100 s/mm2), perfusion effects are more 
pronounced resulting in a biexponential shape, with the IVIM effect appearing as a deviation 
of the tissue diffusion signal decay as D*>D (Koh et al., 2011).                      
Despite advancements in DWI techniques and development of quantitative analysis to 
evaluate ADC values, there are inherent challenges and limitations in DWI interpretation and 
technical issues associated with poor spatial resolution, and lack of standardized image 
acquisition protocols and data analysis procedures. The main technical limitations are 
inherently low signal-to-noise ratio (SNR), susceptibility to artefact with echo-planar imaging 
(EPI) and difficulties with reproducibility. Ghosting may occur due to respiratory motion and 
chemical shift artefact. It is not possible to accurately calculate ADC from areas of very low 
signal intensity on a b0 map, particularly in areas with difficulties with susceptibility changes 
(e.g. haematoma), as the slope of the gradient will be insufficient to obtain a representative 
value. Additionally, there is no standardised recommendation for number of b-values or 
method of ROI construction for determining ADC values for a particular type of lesion. 
 
“T2 shine-through” can cause difficulties with interpretation of high b-value DW images as 
signal intensity is influenced by T2 relaxation time. Lesions with high fluid content, such as 
cysts, mimic restricted diffusion as they have a long T2 relaxation time and high signal 
intensity even at high b-values. Referring to the ADC map is helpful as a cyst will 
demonstrate high signal intensity on both T2 weighted images and the ADC map, whereas 
true restricted diffusion will show low signal intensity on the latter. A further consideration 
when interpreting DWI is that slow flowing blood may demonstrate the same signal intensity 
characteristics as highly cellular lesions. A haemangioma with low signal intensity on an 
ADC map may be mistaken for a solid tumour, although interpretation should be performed 
in the context of other MR sequences to determine other characteristic imaging features. 
 
Quantitative analysis can provide numerical ADC values that are robust against the effect of 
imaging artefact and subjective interpretation. ADC measurements can be produced for a 
given region by drawing regions of interest (ROIs) on the ADC map. This quantitation can 
reduce ambiguity, increase objectivity and allow more direct comparison of values. 
 
MRS is an advanced, non-invasive MR technique that allows biochemical characterisation of 
tissue in vivo. MRS is performed following conventional MRI by placing a voxel on an 
appropriately placed region of interest (ROI) and measuring the level of different metabolites 
in the selected tissue through producing a spectrum of resonances. The raw MR signal or Free 
Induction Decay (FID) is measured as a function of time. Fourier Transform (FT) converts 
this oscillating signal into a display of its frequency components (Jiru, 2008).  
 
MRS detects the resonance frequency of protons subjected to a magnetic field. Metabolites in 
tissue are identified due to chemical shift, allowing detection of specific molecules or 
metabolites which are seen as peaks at different positions on a spectrum (Warren, 2004). 
Chemical shift occurs due to weakening of the applied magnetic field by the electron cloud 
surrounding the nucleus. Individual protons resonate with slightly different frequencies 
depending on their chemical environment, resulting in a spectrum consisting of various peaks 
at different radiofrequencies. The chemical shift is measured in parts per million (ppm) 
which, unlike frequency (Hz), is independent of magnetic field strength and is the same in all 
MR scanners enabling comparison of spectral profiles.  
 
Single metabolites may give a single peak or a combination of singlets and multiplets (Figure 
2.7.). When an atom is placed within a magnetic field (Bο), protons induce their own effective 
magnetic field. Nuclei in close proximity connected through covalent bonds influence one 
another’s effective magnetic field. Equivalent nuclei (identical protons in the same magnetic 
environment) experience the same chemical shift and produce no observable peak splitting, 
whereas non-equivalent protons experience different chemical shifts. The effect in molecules 
containing more than one non-equivalent proton, known as J-coupling or spin-spin coupling, 
results in additional splitting of peaks in the spectrum (de Graaf, 2009) (e.g. the doublet 
shown by lactate). Signals at two or more resonant frequencies are then seen, rather than one 
signal as with equivalent nuclei (Klose, 2008). 
a) Creatine, two singlets with no peak splitting       b) Lactate, a doublet around 1.3ppm and a quartet 
                                                                                                                                             around 4ppm 
Figure 2.7.  Examples of peak splitting of different metabolites 
An MR spectrum (Figure 2.8.) comprises a graphical representation in which signal intensity 
is displayed as a function of chemical shift, with peaks corresponding to individual 
metabolites. The x-axis is the chemical shift in ppm: the majority of spectra acquired in vivo 
range from 0.5 to 9.0 ppm, with metabolite information extending from 0.5 ppm to 4.5 ppm. 
The y-axis represents signal intensity, which increases with the concentration of the chemical 
within the ROI (Panigrahy et al., 2010; McRobbie et al., 2007). The area under each peak is 
proportional to the concentration of the corresponding metabolite.  
Figure 2.8. Example MR spectrum from normal brain with key metabolites labeled. Key Metabolites: 
Myo-inositol (mIns) - role uncertain; total choline (tCho) - cell turnover; creatine (Cr) - energy state; 
N-acetyl aspartate (NAA) – neuronal marker; Lipids/Macromolecule (LMM) - apoptosis and necrosis 
For In vivo MRS, complex pulse sequences are used to ensure that the signal is acquired from 
a specific volume of tissue. Sequences, such as point-resolved spectroscopy (PRESS) or 
simulated echo acquisition mode (STEAM), are applied to excite a pre-selected ROI with 
minimum excitation of the rest of the brain. Both techniques apply three slice-selective pulses 
along x, y and z in a single pulse sequence (Ross and Bluml, 2001). 
 
Point-RESolved Spectroscopy (PRESS) (Bottomley, 1987) was used to acquire MRS data for 
studies described in this thesis.  PRESS involves application of a 90° radiofrequency pulse 
(RF) followed by two 180° RF pulses, allowing the primary spin-echo to be refocused by the 
third pulse (Figure 2.9.) (Ross and Bluml, 2001). The echo time (TE) is the time between the 
90° pulse and signal sampling, and repetition time (TR) the time interval between 
consecutive 90° pulses. Pulse sequences are repeated multiple times and the data added 
together to improve the SNR. 
Figure 2.9. PRESS pulse sequence. Volume selection using the PRESS pulse sequence with the 
application of three radiofrequency pulses. The first 90°radiofrequency pulse is applied in the along 
the gradient Gx axis followed by a 180° pulse along Gy and another 180° pulse along Gz. 
STEAM involves application of three 90° slice-selective pulses along Gx, Gy and Gz in a 
single pulse sequence (Ross and Bluml, 2001). It allows shorter echo times (TE) to be 
achieved, as TE is not influenced by time between the second and third RF pulses (Ross and 
Bluml, 2001). However, it produces lower SNR than PRESS. 
 
Tissue water is present in much higher concentrations than metabolites. As the water peak at 
4.7 ppm is 10 000 fold greater than metabolite signals within a 1H-MR spectrum, water 
suppression prevents its dominance from limiting metabolite information (Castillo et al., 
1996). Once data is obtained, an additional unsuppressed water spectrum is acquired from the 
same volume to provide an internal reference signal to quantify metabolite signal intensities 
(van der Graaf, 2010).  
 
An echo is the refocusing of spin magnetization by a pulse of resonant electromagnetic 
radiation. MRS may be performed at short echo time (TE) (<135ms, usually 20-40ms) or 
long echo time (TE) (>135ms, usually 135 or 270ms). After application of an initial 90° RF 
pulse, applying a second RF pulse with a precession angle of 180° after a time delay enables 
detection of a spin-echo. The echo time (TE) is the time between the initial application of the 
90° RF pulse and the echo peak. TE determines the presence of different amounts of 
metabolite information in the resultant spectrum and influences the baseline, which appears 
flatter at long TE. The MRS signal decays at a rate dependent on T2 as the echo time 
increases and so the SNR is lower at longer TE. 
 
Collecting data at different echo times allows information to be obtained from different 
metabolites. This is due to metabolite signals having different rates of T2 decay, and J-
coupling splitting resonances into multiple components. Short TE provides more metabolite 
information as signals from lipids, small metabolites (e.g. myo-inositol) and metabolites with 
complex spectral patterns (e.g. Glu, Gln) decay at longer echo times, but overlapping peaks 
and signals from lipids and macromolecules can make analysis complex. Spectra obtained at 
longer echo times (TE >135 ms) have fewer peaks as more metabolites have decayed and are 
clearer to interpret. Examples of MR spectra obtained at short and long echo times are shown 
in Figure 2.10. 
Figure 2.10.  MRS acquired on the same patient with medulloblastoma at a) short TE and b) long TE.  
mIns: myo-inositol; Tau: taurine; tCho: total choline; Cr: creatine; Glx, Glutamate+Glutamine; NAA: 
N-acetyl aspartate; LMM: lipids and macromolecules 
Long TE MRS has benefits of easy peak assignment and is useful for looking at metabolites 
such as N-acetyl aspartate, choline and creatine. Determining N-acetyl aspartate 
concentration in a short TE spectrum is difficult (Clementi et al., 2005) as overlapping 
metabolite peaks lead to  overestimation, whereas Glu, Gln and LMM signals decay at long 
TE giving a clear N-acetyl aspartate peak. Lactate is more easily assigned as it is inverted at 
echo times around 135 ms. The main disadvantage with long TE MRS is loss of metabolite 
information, particularly as those that decay quickly (e.g. myo-inositol and LMM) are 
important when analysing tumours (Preul et al., 1996; Calvar et al., 2005; Kim et al., 2006; 
Peet et al., 2007; Wang et al., 1995; Astrakas et al., 2004; Marcus et al., 2007; Tzika et al., 
2004). Short TE spectra are commonly acquired in clinical practice due to increased 
metabolite information and high SNR.  
 
Magnetic field strengths of 1.5T or 3T are used in clinical practice. The appearance of 1H-
MRS is characterised by chemical shift and J-coupling and varies at different field strengths. 
Chemical shifts are dependent on the strength of the applied magnetic field: as field strength 
increases, the chemical shifts of proton groups also increase. This effectively stretches the x-
axis scale, improving resolution and leading to better separation of peaks. Chemical-shift is 
expressed in ppm because this dimensionless unit is independent of field strength and enables 
direct comparison with measurements at different field strength (choline, for example, will be 
positioned at 3.2 ppm at 1.5 or 3T).  Chemical shifts expressed in Hz are spread out in 
proportion to the applied magnetic field.  As coupling constants are independent of field 
strength, J-coupling is unaffected. This results in the appearance of multiplets changing with 
split peaks of individual metabolites appearing closer together at higher field strengths. 
 
This can be explained by considering lactate, characterised by a doublet peak at 1.3 ppm. The 
prominent peak of LMM at 1.3/1.4ppm often overlaps with the lactate doublet at low field 
strengths, leading to miss-assignment and inaccurate quantitation. This overlap can be 
improved by performing MRS at higher field strengths, with separation of the lipid and 
lactate peaks at 3T but not 1.5T. The peaks of the lactate doublet would also appear closer 
together at 3T as coupling constants are independent of field strength. The effect of 
increasing field strength on lactate can be seen in Figure 2.11. 
 
Lactate at 1.5 T                                                           Lactate at 3 T 
Figure 2.11. Lactate measured at 1.5T and 3T. 
In vivo MRS is acquired following conventional MRI. 1H-MRS is most commonly used in 
vivo as protons provide a stronger signal in a short time than other nuclei due to their high 
gyromagnetic ratio and prevalence in human tissue. MRS acquisition involves selecting an 
ROI or voxel based on reference images, refining the magnetic field within the voxel to make 
it uniform by shimming, and suppressing the protons of water within the voxel (Ross and 
Bluml, 2001). Processing is subsequently applied to construct a high quality MR spectrum. 
 
MRS may be acquired as single voxel (SVS) or multivoxel spectroscopy, also termed 
magnetic resonance spectroscopic imaging (MRSI) or chemical shift imaging (CSI). SVS was 
used predominantly in this thesis, measuring an MR signal from a single ROI following 
placement of a single voxel in the desired region.  
 
Voxel positioning is of paramount importance to obtain an MR spectrum representative of the 
region being assessed. The voxel should be placed fully over the ROI away from bone, scalp 
and air interfaces, and should not predominantly contain normal brain. Reference images 
from planes of all three axes are used to assess accurate voxel placement, as in Figure 2.12. 
Figure 2.12. Voxel positioning. Example of voxel positioning over a tumour (medulloblastoma). 
Reference images from a) coronal, b) sagittal and c) axial planes
Shimming produces a homogeneous magnetic field to ensure equivalent nuclei within an ROI 
are subjected to the same magnetic field. Good shimming leads to a high SNR and good peak 
resolution, whereas poorly shimmed spectra have broad metabolite peaks or line-width. 
Shimming is usually performed automatically. It is usually reported as the full width at half 
maximum height (FWHM) of the water peak or other peaks in the MRS, and is an important 
quality control parameter. 
 
In order to produce a high quality spectrum, several processing steps are performed on the 
acquired FID either before (time-domain) or after (frequency-domain) the Fourier Transform. 
These can be applied automatically and integrated in quantification software (Jiru, 2008), 
such as TARQUIN (Wilson et al., 2011), LCModel (Provencher, 2001) and QUEST 
(Mansson et al., 2006). Processing steps include pre-processing, including removal of 
residual water, phase-correction and baseline correction, prior to metabolite quantification. 
Data in this thesis were processed using TARQUIN software (Wilson et al., 2011). 
 
TARQUIN (Wilson et al., 2011) performs quantitation of metabolites in the time domain. As 
it is difficult to accurately quantitate short TE spectra due to their overlapping metabolite 
peaks, the entire spectrum is fitted to a set of individual metabolite spectra acquired by 
simulation. Fitting may be applied automatically to obtain a list of quantifiable metabolites 
and their relative concentrations (expressed in standard units of millimolar (mM)), with use 
of the water signal as a concentration reference. Fourier transformation is subsequently 
applied to enable visualisation of the spectrum.  An example MRS with metabolite fitting 
using TARQUIN is shown in Figure 2.13. 
Figure 2.13. Metabolite fitting using TARQUIN 
Linear Combination Model (LCModel™)(Provencher, 2001) uses fitting in the frequency-
domain to generate a list of metabolite concentrations (relative to water) and their confidence 
estimates, using a linear combination of empirically obtained metabolite spectra to ‘fit’ to 
experimentally obtained spectra.  LCModel has a choice of basis sets acquired at different 
echo times on a variety of scanners. The whole MR spectrum can be fitted automatically to 
produce a list of metabolites and their relative concentrations (Figure 2.14).  
Figure 2.14. LCModel Fitted Spectrum
MRS from the human brain comprises 18-20 metabolites and nine lipids and 
macromolecules. Metabolite profiles in normal brain differ from those in pathological brain, 
and pathologies differ with presence and absence of varying concentrations of different 
metabolites (Panigrahy et al., 2010). The following metabolites have been identified, of 
which the main features used in visually interpreting the spectrum will be described: 
 
N-acetyl aspartate (NAA) (2.0 ppm) 
N-acetyl aspartate (NAA), a marker of neuronal density and axonal integrity, is one of the 
most predominant metabolites and the largest peak seen in normal brain. Its main peak can be 
seen at around 2.0 ppm and is exclusively located in the central and peripheral nervous 
system. NAA is the most reliable marker of CNS pathology, with decreased levels in spectra 
of brain tumours (Wang et al., 1995; Peet et al., 2007; Harris et al., 2007; Tzika et al., 2004; 
Warren et al., 2000). N-acetyleaspartylglutamate (NAAG), a neurotransmitter, is closely 
linked to N-acetyl aspartate and may overlap as it is found at 2.04 ppm on the shoulder of the 
N-acetyl aspartate peak. 
 
Total Choline (tCho) (3.2 ppm) 
The total choline peak around 2ppm is comprised of free choline, phosphocholine (PCH) and 
glycerophosphocholine (GPC). As it is difficult to separate these three metabolites at 1.5T, 
the resultant complex peak at 3.2 ppm is termed total choline (tCho). These metabolites also 
give rise to resonances between 3 and 4ppm but these are small and difficult to visualise. 
Choline is involved in membrane synthesis and degradation and is a marker of membrane 
turnover, increasing with cell proliferation and being elevated in brain tumours (Panigrahy et 
al., 2006; Peet et al., 2007; Astrakas et al., 2004; Marcus et al., 2007; Davies et al., 2008; 
Londono et al., 2003). Evidence suggests elevated choline is representative of CNS 
malignancy (Peet et al., 2007; Marcus et al., 2007; Astrakas et al., 2004). 
 
Creatine (Cr) (3.0 ppm) 
The creatine (Cr) peaks are comprised of creatine and phosphocreatine, with singlet peaks at 
3.02 ppm and 3.94 ppm. Creatine is present in neuronal and glial cells and is involved in 
energy storage and metabolism as it provides phosphate for ATP through phosphocreatine. 
Although creatine levels are stable in normal brain they vary in pathology, being decreased in 
gliomas (Panigrahy et al., 2006; Davies et al., 2008). 
 
Myo-inositol (mIns) (3.6 ppm) 
Myo-inositol (mIns) is an osmolyte and astrocyte marker with a complex peak at 3.6 ppm at 
1.5T and two peaks close to this at 3T, although its function is poorly understood (Castillo et 
al., 2000; Panigrahy et al., 2010). Increased mIns in glial tumours may reflect the cellular 
density of reactive astrocytes or membrane turnover in highly proliferative tumour cells 
(Hattingen et al., 2008), with varying concentrations of mIns in other brain tumours due to 
altered membrane metabolism (Castillo et al., 2000; Kim et al., 2006; Peet et al., 2007; 
Davies et al., 2008; Londono et al., 2003; Panigrahy et al., 2006; Harris et al., 2008; 
Panigrahy et al., 2010). mIns has been used in grading astrocytomas (Castillo et al., 2000; 
Kim et al., 2006) and is elevated in ependymomas (Davies et al., 2008; Harris et al., 2007) 
and diffuse pontine gliomas (Harris et al., 2007). 
 
Glutamate (Glu), glutamine (Gln) and Glutamate+Glutamine (Glx) (2.0 to 2.6 ppm) 
Glutamate (Glu) is the most abundant amino acid in the brain and has a role as an excitatory 
neurotransmitter, and glutamine (Gln) is a storage form of glutamate and an amino acid 
precursor (Panigrahy et al., 2010). Both metabolites indicate abnormal brain tumour 
metabolism in adults (Howe and Opstad, 2003). They are present as complex overlapping 
multiples between 2.0 and 2.6 ppm and, as they are difficult to separate below 3T due to 
complex spectral overlap, Glu and Gln are often reported as a sum (Glx).  
 
Lactate (Lac) (1.3 ppm) 
Lactate is an end product of anaerobic glycolysis present as a doublet peak at 1.3 ppm. It 
occurs in normal brain in low concentrations and is elevated in CNS pathology (Panigrahy et 
al., 2010) as a marker of cell death and necrosis. Lactate levels increase with hypoxia where 
glycolysis is initiated in an oxygen deficient environment. Lactate levels are variable in brain 
tumours (Govindaraju et al., 2000; Astrakas et al., 2004; Davies et al., 2008) and the 
metabolite has been useful in grading gliomas (Kim et al., 2006) and identifying pilocytic 
astrocytomas (Wang et al., 1995). Assignment may be difficult at short TE when signals from 
lipids and macromolecules overlap (Marcus et al., 2007), but easier at longer echo times as 
lactate peaks are inverted and lipids usually less prominent. A metabolite with two visible 
doublet peaks is more likely to be lactate than lipid contamination. 
 
Taurine (Tau) (3.3 ppm) 
Taurine (Tau) has possible roles as an osmoregulator and modulator of neurotransmission, 
but its function is not fully understood. Increased levels have been found in CNS tumours 
(Panigrahy et al., 2006; Harris et al., 2011; Opstad et al., 2009).  As taurine closely overlaps 
with other metabolites (e.g. tCho) at around 3.3 ppm) it may be difficult to identify at 1.5T 
but is split into two resonances at 3T, which can make its identification easier.  Elevated 
levels of taurine are seen in medulloblastomas (Panigrahy et al., 2006; Davies et al., 2008) 
and pineal germinomas (Panigrahy et al., 2006). 
Glycine (Gly) (3.55 ppm) 
Glycine (Gly) is an inhibitory neurotransmitter and antioxidant (Davies et al., 2010b; 
Govindaraju et al., 2000). It forms a singlet peak at 3.55 ppm and is better seen at long TE as 
it overlaps with mIns at 1.5T. Increased Glycine has been observed in higher grade brain 
tumours (Davies et al., 2010b; Lehnhardt et al., 2005). 
 
Citrate (Cit) (2.6 ppm) 
Citrate (cit) is an intermediate product of the tricarboxylic acid (TCA) cycle observed at 2.6 
ppm. Increased levels of citrate may occur in malignant progression (Seymour et al., 2008), 
with prominent peaks in a number of tumours including DIPG (Seymour et al., 2008; 
Costello et al., 1999). 
 
Lipids and macromolecules (LMM) (0.9 ppm, 1.3 ppm, 2.0 ppm) 
Lipids reflect membrane degradation, necrosis and apoptosis (Tzika et al., 2003), and form 
broad resonances at 0.9 ppm, 1.3 ppm and 2.0 ppm. Lipids occur in very low levels in normal 
brain but increase in brain tumours. Macromolecules occur due to cytosolic proteins or lipids 
(Panigrahy et al., 2010), and are difficult to assign being masked by lipid signals. Lipids may 
be indicators of tumour growth, with variations occurring in response to treatment (Astrakas 
et al., 2004; Peet et al., 2007). LMM may be due to necrosis, being high in high-grade 
tumours (Calvar et al., 2005; Peet et al., 2007; Astrakas et al., 2006; Marcus et al., 2007) and 
increasing prior to progression (Sankar et al., 2008). Caution should be exercised when 
interpreting lipid levels in tumours to ensure adequate voxel positioning, as high lipid levels 
may reflect lipid contamination from surrounding scalp tissue, inclusion of necrotic cysts or 
proximity to bone (Rosen and Lenkinski, 2007). 
Several challenges remain to the routine implementation of functional imaging in clinical 
practice. These include developing standardised acquisition protocols with appropriate 
quality control measures, processing and presenting information and in particular the 
handling of quantitative data that represents a departure from traditional radiological 
working. 
 
It is essential to ensure correct voxel placement to obtain a valid spectrum, and classification 
rates can vary dependent on voxel placement (Ricci et al., 2000). Inclusion of normal brain 
within a voxel may increase N-acetyl aspartate within the MRS, causing difficulties with 
interpretation. Voxel placement which includes a significant component of CSF decreases the 
SNR but is preferable to including normal brain in the voxel which leads to contamination of 
the tumour signal by metabolites such as NAA.  
 
Spectral congestion at short echo times (TE) causes lack of distinction between metabolite 
peaks (Clementi et al., 2005; Kim et al., 2006; Barker et al., 2001; Bartha et al., 2008) 
resulting in difficulties with peak assignment and quantification. Using a higher field strength 
may improve the SNR and resolution. Age-related variations in CNS metabolite 
concentrations may cause problems with paediatric MRS interpretation (Pouwels et al., 1999; 
Grachev and Apkarian, 2000). Concentrations of choline, myo-inositol and Glu alter in the 
first year of life and then remain relatively stable (Pouwels et al., 1999), and N-acetyl 
aspartate increases in grey matter throughout the first year (Pouwels et al., 1999). Infants 
have high cerebellar and grey matter concentrations of taurine, which decreases and stabilises 
later in life, although taurine concentration in the basal ganglia remains constant with age 
(Pouwels et al., 1999). Metabolite concentrations may also vary in different regions 








Children presenting to Birmingham Children’s Hospital between December 2012-July 2018 
with radiological features of a brain or solid body tumour were eligible for inclusion in the 
studies described in this thesis. Patients were recruited prospectively following presentation 
during the study period into an ethically approved study entitled “Functional Imaging of 
Tumours”. Ethical approval was granted by the East Midlands–Derby Research Ethics 
Committee (REC 04/MRE04/41). Informed parental consent was obtained for all participants 
following image acquisition, performed as part of standard care or prior to imaging if this was 
not considered part of standard of care. 
 
Patients appropriate for each analysis presented in this thesis were identified retrospectively 
through searches of computerized records.. All children with suspected malignancy undergo 
standard clinical diagnostic imaging investigations including MRI and MRS for brain lesions 
and multi b-value DWI for body tumours. Exclusion criteria were having received treatment 
(chemotherapy or surgery) prior to diagnostic imaging, incomplete MRI study and solid body 
lesions with the largest area on a single slice <3 cm2 in view of risk of partial volume effects. 
Children were aged between fetal 36 weeks gestation and 16.4 years at diagnosis.  
 
MRI was performed on paediatric solid body tumours at diagnosis and following induction 
chemotherapy using a Siemens Avanto 1.5T (Siemens Healthcare, Erlangen, Germany) 
scanner and a 4-channel body receive coil. The imaging protocol consisted of fat-suppressed 
axial and coronal pre-and post-gadolinium T1-W turbo spin-echo (repetition time / echo time 
[TR/TE] 760 to 817/7.7 msec), axial T2-weighted turbo spin-echo (TR/TE 3000 to 5640/67 
to 87 msec) and DWI acquisition. Children were awake, sedated or under general anaesthesia 
depending on their ability to cooperate. 
 
DWI was acquired using a single shot spin-echo planar imaging (EPI) sequence with up to 
six b-values (b = 0, 50, 100, 150, 600, 1000 s/mm2) in an axial acquisition plane. The field of 
view (FOV) ranged from 221 to 350 x 172 to 317 mm, matrix size 122 to 192 x 128 to 192 
depending on patient size. Slice thickness was 5.0 mm with no gap between slices.  DWI was 
acquired in three orthogonal directions with echo time of TR/TE 3200 to 9900/92 ms and b-
values including 0 and 1000 s/mm2. For this protocol, total scan duration ranged from 1 min 
37 sec to 7 min 32 sec when acquiring all six b-values. ADC maps were automatically 
generated from scanner software. Repeat MRI scans were performed during and following 
chemotherapeutic treatment as routine clinical care.  
 
MRI datasets including ADC maps were transferred from the scanner to a local research and 
advanced applications PACS (Pukka J DICOM explorer version 6.1.1) and subsequently 
loaded into an in-house analysis tool (MIROR).  
 
A modular medical image region of interest analysis tool and repository (MIROR) was 
developed by our research team using MeVisLab (v. 2.7.1, MeVis Medical Solutions, 
Bremen, Germany) (Zarinabad et al., 2018), a rapid prototyping platform for medical image 
processing. MIROR allows automatic processing and classification of advanced MRI data, 
including multi b-value DWI. Post-processing, quantitative and statistical analysis 
functionalities were developed using Python (v. 2.7, embedded within Mevislab). Research 
conducted during this PhD contributed to development of MIROR as a clinical decision 
support system (CDSS) to facilitate interpretation and analysis of advanced MRI techniques. 
Development of MIROR as a CDSS involved translational work aiming to integrate advanced 
MRI techniques into a clinical setting by presenting complex information to clinicians in an 
accessible and comprehensible way. This necessitated liaison between computer scientists 
involved in the technical design of MIROR and radiologists as end-users to collate feedback 
and make suggestions for on-going improvement for clinical use. Each independent 
component of MIROR was developed, evaluated and tested by radiologists prior to 
subsequent modification as an intrinsic part of the research described in this thesis. 
 
Developing a graphical user interface (GUI) acceptable to radiologists, for example, 
necessitated several iterations of re-design to ensure clinical applicability. The final version 
of the user interface for patient view (Figure 3.1.) required import of an MR image containing 
sufficient structural information to allow construction of a ROI, which would subsequently be 
transferred to a matched ADC map for quantitative analysis. It was not appropriate to draw an 
ROI directly on to the ADC map due to risk of bias, with the eye being drawn to areas 
showing the greatest diffusion restriction. As T2-weighted and multi b-value DWI images 
were not registered, the tool was adapted to allow import of b0 images for ROI construction, 
which was acceptable to radiologists in terms of image quality. The relative size and layout of 
display windows for MR images (b0 and ADC maps), the volume of interest, the ADC 
histogram and quantitative histogram parameters, and output colours were also adjusted in 
conjunction with input from radiologists.  
 
Prior to commencing the studies described in results chapters of this thesis, we developed a 
preliminary version of MIROR suitable for research use. At this stage, MIROR allowed 
radiologists to draw a ROI on a b0 image that could be transferred to a matched ADC map, 
and could measure the volume of the defined ROI, perform statistical analysis on the ROI 
values, create a histogram, and extract and store histogram parameters such as median and 
different percentile ADC values, skewness, kurtosis and entropy in a repository. 
Figure 3.1. MIROR graphical user interface patient view depicting analysis of a malignant Wilms 
tumour. The ROI is drawn on a high-resolution b0 image and overlaid on the corresponding 
parametric ADC map. An ADC histogram (top left) and volumatic representation of the tumour (top 
right) are generated. 
The refinement, further development and evaluation of MIROR for clinical use is described 
in the body of the thesis. In addition to design, evaluation and translation, this research 
contributed to development of the CDSS through recruitment of patients whose tumours 
formed part of the inbuilt repository, maintaining a clinical database of patient details 
including serial imaging, treatments and outcome, and drawing ROIs from which ADC 
histograms were generated for benign and malignant tumours and individual tumour types. 
Whole tumour (WT) ROIs were drawn manually around solid tumours on high-resolution b0 
images by a clinician and refined by a consultant radiologist (KF, 10 years’ experience) 
Alterations to ROIs were made following consensus of the two individuals. ROIs were 
transferred to a matched ADC map and an embedded image registration component of 
MIROR ensured alignment of parametric maps and imported image data. Conventional MR 
images guided delineation of tumour at each consecutive tumour-containing slice, excluding 
peri-tumoural oedema. To minimise partial volume effect, only sections where tumour was 
>50% of the adjacent more central slice and at least 3 cm2 were included. The entire tumour 
volume including cystic and necrotic areas was included in the ROI to determine 
representative data for heterogeneous tumours. This process was repeated for images 
acquired following neo-adjuvant chemotherapy. Figure 3.2. depicts a WT ROI constructed 
within MIROR. 
Figure 3.2. A Whole Tumour (WT) ROI constructed within MIROR (Wilms Tumour) 
A second ROI was drawn around the largest single axial slice (SS) in a subset of tumours to 
ascertain the optimum method of ROI construction for inter-rater reproducibility and 
discrimination between benign and malignant lesions. A second consultant radiologist (SA, 1 
years’ experience) drew WT and SS ROIs blind to the results of first radiologist to allow 
comparison of histogram parameters between the two raters and the two techniques. 
Post-processing was performed in MIROR. ADC values were computed using a 
monoexponential linear fit of the b-values 0 and 1000 s/mm2. IVIM modelling was carried 
out for all cases where six b-values had been acquired. An algorithm for IVIM analysis using 
biexponential fitting was developed using Python (v. 2.7), enabling calculation of D and f 
parameters (Le Bihan et al., 1988). Linear regression was performed using high b-values 
(>100 s/mm2), to calculate the D parameter from the gradient of fit as perfusion effects are 
negligible at high b values when D* >> D (Taouli et al., 2016). The f parameter was deduced 
from the same fit, by extrapolating the fit to the y axis and taking the difference from the 
intercept to the b0 signal. D* was not calculated due to the large errors involved, particularly 
as the study involved a comparison of longitudinal data. 
 
Advanced histogram analysis of the overlaid ROI on voxel-by-voxel parametric maps was 
performed in MIROR using its quantitative and statistical analysis components. The area 
under the histogram was normalized to unity to dissociate histogram parameters from lesion 
size. For each patient, tumour volume and ADC and IVIM parameter median, 15th, 25th, 75th 
and 95th centiles, skewness, kurtosis, volume and entropy were calculated and exported for 
detailed analysis.  
 
The morphology or shape of histograms can be described in terms of skewness, kurtosis and 
entropy. Skewness is a measure of symmetry: a histogram with a symmetrical or normal 
distribution is characterised by two halves which mirror one another, whereas one with a 
skewed distribution is asymmetrical. A right-skewed distribution is also termed positively-
skewed and has a tail on the right, whereas a left or negatively-skewed distribution has a tail 
on the left (Figure 3.3). Skewness can be quantified to define the extent to which a 
distribution differs from the normal distribution.  
Figure 3.3. Histogram Skewness 
Kurtosis is a measure of how peaked a histogram appears: a histogram with a standard 
normal distribution has kurtosis of 3. Increased kurtosis (>3) is visuallised as a thin ‘bell’ 
with a high peak, whereas decreased kurtosis (<3) is seen as a broadened peak with a 
‘thickening’ of the tails of the histogram (Figure 3.4.) 
Figure 3.4. Kurtosis 
Entropy is a measure of disorder, with the entropy of a historgram reflecting an estimation of 
its randomness. Entropy can be thought of as a measure of the sharpness of the peak of a 
histogram, as shown in Figure 3.5. 
Single-voxel MRS was acquired on children presenting with radiological features suggestive 
of a brain tumour as standard diagnostic imaging prior to treatment or surgical intervention. 
MRS was performed on one of three MR scanners, two 1.5T (GE Signa Excite, or Siemens 
Avanto) or one 3T (Phillips Interna Achieva) following conventional MRI, including axial T1 
and T2-weighted, diffusion EPI and fluid-attenuated inversion recovery and post-contrast T1-
weighted sequences. At 1.5T, a single-voxel MRS protocol was used with point-resolved 
spectroscopy (PRESS) localization, short echo time (TE) 30 ms, repetition time (TR) 
1500ms. Cubic voxels had 1.5 cm or 2 cm side length, acquiring 256 or 128 repetitions 
respectively. At 3T, a short echo time 35 ms and repetition time 2000ms were used, with 
cubic voxels of side length 1.3 cm, 1.5 cm or 2 cm and 196, 128 and 196 repetitions 
respectively.  
 
MRI confirmed accurate voxel placement within solid tumour, avoiding cysts, necrosis and 
non-tumoural tissue and located >3mm from bone, scalp and air. As MR spectra can appear 
different if voxels are placed over high or low-grade elements within the same tumour, it was 
ensured that placement was over the solid enhancing tumour component if possible, which 
should correspond to the most malignant section.  
 
Spectroscopy processing was performed using standard scanner software exported to hospital 
clinical PACS (Agfa IMPAX 6.5.2.2016). The majority of raw data were also processed 
using TARQUIN (Totally Automatic Robust Quantitation in NMR) v3.2.2 (Wilson et al., 
2011). Example MR spectra processed using scanner software and TARQUIN are shown in 
Figure 3.6. 
Figure 3.6. Example MR spectra processed using scanner software (a) and TARQUIN (b) 
Raw MRS data were sent from scanners to a research and advanced applications PACS 
(Pukka J DICOM explorer version 6.1.1) and exported to a dedicated server for processing 
with results added back to that PACS system. Data were made available to radiologists 
through the automatic export to the hospital clinical PACS. Processing provided a graphical 
magnetic resonance spectrum (MRS) and tissue metabolite profile, as depicted in Figure 3.6.  
 
Radiologists in Birmingham Children’s Hospital were invited to attend one of two 1.5 hour 
teaching sessions on the theory and interpretation of MRS, conducted by a researcher (K.M.) 
and expert spectroscopist and paediatric oncologist (A.P.). The information in this section 
summarises the content of those sessions. 
 
As with all imaging investigations, quality of MRS must be assessed prior to interpretation. 
Radiologists were taught to perform a visual quality control assessment of all MR spectra 
included in the studies described in this thesis. There are two main aspects to determining if a 
spectrum meets quality control criteria: 
1) Assessing the proportion of tumour and other tissues in the voxel. The spectrum 
obtained will be a combination of the spectra from these tissues, and normal brain 
in particular contains many metabolites.  
2) Assessing the spectral quality itself – signal:noise ratio (SNR), line width, 
phasing, baseline and artefact. For this, it is important to determine if the choline 
peak is at least 5 times that of the noise, and if the choline and creatine peaks are 
well separated. 
Figure 3.7. Examples of MR spectra failing quality control (Harris et al., 2007)  
A) Example of poor SNR. The choline peak is less than 5 times that of the noise. The poor SNR may 
be due to voxel placement over cyst or too few averages for voxel size. In this example, the large lipid 
peaks are due to voxel placement over scalp. (
B) Example of poor line width. Choline and creatine peaks are coalesced. Poor line width may be due 
to voxel placement close to bone, or heterogeneity within the voxel. In this example, the voxel 
placement includes normal brain as suggested by high N-acetyl aspartate.  
 
Mean MR spectra are derived from combining data from all spectra obtained from tumours of 
a certain type in a certain location at a specified field strength. Mean spectra vary 
considerably between tumour types. In the example mean spectra below (infratentorial 
pilocytic astrocytoma at 1.5T) (Figure 3.8.), mean metabolite peaks are depicted by a solid 
black line, with standard deviation represented by grey shading. The number of cases from 
which the mean spectrum is determined is provided, with spectra being more accurate when 
containing data from a large number of cases. 
Figure 3.8. Example mean MR spectrum (n=15) – pilocytic astrocytoma 
Radiologists were advised to reduce their differential diagnosis as much as possible on 
clinical features and conventional imaging prior to using mean MR spectra to facilitate 
diagnosis. It is thought that MRS is most likely to be helpful if radiologists have two 
candidate diagnoses with very different mean spectra than if they are looking for a match 
from the spectra of a large set of diagnoses each with slightly different spectra. 
 
Radiologists were provided with a booklet containing mean MR spectra for common tumour 
types in different locations (supratentorial and infratentorial) at 1.5T and 3T, which was 
designed and compiled as part of this PhD (Appendix 3). The following instructions for use 
of mean spectra to facilitate diagnosis were provided: 
1. Formulate a list of differential diagnoses using clinical features and conventional 
imaging sequences 
2. Assess data quality of case spectrum: 
  Is the voxel positioned correctly? 
 Are the SNR and line width acceptable? 
     3.   Compare the mean spectra from the main differential diagnoses to that of the case 
spectrum 
 
Radiologists were taught that differences in mean spectra are accounted for by location 
(supratentorial or infratentorial), echo times and field strength (1.5T or 3T).  
 
Histopathology reports for all biopsied or surgically excised body and brain tumours were 
obtained from the official hospital results reporting system (Sunquest ICE Desktop Live, 
version 541). Results of first authorised histopathology reports, central review, and alterations 
in initial histopathological diagnosis were documented. The time from initial imaging and 
biopsy or surgery to definitive histopathological diagnosis was recorded. Unbiopsied cases 
and those with inconclusive histopathology were reviewed, and the reasons for lack of biopsy 
or tissue diagnosis were documented.  
 
Body tumours were diagnosed by histopathological review of tissue obtained through biopsy 
or following surgical resection, with diagnosis confirmed by the Solid Tumour Multi-
Disciplinary Team (MDT). The Solid Tumour MDT consisted of paediatric oncologists, 
paediatric radiologists, paediatric surgeons, clinical oncologists and histopathologists The 
reference standard for brain tumour diagnosis was the Paediatric Neuro-Oncology MDT 
consensus diagnosis, incorporating clinical information, MRI, MRS, histopathology, second 
opinion, genetics and follow-up information about treatment response and tumour behaviour. 
The Neuro-Oncology MDT consisted of paediatric oncologists, paediatric radiologists in part 
specializing in neuroradiology, neurosurgeons, clinical oncologists and histopathologists. 
Consensus diagnosis was confirmed once clinical course had been established at study end.  
 
Statistical analysis was performed using SPSS Statistics (v. 23, Chicago, IL) and MiniTab (v. 
17.1) software. 
 
ADC and IVIM histogram parameters (median ADC, skewness, kurtosis, entropy and 5th, 
15th, 25th, 75th and 95th centile values) are continuous variables and not normally distributed. 
The Mann-Whitney U and Kruskal-Wallis tests were used to perform comparison of 
differences in non-normally distributed histogram parameters between two tumour types or 
between individual tumours at diagnosis. P<0.05 was taken as indicating statistical 
significance.  
 
The issue of multiple comparisons was considered, given concurrent evaluation of various 
ADC percentile values, skewness, kurtosis and entropy. The area under the ROC curve 
(AUC) was examined to assess diagnostic abilities of ADC median and attempt identify a 
cut-off value for differentiating benign from malignant lesions, aiming to maximize the sum 
of sensitivity and specificity. 
 
Comparisons of ADC and IVIM histogram parameters (median, skewness, kurtosis, entropy 
and 15th, 25th and 75th centile values) from pre- and post-chemotherapy parameters were 
performed using the Wilcoxon signed rank test with p<0.05 considered statistically 
significant. The Wilcoxon signed ranked test is used for paired analyses of non-normally 
distributed data. Histogram shift in response to treatment was analyzed through comparing 
changes in median, 15th, 25th and 75thcentiles, skewness, kurtosis and entropy to identify the 
optimal parameters for identifying response to chemotherapy. Correlations between change in 
tumor volume and histogram parameters were ascertained using Spearman rank correlation. 
Pre-treatment ADC and IVIM parameters and change in tumour volume and histogram 
parameters in survivors and patients who had died were analyzed and compared. The volume 
of highly malignant tumour pre- and post-chemotherapy was compared and reviewed in 
context of clinical course. 
 
To assess significance of inter-rater variability of ADC histogram parameters, comparison of 
not normally distributed data (median, 15th, 25th, 75th and 95th percentile ADC) was 
performed using the Wilcoxon test. The Friedman test compared the WT and SS methods of 
ROI construction for determining ADC parameters for each radiologist separately, and 
investigated any interaction between method and inter-rater variability. The Mann-Whitney U 
test was used to compare ADC histogram parameters of benign and malignant tumour groups 
determined from WT and SS ROI construction. 
 
Assessment of inter-rater variability of ROI construction was performed using Bland Altman 
Statistics. Bland-Altman plots (Figure 3.9.) with limits of inter-observer agreement (mean 
difference +/- 1.96 x standard deviation) were constructed to analyse ADC histogram 
parameter reproducibility between radiologists and WT and SS methods of ROI construction.  
Figure 3.9.  Example Bland-Altman Plot used to assess inter-rater agreement and estimate bias. The 
line of mean difference indicates bias resulting from systematic differences between the two readers. 
This example demonstrates a randomly distributed error with the majority of points falling within the 
2SD cut-off, suggesting a high level of inter-rater agreement. 
Comparison of post-MRI and post-MRS diagnosis with MDT consensus determined how 
many cases were correctly diagnosed in accordance with the reference standard at each stage. 
Accuracy of MRI +/- MRS for each category of brain tumour (all locations, and 
supratentorial, and infratentorial) was made through estimates of sensitivity. Proportions were 
reported with 95% confidence intervals calculated from the Binomial distribution. 
McNemar's test was used to determine if MRS had a statistically significant effect on correct 
diagnosis compared with MRI alone. Significance of direction of change towards 
improvement with MRS was established using the McNemar Ordered Category test of 
Directional Change, and increase in radiologists’ agreement on correct diagnoses was 
assessed using the Bhapkar Chi-squared test (Bhapkar, 1966). 
 
As different types of solid paediatric tumours have overlapping imaging characteristics, non-
invasive discrimination of benign from malignant lesions can be difficult using conventional 
MRI alone (Abdel Razek et al., 2012). Diffusion-Weighted Imaging (DWI) has shown 
promise in facilitating non-invasive diagnosis of paediatric tumours through calculation of 
ADC (mm2/s), a quantitative measure of diffusion with an inverse relationship with 
cellularity (Kralik et al., 2014). Studies have shown median ADC of malignant paediatric 
body lesions to be significantly lower than benign lesions (Abdel Razek et al., 2009; 
Kocaoglu et al., 2010), with recent research suggesting ADC can characterise tumours and 
differentiate between tumour types (Abdel Razek et al., 2009; Kocaoglu et al., 2010).  
 
ADC histograms, constructed by drawing a region of interest (ROI) around a tumour, could 
provide additional visual and quantifiable information about imaged tissue through 
demonstrating peaks that correspond to distinct cellular subpopulations (Hales et al., 2015). 
Although median ADC provides an overall measure of average cellularity across a lesion, 
tumours are heterogeneous masses consisting of a mixture of histological cell types 
interspersed with cysts and necrosis. Visual interpretation of histogram shape may add value 
to information obtained from conventional imaging, and calculating quantitative histogram 
parameters such as ADC values at different centiles, skewness, kurtosis and entropy could 
facilitate more detailed and objective tumour characterisation. Whole tumour ADC histogram 
analysis has shown promise in diagnosing and grading paediatric brain lesions (Bull et al., 
2012), differentiating tumour type and grade in adults (Pereira et al., 2015; Mimura et al., 
2016; Hao et al., 2016) and characterising the cellular composition of Wilms tumours 
following induction chemotherapy (Hales et al., 2015). 
 
The measured DW signal is influenced by perfusion in addition to diffusion, which can limit 
the reliability of the ADC measurement. The intravoxel incoherent motion (IVIM) model 
uses information from multi b-value DWI to separate the pure diffusion component (D) from 
pseudodiffusion (D*) arising from microcirculatory perfusion, and allows calculation of a 
perfusion fraction (f) reflecting signal from the vasculature (Le Bihan et al., 1988). D* is not 
commonly reported in the literature as it is difficult to determine accurately. Although IVIM 
provides additional information for tumour characterisation, acquisition and analysis are 
more complex than ADC, which can be calculated from only two b-values. IVIM parameters 
can be helpful in discriminating benign from malignant lesions in adults (Kang et al., 2014; 
Klauss et al., 2016), but additional value over ADC has not been established in children.  
 
There is a paucity of evidence evaluating ADC or IVIM histogram analysis for discriminating 
benign from malignant paediatric tumours or distinguishing tumour type at diagnosis. 
Research is needed to determine the added value of visual interpretation of DWI histograms 
and quantitative analysis of histogram parameters over conventional MR imaging, and 
establish how to present this information to clinicians to facilitate clinical decision-making. 
 
Developing a clinical decision support system (CDSS), MIROR, could make complex 
information from DWI histogram analysis more accessible and comprehensible for clinicians. 
Building a tumour repository within MIROR incorporating information from statistical 
parameters found to differ significantly between benign and malignant tumour groups would 
allow development of a diagnostic tool to facilitate tumour classification through comparison 
of new cases with data representative of different tumour types. 
 
This chapter aimed to explore the role of visual interpretation and quantitative analysis of 
ADC histograms in discriminating benign from malignant solid tumours in children, and 
ascertain the potential for differentiating tumour type. The potential additional value of IVIM 
analysis will also be explored. A further aim was to develop MIROR as a CDSS through 
creating a repository of benign and malignant tumours with which future cases could be 
compared to facilitate classification. 
 
Children with solid tumours (ages 0-16 years) undergoing diagnostic MRI with DWI at 
Birmingham Children’s Hospital from June 2012 - September 2016 were eligible for 
inclusion in this observational study. Data were acquired both retrospectively and 
prospectively. Patients with lymphatic malformations were excluded because of characteristic 
findings on routine MRI. 
 
Patients underwent 1.5T MR examination using the imaging protocol described in Methods, 
Chapter 3. DWI was acquired using between two and six b-values (b = 0, 50, 100, 150, 600, 
1000 s/mm2). Total scan duration ranged from 1 min 37 sec to 2 min 42 sec for two b-values 
(b = 0 and b = 1000 s/mm2 for ADC calculation), and up to 7 min 32 sec to acquire all six 
necessary for IVIM analysis.  
MRI datasets including ADC maps were transferred into MIROR, where ROIs were drawn 
around the entire solid tumour on high-resolution b0 images after review of the whole 
conventional MRI set by an experienced radiologist (KF, 10 years’ experience) and overlaid 
on matched parametric ADC maps. 
 
Advanced histogram analysis was performed in MIROR. All patients were imaged with at 
least the two b-values necessary for ADC histogram analysis. IVIM analysis was performed 
in a subset of patients in whom all six b-values had been acquired, obtaining histograms for 
the parameters D and f. Mean ADC histograms for benign and malignant tumours, and for 
individual tumour types, were created using pooled data and visually compared. ADC and 
IVIM histogram parameters including median, 5th, 15th, 25th, 75th and 95th percentile values, 
skewness, kurtosis and entropy were calculated and compared between groups. 
 
MIROR was developed as a clinical decision support system (CDSS) for DWI of body 
tumours children using this tumour cohort. Information derived from statistical analysis of 
ROIs of parametric ADC maps of individual benign and malignant tumours was extracted 
and stored in the repository for future comparison with new cases.  
 
Comparisons of non-normally distributed data (median, 5th, 15th 25th, 75th and 95th centile 
ADC or IVIM parameters, skewness, kurtosis and entropy) from pre-treatment images of 
benign and malignant tumours were analyzed using the Mann-Whitney U test, with p<0.05 
considered statistically significant. Sample sizes for individual tumour types were too small 
to make statistical comparisons meaningful or reliable. Area under the ROC curve (AUC) 
analysis was used to assess diagnostic ability of ADC median as a representative parameter 
and attempt to identify a cut-off value for malignancy.  
 
Fifty-five children were identified, of which fifty (37 malignant and 13 benign tumours) were 
recruited. Five patients were excluded because of incomplete images (n=2), inadequate size 
(n=2), and diagnosis of lymphatic malformation (n=1). Demographic data for all patients is 
shown in Table 4.1. A subset of forty-two patients (32 malignant and 10 benign tumours) had 
multi-b-value DWI data available as required for IVIM analysis.  
Table 4.1. Demographic data of all patients (cases with IVIM in brackets) 
Lesion Cases (IVIM) Mean age, range (yrs) Sex (F/M) 
Malignant 37  (32) 3.94 (0.03-11.82) 16/21 
    Wilms’ tumour 14  (9)   
    Neuroblastoma 11  (11)   
    Hepatoblastoma 4    (4)   
    Rhabdomyosarcoma 3    (2)   
    Rhabdoid 2    (2)   
    Clear cell sarcoma 1    (1)   
    Ewing’s sarcoma 1    (1)   
    Germ cell 1    (1)   
    Osteosarcoma 1    (0)   
Benign 13 (10) 3.63 (0.03 – 14.22) 6/7 
    Liver haemangioma 1    (1)   
    Ganglioneuroma 4    (3)   
    Mesoblastic nephroma 2    (1)   
    Lipoma 1    (1)   
    Infantile myofibromatosis 1    (1)   
    Haematocolpos 1    (0)   
    Vascular malformation 1    (1)   
    Ovarian immature teratoma 1    (1)   
    Abscess 1    (1)   
 
An example T2-weighted MRI, ADC map, ROI and corresponding ADC histogram from a 3 
year-old patient with a Wilms tumour is shown in Figure 4.1. 
 
Figure 4.1. a-c. Example ROI and corresponding ADC histogram: Wilms tumour. MRI shows a 
heterogeneous tumour arising from the right kidney. Solid components restrict diffusion. ADC map 
was obtained and a whole-tumour ROI selected (b). The corresponding histogram (c) appears shifted 
to the left and positively skewed with a sharp peak, as reflected through quantitative values obtained: 
ADC median 0.74 x 10-3 mm2/s, skewness 0.0238, kurtosis 2.18, and entropy 6.83.  
Mean ADC histograms of benign and malignant tumours appear morphologically different, as 
shown in Figure 4.2. The pooled mean histogram of malignant tumours is shifted to the left, 
positively skewed and peaked with a higher kurtosis, whereas that of benign tumours is 
shifted to the right, negatively skewed, and flatter with a lower kurtosis.  
Figure 4.2. The morphological differences between pooled mean histograms of benign (n=13) and 
malignant (n=37) tumours. The mean is represented by the solid line, and Standard Deviation (SD) by 
the shaded area. 
Mean pooled histograms of individual tumour types also different visually (Figure 4.3.), 
indicating potential value of ADC histogram analysis in distinguishing tumour type in a 
larger cohort. 
Figure 4.3. The morphological differences in appearance of mean pooled histograms of benign 
tumours (n=13), neuroblastoma (n=11), rhabdomyosarcoma (n=3), hepatoblastoma (n=4) and Wilms 
tumours (n=14).
Quantitative differences in ADC histogram parameters between benign and malignant 
tumours are shown in Table 4.2. As the median volume of benign lesions was significantly 
less than malignant ones, histograms were normalised to an area of unity.  
 
Malignant tumours demonstrated significantly lower median, 5th, 15th, 25th, and 75th centile 
ADC values, more positive skewness, higher kurtosis and higher entropy than benign lesions. 
ADC centile values at the extreme right of histograms did not differ significantly between 
benign and malignant tumours, with no significant difference between 95th centile ADC 
values.  Detailed histogram parameters from ADC maps of benign and malignant tumours are 
summarised in Table 4.2. Comparison of histogram parameters (median ADC, skewness, 
kurtosis and entropy) of benign and malignant tumours is shown in box plots (Figure 4.4.). 
Table 4.2. Comparison of ADC histogram parameters between benign and malignant childhood 
tumours  
 Malignant  (n=37) Benign (n=13) P value 
Volume* (ml) 31791 (624-149554) 4943 (376-142436) 0.006* 
ADC median* 0.97 (0.42-1.57) 1.57 (0.73-2.64) 0.015* 
ADC 5%* 0.55 (0.30-1.00) 0.98 (0.22-1.37) 0.008* 
ADC 15%* 0.71 (0.35-1.11) 1.07 (0.39-1.54) 0.005* 
ADC 25%* 0.75 (0.39-1.29) 1.37 (0.52-2.17) 0.001* 
ADC 75%* 1.31 (0.47-1.93) 1.68 (0.93-2.92) 0.011* 
ADC 95% 1.99 (0.86-2.87) 1.91 (1.21-3.23) 0.514 
Skewness* 0.0226 (0.0139-0.0269) -0.0006 (-0.023-0.0292) <0.001* 
Kurtosis* 2.22 (1.99-2.25) 2.03 (1.80-2.03) <0.001* 
Entropy* 7.27 (5.79-7.84) 6.80 (6.22-7.67) 0.05* 
Data are presented as median and range; asterisks denote statistical significance p<0.05. 
The unit for ADC value is x 10-3 mm2/s 
Figure 4.4. Box plots show comparison of ADC histogram parameters (ADC median, skewness, 
kurtosis and entropy) for benign and malignant paediatric tumours. Line in box represents the median, 
height of the box represents the interquartile range, whiskers are the lowest and highest data points 
within 1.5 interquartile range, and asterisks indicate outliers. 
4.3.3. Quantitative discrimination between Malignant and Benign Childhood Tumours 
using IVIM parameters 
The differences in ADC and IVIM histogram parameters D and f between benign and 
malignant tumours in the subset of patients undergoing IVIM analysis is shown in Table 4. 
 
Table 4.3. Comparison of benign (n = 10) and malignant (n = 32) lesions with ADC, D and f 
histogram parameters 
Parameter Mann-Whitney test  
 ADC D F 
Median 0.001* 0.049* 0.320 
5% 0.005*              0.056 0.919 
15% 0.003*              0.051 0.543 
25% 0.002* 0.045* 0.248 
75% 0.007*              0.052 0.494 
95%              0.202              0.112 0.760 
Skewness <0.001* 0.018* 0.122 
Kurtosis <0.001*              0.740 0.631 
Entropy        0.036*             0.081    0.965 
Asterisks denote statistical significance p<0.05 
In this subset of cases, both ADC and D were lower in malignant tumours. There was a 
significant difference in all ADC histogram parameters between benign and malignant 
tumours other than 95th centile, with the latter demonstrating significantly lower median, 5th, 
15th, 25th, and 75th percentile ADC, and higher kurtosis, skewness and entropy. Significant 
differences in the D parameter were only observed through lower median and 25th percentile 
and higher skewness in malignancy. There were no significant differences in any measure of 
the f parameter between benign and malignant lesions. 
It was not possible to discriminate individual malignant tumour types in this small cohort. 
Given the small numbers involved, it was inappropriate to look for statistically significant 
differences in ADC histogram parameters between individual malignant tumour types or 
attempt to construct accurate predictive models. Patients with Wilms tumours, 
neuroblastomas, hepatoblastomas and rhabdomyosarcomas had ADC median values of 0.90, 
0.96, 1.00, and 1.02 x 10-3 mm2/s, kurtosis of 2.21, 2.25, 2.23 and 2.10, and skewness of 
0.0229, 0.0227, 0.0224 and 0.0183 respectively. 
 
Of clinical relevance, malignant neuroblastoma (n=11) appears distinguishable from benign 
ganglioneuroma (n=4) through morphologically different ADC histograms, with those of the 
former demonstrating left shift with significantly lower median, 5th, 15th, 25th and 75th centile 
ADC, more positive skewness and higher kurtosis. Entropy did not differ significantly. The 
small group sizes imply this pattern needs confirmation with more cases. Example ADC 
histograms of neuroblastoma and ganglioneuroma are shown in Figures 4.5a and b, with 
detailed histogram parameters presented in Table 4.3. 
Figure 4.5.a Neuroblastoma                                       b. Ganglioneuroma 
 
4.5.a. A 2 year-old girl with a left sided neuroblastoma. Axial T2-weighted image (a) shows a large 
abdominal mass lying anterior to the left kidney. ADC map was obtained and a whole-tumour ROI 
selected (b). The corresponding histogram of the neuroblastoma (c) is shifted to the left and positively 
skewed, as reflected by ADC median 0.99 x 10-3 mm2/s, skewness 0.0217, kurtosis 2.25 and entropy 
7.47 
 
4.5.b. A 6 year-old boy with a left-sided ganglioneuroma. Axial T2-weighted image (a) shows a well-
defined round mass in the left side of the abdomen. The mass enhances heterogeneously and does not 
restrict diffusion.  ADC map was obtained and a whole-tumour ROI selected (b). The corresponding 
histogram of the ganglioneuroma (c) is shifted to the right and negatively skewed as reflected by ADC 
median 1.58 x 10-3 mm2/s, skewness -0.0196, kurtosis 2.029 and entropy 6.50. 
Table 4.4. Comparison of ADC histogram parameters between neuroblastoma and ganglioneuroma 
 Neuroblastoma (n=11) Ganglioneuroma (n=4) P value 
Age* 1.48 (0.05-5.63) 7.45 (0.79-9.72) 0.01* 
Volume (ml) 17642 (624-75125) 3870 (376-24196) 0.117 
ADC median* 0.96 (0.63-1.31) 1.64 (1.40-1.91) 0.004* 
ADC 5%* 0.53  (0.31-0.82) 0.99 (0.86-1.29) 0.004* 
ADC 15* 0.64 (0.42-0.89) 1.23 (1.03-1.35) 0.004* 
ADC 25%* 0.72 (0.54-0.99) 1.42 (1.26-1.49) 0.004* 
ADC 75%* 1.31 (0.91-1.92) 1.92 (1.54-2.26) 0.009* 
ADC 95% 1.83 (1.34-2.86) 2.19 (1.74-2.57) 0.296 
Skewness* 0.0227 (0.0179-0.0269) -0.0192 (-0.0230 -0.0136) 0.004* 
Kurtosis* 2.25 (2.029-2.25) 2.04 (1.95-2.10) 0.009* 
Entropy 7.37 (6.26-7.81) 6.59 (6.22-7.55) 0.19 
Data are presented as median and range; asterisks denote statistical significance p<0.05. 
The unit for ADC value is x 10-3 mm2/s. 
The representative parameter median ADC has an AUC of 0.77; 95%CI 0.69-0.87; p=0.001) 
in differentiating benign from malignant lesion, with a 1.01 x10-3 cut-off value yielding 
sensitivity 80.1%, specificity 81.2%. The ROC curve is shown in Figure 4.6. 
 
Figure 4.6. ROC curve analysis for ADC median distinguishing benign from malignant tumours 
 
The statistical information derived from ADC histogram analysis of individual benign and 
malignant tumour cases was incorporated into the tumour repository within MIROR to allow 
its development as a CDSS and diagnostic tool. Following this study, MIROR contained a 
repository of 13 benign and 37 malignant tumours from which comparisons can be made with 
new cases to facilitate discrimination. Statistical data concerning histogram parameters found 
to be significantly different between benign and malignant tumour groups were incorporated 
into the diagnostic tool to allow comparison of values from new cases with those in the 







Figure 4.7. MIROR user-interface analysis tab, demonstrating MIROR as a decision support system 
to differentiate benign from malignant tumours. The green histogram line represents the index case, 
and the red line and grey area represent the mean and standard deviation of malignant (a) and benign 
tumours (b) respectively. The example box-plots compare median, 25th percentile, skewness and 
entropy values of the index case with tumour types in the repository. 
ADC histograms derived from benign and malignant paediatric body tumours are different, 
which is apparent both through visual interpretation of histogram shape and through 
quantitative analysis of ADC histogram parameters. The morphological differences between 
ADC histograms of benign and malignant tumours could potentially be used in clinical 
practice, with visual interpretation of ADC histograms enhancing radiological interpretation 
of DWI and facilitating non-invasive diagnosis. Quantitative histogram parameters, such as 
ADC percentile values, skewness and kurtosis, were significantly different between benign 
and malignant lesions. IVIM analysis does not confer any additional advantage over the more 
easily acquired and clinically applicable ADC. Incorporating the statistical information 
acquired in a repository within MIROR has contributed to development a clinical decision 
support system (CDSS) aiming to facilitate discrimination of benign and malignant tumours 
in clinical practice. 
 
Visual interpretation of ADC histograms or quantitative analysis of histogram parameters has 
not previously been used to discriminate childhood tumours. Paediatric studies evaluating 
mean or median ADC (Kocaoglu et al., 2010; Lope et al., 2010) do not account for tumour 
heterogeneity, which cannot be conferred though a global parameter. Macroscopic and 
microscopic intra-lesional necrotic and cystic areas may impact ADC, with necrotic 
components demonstrating high values, and cysts a range of values reflecting haemorrhage, 
mucinous and serous fluids. Rather than simply providing a numerical ADC value, 
histogram-based evaluation elucidates visual information and statistical features that reflect 
overall histological tumour characteristics and may be useful for qualitative and quantitative 
radiological evaluation.  
 
ADC histograms of malignant tumours were more positively skewed than those of benign 
tumours; this was apparent visually and confirmed as statistically significant on quantitative 
analysis. Positive skewness could equate to high cellularity reflected by dense population of 
the left end of the histogram, with more pixels with low ADC lying left of the mean but 
supportive tissue giving a long tail at high ADC values. Similar findings have been reported 
in adults (Suo et al., 2014), with higher grade tumours demonstrating more positively skewed 
histograms than lower grade lesions (Pereira et al., 2015).  
The finding of a visually apparent and significantly higher kurtosis in ADC histograms in 
malignant tumours, with a distinct peak and rapid decline, implies more uniform cellularity. 
Homogeneous tumours with uniform arrangement of malignant cells have a steep histogram 
peak, whereas heterogeneous lesions with cystic, necrotic or haemorrhagic components show 
low kurtosis (Takahashi et al., 2015). Studies in adults have reported significantly higher 
kurtosis in malignant (Suo et al., 2014) and high-grade tumours (Pereira et al., 2015).  
 
Statistical parameters representing the left side of the histogram may be most discriminatory 
of tumour type as more aggressive components are represented by lower ADC centiles. The 
extreme right may correspond to non-malignant tissue included in the whole-tumour ROI, 
such as normal renal tissue or stromal components. We found ADC centiles representing the 
extreme left of the histogram (5nd-25th centile) significantly different between malignant and 
benign lesions, whereas those corresponding to the extreme right  (95th centile) were not. The 
adult literature has reported high levels of significance of 10% ADC (Mimura et al., 2016) in 
discriminating benign from malignant lesions, with a report of ADC parameters representing 
the left side of the histogram distinguishing degrees of differentiation of hepatic malignancy 
(Drevelegas et al., 2016).  
 
ADC histogram analysis performed better than IVIM in differentiating benign and malignant 
tumours. Although discrimination was possible with certain parameters derived from 
histogram analysis of IVIM D, robustly significant differences in ADC were consistently 
observed across all percentiles (other than 95th) and descriptors of histogram shape. 
The f parameter did not reach significance, which may be due to the variation in vascularity 
between tumours in our cohort.  As ADC is influenced by both D and D*, the combination of 
diffusion and perfusion into a single parameter may allow for its higher diagnostic 
performance. The excellent comparative performance of ADC has important implications for 
clinical practice as quantitative ADC analysis is far simpler and quicker to perform than 
IVIM, and may be more easily incorporated into the clinical workflow. 
 
It is important to consider clinical application of ADC histogram analysis and potential to add 
value to conventional imaging. Distinguishing between tumours with similar morphological 
appearances on conventional MRI, such as neuroblastoma and ganglioneuroma, or Wilms 
and rhabdoid tumours, would be of considerable clinical benefit.  We were able to show 
clearly visually apparent and quantifiably significant differences in ADC histogram 
parameters between neuroblastomas and ganglioneuromas. This should be interpreted 
cautiously given small numbers involved, but nonetheless is a promising finding warranting 
further investigation. ADC was found to be significantly lower in neuroblastoma than 
ganglioneuroma in a small paediatric study (Gahr et al., 2011), and further work is needed to 
establish the role of histogram analysis in this area. 
 
The possibility of translating research findings into clinical practice is an important 
consideration when determining added value of advanced imaging techniques. ADC values 
derived from b0 and 1000 s/mm2 values calculated by scanner software were used as these 
are readily available to radiologists and reflect what is currently possible in a clinical setting. 
Incorporating DWI data into MIROR as a CDSS may prove a valuable way of integrating 
advanced ADC histogram analysis into the diagnostic pathway and allowing objective 
classification according to quantifiable parameters. Prospective testing is necessary to 
ascertain the added value of ADC histogram analysis through MIROR over conventional 
MRI in differentiating benign from malignant childhood tumours in clinical practice. 
 
Study limitations should be considered.  Groups of benign and malignant tumours are 
unbalanced, and the current version of MIROR was developed with a limited set of 
retrospective data. There were insufficient cases of individual malignant tumour types to 
explore the role of these techniques in differentiating tumour type. Future work will involve 
adding new tumours to the continually evolving repository within MIROR to improve the 
predictive ability of identified biomarkers for benign and malignant lesions. 
 
ADC histograms of benign and malignant tumours are morphologically and quantifiably 
different. ADC histograms of malignant lesions are shifted to the left, with more positive 
skewness and higher kurtosis than benign tumours. Incorporation of this data into MIROR 
has facilitated its development as a CDSS and diagnostic tool to make ADC histogram 
analysis accessible and comprehensible to clinicians in the future. Prospective evaluation is 






Incorporating information from quantitative ADC histogram analysis into the clinical 
decision-making process could facilitate confident non-invasive diagnosis of solid paediatric 
body tumours. Earlier work described in this thesis suggests both visual interpretation of 
ADC histograms and quantitative analysis of derived parameters could assist radiological 
discrimination of benign from malignant tumours. Radiologists currently use DWI clinically 
in a purely qualitative manner to help tumour characterisation, reviewing and commenting on 
diffusion restriction as a possible marker of malignancy. Although quantitative ADC 
histogram analysis may provide a more objective evaluation of the diffusion characteristics of 
an imaged lesion and confer valuable additional information regarding its malignancy, the 
techniques involved are not yet validated and remain unavailable clinically. 
 
Work described in Chapter 4 shows ADC histograms for benign and malignant tumours 
appear morphologically different, with visually observable variances substantiated by 
significant quantitative differences in parameters related to histogram shape. Histograms of 
malignant tumours tend to be positively skewed, with left shift and high kurtosis, whereas 
those of benign tumours are comparatively negatively skewed and shifted to the right with a 
lower kurtosis. Visual comparison of the histogram of an undiagnosed tumour with mean 
histograms of benign and malignant lesions could thus facilitate tumour categorisation.  
 
Quantitative histogram parameters may provide additional information to aid classification. It 
was shown in Chapter 4 that malignant tumours have significantly lower median, 5th, 15th, 
25th and 75th centile ADC values, higher kurtosis, more positively skewed histograms and 
higher entropy than benign lesions. Although increasingly recognised in the adult literature 
(Pereira et al., 2015; Mimura et al., 2016; Hao et al., 2016), no study has prospectively 
evaluated the added value of either visual interpretation of ADC histograms, or parameters 
derived from quantitative ADC histogram analysis, over conventional MRI in discriminating 
benign from malignant paediatric solid tumours at diagnosis.  
 
The advanced imaging data necessary for ADC histogram analysis is complex to acquire and 
interpret, forming a barrier to its clinical use. Clinical decision support systems (CDSSs) 
facilitate interpretation and analysis of novel MRI techniques through presenting information 
to clinicians in a clear and intelligible way. As previously described, a modular medical 
image region of interest analysis tool and repository (MIROR) is being developed by our 
research team as a CDSS for automatic processing and classification of advanced MRI data 
(Zarinabad et al., 2018). MIROR uses advanced quantitative analysis to evaluate multi b-
value DWI data and compare it with results from previous cases stored within a repository, 
the formation of which is described in Chapter 4.  
 
MIROR could potentially guide clinicians through ADC histogram analysis in real time, 
enabling integration of this technique into clinical practice. A clinician can draw a ROI 
around a tumour and derive an ADC histogram, from which parameters such as median and 
various percentile ADC values, skewness, kurtosis and entropy are extracted and stored. 
MIROR allows visual comparison of a case histogram with mean histograms of benign and 
malignant tumours, and comparison of quantitative histogram parameters with those 
previously shown to discriminate between tumour types. CDSS cross-validation of MIROR 
has shown high sensitivity and specificity in discriminating between benign and malignant 
tumours using quantitative histogram parameters, with median, 15% and 75% ADC highly 
discriminatory (Zarinabad et al., 2018). Quantitative values for skewness, kurtosis and 
entropy show promise in this area, but further work is required to determine robust 
discriminatory cut-off values for these more novel descriptors. Additional information 
derived from ADC histogram analysis may add value to that obtained through conventional 
imaging to facilitate diagnosis, particularly in more difficult or ambiguous cases. 
 
This chapter aimed to prospectively evaluate the added value of quantitative ADC histogram 
analysis using MIROR as a CDSS in aiding clinicians to non-invasively discriminate between 
benign and malignant solid paediatric tumours. Both visual interpretation of ADC histogram 
shape and quantitative analysis incorporating previously published values of median, 15% 
and 75% ADC for benign and malignant tumours (Zarinabad et al., 2018) were investigated.  
 
Children aged 0-16 with solid lesions having imaging characteristics sufficiently suggestive 
of malignancy to require discussion at the Solid Tumour Multidisciplinary Team Meeting 
(MDT) were eligible for inclusion in this prospective study. All included children underwent 
diagnostic MRI with DWI at Birmingham Children’s Hospital between February 2017 and 
July 2018. Exclusion criteria were treatment prior to imaging, incomplete MRI, and lack of 
available DWI for advanced analysis. Thirty-three children were included.  
 
Patients underwent 1.5T MR examination with multi b-value DWI using the imaging 
protocol described in Methods, Chapter 3. MRI datasets including ADC maps were 
transferred to local research PACS prior to upload into MIROR for further analysis. 
 
Two radiologists (SA, 1 year experience and KF, 10 years’ experience) reviewed all imaging 
and ADC histogram outputs. Radiologists were given information about the age and gender 
of each child and their clinical presentation, and asked to sequentially view 1) conventional 
imaging sequences and 2) DWI and ADC maps processed using scanner software, as 
currently performed in routine clinical practice. Radiologists were asked to comment at each 
stage as to whether the lesion appeared benign or malignant and whether they would 
recommend biopsy. A list of up to four differential diagnoses was requested at each stage. All 
reporting was undertaken independently and blind to histopathological and final diagnoses. 
 
Radiologists used MIROR to construct a whole tumour ROI guided by conventional imaging, 
and derived an ADC histogram with quantitative ADC parameters. Following 3) visual 
comparison of the ADC histogram of the index case with mean histograms of benign and 
malignant tumours from the MIROR repository, radiologists were asked to determine 
whether the lesion was benign or malignant, whether biopsy was recommended, and to 
provide a revised list of differential diagnoses. Radiologists were finally asked to 4) compare 
the quantitative median, 15th and 75th percentile ADC of the lesion calculated in MIROR with 
previously determined median values for benign and malignant tumours (Zarinabad et al., 
2018).  
 
Factors contributing to the clinical decision-making process in discriminating benign from 
malignant lesions were documented for each case. A semi-structured interview was 
conducted at study end to determine radiologists’ perception of the added value and clinical 
applicability of ADC histogram analysis and MIROR as a CDSS. 
 
Figure 5.1. shows an example of the decision support system within MIROR for 
differentiating between benign and malignant tumours. Example mean histograms from the 
repository for benign and malignant tumours are shown in Figure 5.2. 
Figure 5.1. Extracts from the CDSS within MIROR for differentiating between benign and malignant 
tumours (The GUI for benign v malignant is shown in Chapter 4, Figure 4.7). The index case 
histogram (green) is superimposed on mean histograms for benign and malignant tumours (mean = 
red line; standard deviation = grey shaded area). In this example of a Wilms tumour, it can be seen 
that the green index case histogram closely matches the mean histogram for malignant tumours. 
Example mean histograms for benign and malignant tumours. The histogram for benign 
tumours has a negative skew and is shifted to the right, whereas that of the malignant tumours has a 
positive skew and is shifted to the left. 
Accuracy of conventional MRI and MRI+ADC histogram analysis in terms of correct 
classification of benign and malignant tumours was ascertained through estimates of 
sensitivity, following averaging the percentage of correct diagnoses made by the two 
  
radiologists. McNemar's test determined if ADC histogram analysis had a statistically 
significant effect on correct diagnosis compared with MRI alone. The Kruskal-Wallis test 
was used to compare reference ADC histogram parameters with those from the prospective 
cohort.  
 
Thirty-two children were recruited. One was excluded for lack of conclusive diagnosis, 
leaving 31 for analysis of which 20 were malignant and 11 benign. Patient demographics and 
tumour details are presented in Table 5.1. 
Table 5.1. Demographic data of all patients  
Tumour Median age, years 
(range) 
Gender Diagnosis Patients, 
n 
Benign 3.51 (0.03-14.22) F= 8; M= 4 Ganglioneuroma 1 
   Nephroblastomatosis 2 
   Mesoblastic nephroma 1 
   Vascular malformation 2 
   Ovarian dermoid 1 
   Splenic cyst 1 
   Tuberculoma 1 
   Intra-abdominal extrapulmonary 
sequestration 
1 
   Kaposiform 
haemangioendothelioma 
1 
    11 
     
Malignant 3.85 (0.02-11.82) F= 8; M= 12 Neuroblastoma 6 
   Rhabdoid tumor 2 
   Rhabdomyosarcoma 2 
   Wilms tumour 4 
   Germ cell tumour 1 
   LCH 2 
   Ewing Sarcoma 1 
   Fibrosarcoma 1 
   Retiform Sertoli-Leydig cell 
tumour 
1 
    20 
Histological confirmation of diagnosis was available for 30 of the 31 tumours, a median of 38 
(range 2-298) days after initial imaging. Diagnosis of intra-abdominal pulmonary 
sequestration was made clinically in the remaining case. 
 
The percentage of tumours correctly classified as benign or malignant using conventional 
imaging (MRI and DWI) and with addition of ADC histogram analysis, initially involving 
visual interpretation of ADC histogram shape and then following review of quantitative ADC 
parameters, is shown in Table 5.2. 
Table 5.2. Percentage of tumours correctly classified as benign or malignant using conventional 
imaging (MRI and DWI) and with addition of ADC histogram analysis 
 Conventional MRI  ADC histogram analysis 








































     
Percentages given are averages of results of the two radiologists 
 
The diagnosis of benign and malignant lesions after conventional MRI was accurate in 79% 
of all cases, increasing to 90% with addition of ADC histogram analysis (Table 5.2). Of 
benign tumours, 41% were correctly diagnosed with MRI alone with 73% correctly 
diagnosed after MRI and visual interpretation of the ADC histogram. There was no further 
improvement in classification following review of quantitative histogram parameters. All 
malignant tumours were correctly diagnosed on conventional MRI alone. ADC histogram 
analysis had a statistically significant effect on correct diagnosis for all cases (+11%) (p = 
0.04)) and for benign tumours (+ 34%) (p = 0.014) (McNemar’s Test). The improvement in 
diagnostic accuracy following review of conventional DWI available through scanner 
software did not reach significance. None of the cases incorrectly diagnosed after MRI + 
ADC histogram analysis had previously been correctly diagnosed after MRI alone. 
 
Following conventional MRI alone a splenic cyst, two vascular malformations and a 
ganglioneuroma were correctly diagnosed as benign by both radiologists. Addition of 
conventional DWI through review of ADC maps resulted in further correct benign diagnosis 
of nephrogenic rests by radiologist 2. Following visual interpretation of ADC histograms, 
both radiologists correctly re-diagnosed benign ovarian dermoid, mesoblastic nephroma and 
tuberculoma with radiologist 1 also correctly re-classifying extrapulmonary sequestration and 
radiologist 2 kaposiform haemangioendothelioma. 
 
ADC histogram analysis was not performed in two cases, infantile fibrosarcoma and 
nephrogenic rests, as it was not possible to visualise the lesions clearly enough to construct an 
ROI. Although the infantile fibrosarcoma was correctly classified as malignant by both 
radiologists based on conventional imaging appearances, the nephrogenic rests were correctly 
diagnosed as benign by radiologist 2 only following review of qualitative DWI.  
 
The radiologists’ recommendations for the need for biopsy to confirm benign or malignant 
diagnosis at each stage in the diagnostic pathway are shown in Table 5.3. 
 
 
Information from DWI and ADC histogram analysis resulted in a significant 18% reduction 
in the number of recommendations for biopsy in patients with benign lesions (91% to 73%) 
(p = 0.03), although the 7% reduction for all cases (97% to 90%) did not reach significance (p 
= 0.06) (McNemar’s Test). On MRI appearances alone, biopsy was recommended in all but 
one benign lesion, a splenic cyst. Visual ADC histogram analysis allowed further conclusive 
confirmation of benign diagnosis in an ovarian dermoid tumour and a tuberculoma without 
recommendation for biopsy. Review of quantitative histogram parameters did not prevent 
recommendation of any further biopsies. There were no inappropriate recommendations to 
avoid biopsy in any malignant tumours. 
 
The reference values for median, 15% and 75% ADC of benign and malignant lesions 
included in the MIROR repository, and the values obtained from the tumours in this 
prospective cohort, are shown in Table 5.4. The Kruskal-Wallis test revealed no significant 
differences between reference ADC histogram parameters derived from the original cohort 
and those derived prospectively from patients involved in this study.  
  
Table 5.4. Median, 15th and 75th percentile ADC of the original reference cohort (13 benign, 37 
malignant) and prospectively acquired cases (11 benign, 20 malignant). 
 Malignant Benign 
ADC median reference 0.97 (0.42-1.57) 1.57 (0.73-2.64) 
ADC median prospective 1.06 (0.72-1.77) 1.52 (1.11-2.33) 
   
ADC 15% reference 0.71 (0.35-1.11) 1.07 (0.39-1.54) 
ADC 15% prospective 0.70 (0.11-0.98) 0.99 (0.13-1.51) 
   
ADC 75% reference 1.31 (0.47-1.93) 1.68 (0.93-2.92) 
ADC 75% prospective 1.67 (0.3-3.04) 1.91 (0.3-2.59) 
Data are presented as median and range 
The unit for ADC value is x 10-3 mm2/s. 
 
 
The shape of the histogram curve was documented as being a helpful contributing factor in 
diagnosis of 23 of the 28 cases (82%) correctly classified. Quantitative ADC parameters were 
reported to provide useful additional confirmatory information in eight, but did not change 
diagnosis in any case. 
 
Individual cases in which review of information provided from ADC histogram analysis 








Benign Tumours:  
Case 1. Ovarian Dermoid Tumour 
Figure 5.3. Ovarian dermoid misdiagnosed as germ cell tumour 
Axial (a) and sagittal (b) T2-weighted MR images of a 10 year-old girl who presented with a 
large, complex supravesical pelvic mass which consisted of cystic and solid components. 
This was misdiagnosed as malignant by both radiologists following review of conventional 
MR imaging, with a primary differential diagnosis of a well-differentiated germ cell tumour. 
Visual ADC histogram interpretation (c) led to confident diagnosis of benign ovarian 
dermoid with recommendation not to biopsy, which was further confirmed quantitatively by a 
high median ADC (2.33).  
Case 2. Mesoblastic nephroma 
Figure 5.4. Mesoblastic nephroma initially misdiagnosed as probable malignancy 
Axial T2-weighted MRI (a) of a 1 month-old baby with an antenatally diagnosed multicystic 
lesion arising from the right kidney.  Both radiologists diagnosed malignancy after review of 
conventional MRI, but were confident this was a benign lesion following visual ADC 
histogram analysis (b).  
Case 3.  Tuberculoma 
Figure 5.5. Tuberculoma initially misdiagnosed as likely Ewing Sarcoma 
Coronal (a) T2-weighted MR images of a 5 year old boy demonstrating a heterogeneous mass 
on the left chest wall centred around costochondral junction of the left fifth rib, showing 
moderate restriction of diffusion and mixed contrast enhancement. The mass extended 
superficially and internally into the thorax, and was associated with collapse of the adjacent 
lung. This was initially misdiagnosed as a malignant lesion on MRI by both radiologists, with 
a primary differential of Ewing Sarcoma. After visual interpretation of the ADC histogram 
(b), a confident benign diagnosis was made by both radiologists without recommendation for 
biopsy. 
Case 4. Kaposiform haemangioendothelioma 
Figure 5.6. Kaposiform haemangioendothelioma misdiagnosed as probable neuroblastoma 
T2-weighted axial MRI (a) of a 6 month-old baby who presented with bleeding tendencies, 
melaena and a large abdominal mass revealed a large, complex, heterogeneous 
reteroperitonal mass with no restriction of diffusion, with peritoneal involvement that encased 
the abdominal vasculature and appeared to invade the left kidney. Both radiologists 
misdiagnosed this as a malignant lesion on conventional MRI, with a primary differential 
diagnosis of neuroblastoma. Radiologist 2 made a diagnosis of a benign tumour following 
review of the ADC histogram (b), whereas radiologist 1 still considered the lesion to be 
malignant. This is interesting as kaposiform haemangioma is a benign tumour with locally 
aggressive features, reflected by the histogram demonstrating appearances intermediate 
between benign and malignant lesions. 
 
Malignant Tumours 
For comparison, an example MR image and corresponding ADC histogram for a malignant 
extrarenal Wilms Tumour is shown in Figure 5.7. 
  
Figure 5.7. Extrarenal Wilms Tumour 
T2-weighted MRI (a) of a 5 year-old girl who presented with a lower abdominal mass 
demonstrating a large, lobulated lesion of uncertain origin extending into the pelvis. 
Differential diagnosis included sarcoma or an extra adrenal neuroblastoma. The 
corresponding ADC histogram (b) is typical of malignancy, in accordance with the 
histopathological diagnosis of extrarenal Wilms tumour.   
One benign tumour, nephroblastomatosis, remained misclassified as malignant by both 
radiologists following ADC histogram analysis. An MR image for this case and the 
corresponding ADC histogram are shown in Figure 5.8. 
Figure 5.8. Nephroblastomatosis misdiagnosed as malignancy 
Axial T-2 weighted MRI (a) of a 7 month-old girl who presented with an abdominal mass 
revealed numerous large, rounded masses arising from the renal cortex of both kidneys 
bilaterally, causing massive renal enlargement. Both radiologists felt MRI appearances were 
consistent with either large nephroblastic rests or Wilms tumours and recommended biopsy. 
Review of the ADC histogram (b), which is typical of a malignant lesion, led to misdiagnosis 
of malignancy by both radiologists. Nephroblastomatosis is a pre-malignant condition, which 
may be reflected in the malignant appearance of the corresponding histogram.  
  
Radiologists reported finding ADC histogram analysis a valuable diagnostic tool in non-
invasive differentiation of benign from malignant paediatric tumours, with additional 
information from an extra modality confirming or refuting the provisional diagnosis made 
through conventional imaging. The main clinical benefit was increasing diagnostic 
confidence, with potential to avoid biopsy in cases with high certainly of being benign. The 
major disadvantage was that constructing a whole tumour ROI is time-consuming, 
particularly in large tumours, and not always practical in a busy clinical setting. Clinical 
scenarios deriving most potential added value were confirming provisional diagnosis of 
benign tumours, diagnosing malignant tumour type as more mean histograms are acquired, 
and classifying unusual tumours. The least benefit was conferred in very typical cases for 
which diagnosis is straightforward on conventional imaging and clinical features alone. 
MIROR was considered a potentially user-friendly, comprehensive and clinically applicable 
CDSS. 
 
Although both visual interpretation of histogram shape and review of quantitative parameters 
were considered helpful, there was a preference for visual interpretation. Radiologists 
reported a reluctance to rely on numerical parameters in view of the considerable overlap in 
reference values for benign and malignant tumours. Constructing a whole tumour ROI added 
up to 10 minutes to reporting time: this was acceptable if facilitating a difficult diagnosis, but 
quicker techniques such as single slice ROIs would greatly aid clinical application if results 
were as accurate. Further addition of mean histograms for individual tumour types was cited 
as potentially clinically advantageous to enable comparison of an index histogram with those 
of malignant tumours within the differential.   
        
This study suggests quantitative ADC histogram analysis is a promising technique to 
facilitate non-invasive discrimination of benign from malignant paediatric solid tumours in 
clinical practice. The accuracy and confidence of radiological diagnosis of benign lesions 
increased sequentially with addition of information from conventional DWI and visual 
interpretation of ADC histogram shape, with fewer biopsies recommended to confirm 
diagnosis at each step in the proposed diagnostic pathway. Addition of quantitative numerical 
histogram parameters did not further increase diagnostic accuracy. The CDSS MIROR 
allowed presentation of complex data in a comprehensive and intelligible way, facilitating 
discrimination between benign and malignant tumours through comparison of new cases with 
information in the repository. ADC histogram analysis was well accepted by radiologists and 
considered a potentially valuable and clinically applicable additional diagnostic tool. 
 
ADC histogram analysis was found to add most clinical value in confirmation of diagnosis of 
benign lesions. All malignant tumours in this cohort were classified correctly as malignant 
using conventional MRI, leaving no possibility for improvement through incorporation of 
additional information. A higher amount of uncertainty was observed in initial diagnosis of 
benign tumours, with only 41% correctly diagnosed on MRI alone. The diagnostic accuracy 
in the benign group increased significantly when using the information provided by MIROR, 
with 73% of benign tumours correctly diagnosed following visual interpretation of the ADC 
histogram. Biopsy recommendations in benign lesions decreased with the additional 
information as diagnostic confidence increased.  
 
Visual interpretation of ADC histogram shape conferred the most added diagnostic value and 
was reported by radiologists to be more useful than additional numerical information about 
histogram parameters. This suggests illustrative graphical depiction may be the most 
appropriate way to present complex DWI data to radiologists, whose daily work involves 
interpretation of images rather than numerical data. The considerable degree in overlap 
between reference values for benign and malignant lesions may have contributed to the 
reluctance of radiologists to rely on quantitative parameters sufficiently to change their 
diagnosis.  
The morphological differences apparent in ADC histograms of benign and malignant 
paediatric tumours have also been described in tumours in adults. Benign and malignant 
breast tumours have been retrospectively discriminated through whole-tumour ADC 
histogram analysis, with significantly lower median, minimum, 25th, 75th and 90th percentile 
ADC and higher skewness, kurtosis and entropy in malignancy (Suo et al., 2016). Similar 
findings have been reported in differentiating benign and malignant orbital tumours (Xu at 
al., 2016).  Although quantitative histogram parameters and median ADC have been shown to 
prospectively discriminate benign from malignant salivary gland tumours with high 
sensitivity and specicifity (Miland et al., 2017), there are, at the time of writing, no reports of 
prospective evaluation of the added diagnostic value of visually observable differences in 
ADC histograms of benign and malignant lesions. 
 
The CDSS MIROR has potential to facilitate use of quantitative ADC histogram analysis in a 
clinical setting, delivering decision support to allow clinicians to interpret the information 
provided. The increasing amount of complex MRI information available can be 
overwhelming for clinicians, and inherent difficulties with interpretation and analysis may 
prove an obstacle to implementation and clinical use. Making data from advanced MRI 
techniques accessible and comprehensible is an important clinical goal to improve decision-
making. As a diagnostic tool, MIROR allows users to extract morphological features and 
statistical information about a defined region, and compare it with relevant findings available 
in its repository to predict outcome for the index case. Radiologists reported finding ADC 
histogram analysis using MIROR easy to perform and interpret. ROI construction, generation 
of an index case ADC histogram and subsequent visual interpretation and comparison with 
reference histograms from the repository was considered straightforward and possible to 
incorporate into the clinical workflow with minimal training.  
Confident radiological diagnosis of paediatric solid tumours at the time of initial imaging has 
potential to enhance patient care. Histopathological diagnosis requires an invasive procedure 
such as biopsy or surgical resection, and was unavailable for a median of 38 days after 
imaging in this cohort. Biopsy could be avoided completely if a confident non-invasive 
diagnosis were made in a benign lesion that did not require resection on clinical grounds. As 
the available repository for different malignant tumour types grows, accurate discrimination 
of malignant tumours that appear similar on conventional MRI may be possible. This could 
help prevent misdiagnosis and inappropriate treatment, as can occur with Wilms and renal 
rhabdoid tumours given recent recommendations to avoid biopsy in most suspected cases of 
the former (CCLG, 2018). Availability of clearly presented and comprehensible information 
about tumour characteristics in multidisciplinary meetings prior to confirmation of 
histopathological diagnosis would be a particularly valuable aid to diagnostic and 
management decisions. 
 
Although quantitative ADC histogram analysis has considerable potential, there are 
limitations inherent to the technique. It is not always possible to clearly define a lesion and 
draw a ROI, as demonstrated by the radiologist being unable to construct ROIs in two cases 
in this cohort, an infantile fibrosarcoma and nephrogenic rests. The time taken to draw a 
whole-tumour ROI in large tumours (up to 10 minutes) may form a barrier to use in a busy 
clinical setting. Establishing quicker ROI techniques that convey similar information in a 
robust but more time-efficient manner, such as single-slice ROIs, is an important aim for the 
future to improve clinical applicability. 
 
It is important to consider cases in which ADC histogram analysis was not helpful to identify 
scenarios in which additional caution should be taken in interpreting results. One benign 
lesion, nephroblastomatosis, remained misdiagnosed as malignant following visual and 
quantitative ADC histogram interpretation. This was an unusual case involving a 7 month-old 
baby presenting with bilateral kidney enlargement and multiple homogeneous renal lesions. 
Although nephroblastomatosis was diagnosed histologically (“undifferentiated blastema 
together with scattered epithelial lined tubules in keeping with nephroblastomatosis”), 
clinical uncertainty remained as to whether this constituted a Wilms tumour or 
nephroblasomatosis. It is possible that this clinical atypia reflected unusual tumour 
characteristics, with the corresponding ADC histogram appearing more characteristic of 
malignancy. The child was treated with vincristine and actinomycin, to which she 
subsequently showed a good response.  
 
A second case, kaposiform haemangioendothelioma, was diagnosed as malignant by 
radiologist 1 but benign by radiologist 2 following review of the ADC histogram, which 
displayed intermediate malignant and benign features. Kaposiform haemangioendothelioma 
is a locally aggressive vascular tumour, which may appear atypical of a benign lesion due to 
its aggressive behaviour, the influence of the vascular component on diffusion, and the 
possibility of artefact from bleeding into the tumour. Similarly, adult studies of DWI in 
identifying malignancy have reported misclassification of liver hemangioma (Feuerlein et al., 
2009). ADC histograms of vascular lesions should be interpreted cautiously given the 
magnetic properties of static blood, and the impact of perfusion as capillary and sinusoidal 
blood flow in vessels contributes to a large IVIM component. As this could be assessed using 
the intravoxel incoherent motion (IVIM) model (Le Bihan et al., 1988), IVIM analysis may 
be helpful in facilitating diagnosis of vascular lesions and should be explored in future 
studies.  
 
Limitations to this study include the small sample size and unbalanced groups of benign and 
malignant tumours. Confirmation of findings should be performed in a larger cohort of 
tumours with additional evaluation by other radiologists. Whilst ADC has been shown to be 
robust across different scanners (Grech-Sollars et al, 2015), evaluation in a multicentre 
setting would aid clinical adoption. Future work should further explore the use of quantitative 
parameters with the aim of developing robust automated prediction models and their 
presentation to radiologists in a manner which fits with clinical practice. 
 
Additional information from ADC histogram analysis provided to clinicians through the 
CDSS MIROR can allow for better and more informed non-invasive discrimination of benign 
and malignant body tumours in children than possible through interpretation of conventional 
MRI alone. Visual interpretation of ADC histogram shape was well accepted by radiologists, 
who found the technique clinically applicable and potentially valuable as an additional tool to 
confirm or refute a provisional diagnosis of malignancy. As the main barrier to clinical 
implementation in routine practice is the time involved in drawing whole tumour ROIs, 
validation of more limited methods of ROI construction would be helpful to ascertain 
accuracy and reproducibility of less labour intensive techniques that may be more easily 
applied in a clinical setting.  
 
Chemotherapeutic response of paediatric solid malignant tumours is generally assessed 
through measuring change in size on conventional imaging. If a tumour becomes smaller it is 
assumed to have responded to treatment, whereas if it remains static or increases in size non-
response is presumed. Size is a relatively crude measure as tumour shrinkage can take weeks 
or months to become apparent and does not always reflect change at a cellular level (Olsen, 
2015). Some tumours, such as stromal-predominant Wilms tumours which differentiate into 
more mature stromal or mesenchymal types (Anderson et al., 2002), demonstrate minimal 
tumour shrinkage despite good histological response. The lack of reduction or increase in size 
seen on conventional imaging can erroneously suggest that treatment has been ineffective 
(Pizzo et al., 2016).  
 
Additional information provided through diffusion-weighted imaging (DWI) could aid non-
invasive monitoring of oncological response and potentially add value in these difficult cases.  
As discussed in earlier chapters, highly cellular solid malignant tumours restrict diffusion, 
reflected quantitatively by low ADC values. A reduction in cellularity and an increase in 
histological differentiation with chemotherapy should lead to a corresponding increase in 
ADC (Kocaoglu and Bulakbasi, 2016). There are reports in the literature of significant 
increase in mean ADC of paediatric osteosarcoma, neuroblastic and abdominal tumours 
following chemotherapy (Demir et al., 2015; Neubauer et al., 2017; Oka et al., 2010; 
McDonald et al., 2011). Monitoring ADC changes during treatment could facilitate clinical 
decision-making through allowing on-going risk stratification and identification of non-
responders.  
 
ADC histograms, which provide visual and quantitative information about cellular 
subpopulations within heterogeneous tissue, may demonstrate a morphological shift as 
tumour tissue changes in response to treatment. In stromal-type Wilms tumours, for example, 
the predominant viable tissue subpopulation demonstrates a positive shift in mean ADC after 
chemotherapy as it differentiates into more mature tissue (Hales et al., 2015). Visual 
comparison of ADC histograms obtained at diagnosis with those obtained after treatment, and 
quantitative analysis of ADC histogram parameters, may facilitate radiological evaluation of 
treatment response. Although increasingly recognised in the adult literature (Mimura et al., 
2016; Kyriazi et al., 2011), there has been little research evaluating the role of histogram 
analysis for assessing oncological response in childhood solid tumours. 
 
Although the IVIM parameters D and f have not facilitated discrimination between benign 
and malignant childhood tumours (Meeus et al., 2017), they have been found to be useful 
markers of tumour response in adult studies (Xiao et al., 2015). In view of this, the role of 
IVIM analysis in monitoring chemotherapeutic response in childhood tumours should be 
investigated.  
 
As described in earlier chapters, a clinical decision support system (CDSS), MIROR, is being 
developed by our research team for automatic processing of DWI data to facilitate 
discrimination between benign and malignant tumours (Zarinabad et al., 2018). MIROR can 
allow comparison and superimposition of serial ADC histograms from individual cases. ADC 
histogram analysis is a potential tool for monitoring chemotherapeutic response, both through 
visual comparison of serial histograms and through review of changes in quantitative 
histogram parameters with treatment. 
 
This chapter aimed to evaluate the added value of visual interpretation of ADC histograms 
and parameters derived from quantitative ADC and IVIM histogram in determining 
chemotherapeutic response of malignant paediatric solid tumours, and compare this with 
changes in tumour volume. A further aim was to explore and validate MIROR as a CDSS for 
monitoring treatment response. 
 
Children aged 0-16 years with solid body tumours imaged with MRI with DWI at diagnosis 
and following neo-adjuvant chemotherapy at Birmingham Children’s Hospital between 2012 
and 2016 were included. Patients were recruited prospectively following presentation during 
the study period and retrospectively after searches of computerized records.  
 
MRI was conducted at diagnosis and following chemotherapy using a 1.5T scanner following 
the imaging protocol described in Chapter 3, Methods. DWI was acquired using between two 
and six b-values (b = 0, 50, 100, 150, 600, 1000 s/mm2), with a total scan duration ranging 
from 1 min 37 sec to 7 min 32 sec.  
 
Whole tumour (WT) ROIs were drawn manually around the solid tumour on pre- and post-
treatment images in MIROR (Zarinabad et al., 2018) and refined by a consultant radiologist 
(KF, 10 years’ experience). MIROR was adapted to allow comparison of tumours and ADC 
histograms before and after treatment through ROI construction on serial images, with 
superimposition of pre and post treatment histograms allowing response assessment through 
visual comparison of shift and change in shape.  
 
Post-processing was performed in MIROR, with IVIM modelling conducted for all cases in 
which six b-values had been acquired to allow calculation of D and f parameters. Advanced 
histogram analysis of the ROI overlaid on parametric maps was performed. Tumour volume, 
ADC and IVIM parameter median, 15th, 25th and 75th centiles, skewness, kurtosis and entropy 
were calculated and compared for each case to determine the most useful parameters for 
clinical use in monitoring chemotherapeutic response.  
 
Tumour response was categorized using RECIST criteria (Eisenhauer et al., 2009) according 
to conventional imaging parameters. The volume of highly malignant tumour was calculated 
as the volume of tissue with median ADC values <1.01 x10-3 mm2/s, a cut-off determined 
from earlier work on ADC regarding histogram characteristics of benign and malignant 
lesions described in Chapter 4. Differences in total and highly malignant tumour volume, 
quantitative ADC and IVIM values and histogram parameters before and after chemotherapy 
were calculated and compared.  
 
Comparisons of pre- and post-chemotherapy ADC and IVIM histogram parameters were 
performed using the Wilcoxon signed-rank test, with significance taken as p<0.05. Spearman 
rank correlation ascertained correlations between change in total and highly malignant 
tumour volume and individual histogram parameters. Pre-treatment ADC and IVIM 
parameters and change in tumour volume and histogram parameters in patients who had died 
and survivors were compared. The highly malignant tumour volume pre- and post-
chemotherapy was compared and reviewed in the context of clinical course. Patients were 
considered individually to determine the added value of ADC and IVIM histogram analysis 
in specific clinical scenarios. 
 
A computerized search of medical records identified 29 children (15 males, 14 females) with 
solid malignant tumours who had undergone MRI with multi b-value DWI at diagnosis and 
following induction chemotherapy. Children recruited to the study were aged between 2 
months and 9.26 years (median, 3.53 years). IVIM analysis was performed on all but one 
patient for whom post-treatment DWI did not include all 6 b-values. Demographic 
information is shown in table 6.1. 
Table 6.1. Demographic data of all patients  
Lesion Cases Median age, range (yrs) Sex (F/M) 
Malignant Tumours 29 3.53 (0.2-9.26) 15/14 
    Clear cell sarcoma 1   
    Ewing’s sarcoma 1   
    Hepatoblastoma 4   
    Rhabdomyosarcoma 5   
    Wilms tumour 8   
    Neuroblastoma 10   
Children were imaged at diagnosis and following neo-adjuvant chemotherapy with a median 
time interval of 76 days (range 41-224 days) between scans. An example MIROR output for 
superimposition of pre- and post-treatment histograms for a Wilms tumour, demonstrating 
shift to the right with treatment, is shown in Figure 6.1. 
Figure 6.1. MIROR output showing superimposition of pre- (blue) and post-treatment (red) 
histograms (Wilms Tumour) (bottom left). The pre-treatment histogram (top left), pre-treatment 
volume (top right) and post-treatment volume (bottom right) are also displayed on this GUI. 
 
A whole tumour region of interest (ROI) was drawn around diagnostic and post-treatment 
images of a Wilms tumour on a b0 image prior to overlay on a corresponding parametric 
apparent diffusion coefficient (ADC) map. The ADC histograms derived from pre- and post-
treatment imaging were superimposed to allow visual comparison. In the example above, it 
can be seen that the post-treatment histogram (red) is morphologically different and shifted to 
the right compared to the pre-treatment histogram (blue).  
 
Morphological differences in shape were apparent when comparing histograms visually 
before and after chemotherapy. Histograms shifted to the right following chemotherapy 
corresponding to an increase in ADC values. This is shown in Figure 6.2, which demonstrates 
the change in pooled ADC histogram shape for Wilms tumours, and was observed 
consistently across all tumour types. 
Figure 6.2. Change in pooled ADC histogram shape following chemotherapy (Wilms tumours). 
It can be seen that, compared with the pre-treatment histogram (red), the post-treatment histogram 
(blue) is shifted to the right in accordance with the corresponding increase in ADC values, with a 
reduction in kurtosis and a greater skew to the right. 
Table 6.2. describes diagnosis, volume, pre- and post-chemotherapy ADC values, treatment 
and clinical outcome of included cases.  
Table 6.2. Legend: RECIST Criteria: PR – partial response (>30% size reduction); CR – complete 
response (no residual tumour); SD – stable disease (<30% size reduction or <20% size increase); PD – 
progressive disease (>20% size increase); A – alive; D – died; Rapid COJEC: C=cisplatin, 
O=vincristine, J=carboplatin, E=etoposide, C=cyclophosphamide; IVADo: I=ifosfamide, 
V=vincristine, A=dactinomycin, Do=doxorubicin; VA: V=vincristine, A=dactinomycin; VIDE: 
V=vincristine, I=ifosfamide, D=doxorubicin, E=etoposide; Carbo/etop: Carboplatin, etoposide; 
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ADC values following chemotherapy were significantly higher than at diagnosis. There were 
significant increases in ADC mean (+0.23 x 10-3 mm2/s (0.13; 0.33)), ADC median (+0.31 
×10-3 mm2/s (0.20; 0.42)), ADC 15% (+0.24 x 10-3mm2/s (0.15; 0.31)), ADC 25% (+0.29×10-
3 mm2/s (0.17, 0.38)) (all p<0.0001) and ADC 75% (+0.24×10-3 mm2/s (0.11; 
0.37)(p=0.001)). Kurtosis decreased significantly by -0.11 (-0.19, -0.04) (p=0.002) and 
entropy by -0.20 (-0.39, -0.03) (p=0.021). The decrease in skewness of -0.0076 (-0.0187, 
0.0016) did not reach significance (p=0.08). ADC and histogram parameters before and after 
chemotherapy are shown in Table 6.3, with median values across tumour types demonstrated 
in Table 6.4. 
Table 6.3. Pre- and post-chemotherapy volume, ADC measurements and histogram parameters 
Parameter Pre-treatment 
(median and range) 
Post-treatment 



















































































































+0.41 +0.21 +0.44 +0.28 +0.72 +1.04 +0.31 
 








+0.37 +0.02 +0.48 +0.19 +0.54 +0.60 +0.24 
 
Skewness -0.029 +0.0046 +0.0011 +0.0045 -0.0221 -0.0616 -0.0076 
 
Kurtosis -0.25 -0.11 -0.14 +0.01 -0.29 +0.06 -0.11 
 
Entropy -0.18 -0.39 +0.05 -0.18 -0.24 -0.36 -0.20 
 
ADC unit = x10-3 mm2/s  
Histogram parameters for IVIM D changed significantly following chemotherapy. IVIM D 
percentile values were significantly higher following chemotherapy than at diagnosis, with 
significant increases in median (p<0.0001), 15th (p<0.0001), 25th (p<0.0001) and 75th centile 
(p<0.0001) D. Significant reductions were seen in kurtosis (p=0.002) and skewness 
(p=0.016), and although entropy also decreased this did not reach significance (p=0.168). 
IVIM f parameters did not change significantly following chemotherapy. Median changes in 
ADC, IVIM D and f histogram parameters are shown in Table 6.5.   
 
Table 6.5. Changes in ADC and IVIM histogram parameters following chemotherapy 
Change Following 
Chemotherapy 
ADC (n=29) D (n=28) f (n=28) 
Mean 0.23  (<0.0001) 0.22  (<0.0001) 2.53  (=0.108) 
Median 0.31  (<0.0001) 0.32  (<0.0001) 2.5  (=0.13) 
15% 0.30 (<0.0001) 0.28 (<0.0001) 2.0 (=0.18) 
25% 0.29  (<0.0001) 0.24  (<0.0001) 1.0  (=0.178) 
75% 0.24  (=0.001)  0.26  (<0.0001) 4.0  (=0.122) 
Skewness -0.0076  (=0.08) -0.01033  (=0.016) 0.004904  (=0.223) 
Kurtosis -0.11  (=0.002) -0.15  (=0.002) 0.03  (=0.114) 
Entropy -0.20 (=0.021) -0.12  (=0.168) 0.004  (=0.223) 
ADC unit = x10-3 mm2/s; f = % 
Median tumour volume decreased significantly after chemotherapy by 83% (256ml) from 
307 to 51ml (range 98% reduction to 62% increase) (p<0.0001). The median volume of 
highly malignant tumour defined as ADC <1.01 x10-3mm2/s also decreased significantly by 
92% (191ml) from 208 (range 10.2-620mls) to 17ml (range 0.01ml-139ml) (p<0.0001). 
There was no correlation between change in total or highly malignant tumour volume and 
change in ADC or IVIM histogram parameters.  
 
In this cohort, 5 patients died and 24 survived: these are small numbers and groups are very 
unbalanced so observations pertaining to survival should be interpreted cautiously. Survival 
outcome was not related to change in volume, RECIST criteria, or change in ADC or IVIM 
parameters. Reduction in overall tumour volume was categorised as PR on RECIST criteria 
in all 5 patients who died. Of 24 surviving patients, 21 had PR, 1 had SD and 2 had PD. ADC 
or IVIM histogram parameters were not significantly different between those who died and 
those who survived as demonstrated in Table 6.6. 





































0.38 0.31 0.35 0.00029 -0.12 -0.26 -87% -95% PR=5 
 
P value 0.62 0.49 0.90 0.76 0.80 0.32 0.85 0.53 N/A 
ADC unit = x10-3 mm2/s  
Progression according to RECIST criteria with increase in total tumour size was observed in 
two patients. One was a hepatoblastoma that increased in volume by 39% from 112 to 182ml, 
the other a clear cell sarcoma of the kidney, which enlarged by 23% from 81 to 105ml. The 
size increases were interpreted as tumour progression and prompted intensification of 
treatment followed by surgical resection. 
 
Superimposition and visual comparison of the ADC histograms obtained before and after 
chemotherapy (Figure 6.3) reveals marked morphological changes suggestive of evolution of 
imaged tissue.  Quantitative ADC histogram analysis revealed that although total tumour 
volume increased, in both cases the volume of highly malignant tumour characterised by 
ADC <1.01 x10-3 mm2/s decreased prior to treatment intensification. There was a reduction in 
the highly malignant component of hepatoblastoma by 71% from 79 to 23ml, while the 
highly malignant sector of clear cell sarcoma decreased by 92% from 66 to 5.3ml. Both 
tumours demonstrated an increase in ADC values suggestive of oncological response with 
respective increases in median ADC of 0.47 and 0.72 x10-3 mm2/s. Both patients remain well 
and are in remission two years after completion of treatment. 
Figure 6.3. Pre- and post-treatment histograms of a) hepatoblastoma and b) clear cell sarcoma of the 
kidney with RECIST-defined progression on treatment. 
a. Hepatoblastoma
a) The hepatoblastoma increased in volume by 39% during neo-adjuvant chemotherapy. 
ADC histogram analysis revealed a 71% reduction in the highly malignant tumour 
component, characterised by ADC <1.0 x10-3mm2/s, from 79 to 23ml. There was a 
corresponding increase in ADC median of 0.47 x10-3mm2/s. 
b). Clear Cell Sarcoma of Kidney 
b) The clear cell sarcoma of the kidney enlarged by 23% during induction chemotherapy. 
There was a decrease in the highly malignant tumour component by 92%, from 66 to 5.3ml. 
The median ADC increased by 0.72 x10-3mm2/s. 
This work suggests ADC and IVIM histogram analysis have potential to provide promising 
non-invasive biomarkers of oncological response in solid paediatric tumours. Analysis 
revealed observable visual changes in histogram shape and significant quantitative 
differences in histogram parameters following treatment, including increases in ADC and D. 
Presenting this complex data through MIROR made it accessible and visually interpretable to 
clinicians, suggesting this decision support system may facilitate future integration of 
advanced quantitative imaging into clinical paediatric practice. 
 
Visual comparison of histograms obtained at diagnosis and after treatment revealed marked 
morphological differences in shape and a shift to the right corresponding to oncological 
response. The quantitative changes in histogram parameters related to shape and significant 
decreases in kurtosis and entropy were clearly apparent visually. Research in adults assessing 
early treatment response in cervical cancer also demonstrated observable visual changes in 
ADC histogram shape and significant quantitative differences in histogram parameters (Meng 
et al., 2017) including decreases in skewness, kurtosis and entropy (Meng et al., 2016). 
Presenting this complex quantitative information in a clear and visual way to radiologists via 
MIROR through provision of comparative pre- and post-treatment histograms could facilitate 
incorporation of ADC histogram analysis into clinical practice, providing an additional tool 
for non-invasive evaluation of treatment response. 
 
Evidence in the literature suggests ADC and DWI reflect chemotherapeutic response in 
individual categories of childhood solid tumours (Demir et al., 2015; Neubauer et al., 2017; 
Oka et al., 2010). This study provides additional evidence that these ADC histogram 
analysis-derived biomarkers show similar properties across multiple tumour types. The 
significant increase in median ADC in this cohort corresponds to findings of two pediatric 
studies showing a similar rise in neuroblastic tumours (Demir et al., 2015; Neubauer et al., 
2017). It also supports findings of studies showing significant increase in median ADC in a 
paediatric abdominal tumours, (McDonald et al., 2011), significantly higher average and 
minimum ADC in osteosarcoma after chemotherapy (Oka et al., 2010), and reports of 
positive shift in mean ADC in histogram analysis of stromal-type Wilms tumours following 
treatment (Hales et al., 2015). 
 
IVIM is a relatively new technique that has not been particularly studied in paediatric 
oncology. There are no reports of the value of IVIM histogram analysis in monitoring 
chemotherapeutic response in children. The observation that IVIM D behaved in a similar 
way to ADC suggests short acquisition and a mono-exponential fitting model is sufficient for 
clinical use. This finding is important for integrating quantitative DWI into clinical practice 
as it is quicker and easier to obtain data using only 2 b-values than it is to perform multi b–
value DWI and analysis with bi-exponential fitting. Data acquisition with a shorter scanning 
time improves clinical applicability and feasibility of use in the paediatric population.  
 
IVIM f did not change significantly following chemotherapy. This is interesting as decrease 
in tumour vascularity with treatment should equate to a reduction in f, which relates to the 
tissue perfusion fraction. The f parameter is, however, dependent on factors other than 
vascularity, being also influenced by tissue heterogeneity and complex interactions within the 
microcirculatory network (Le Bihan., 2017). Chemotherapeutic response is characterised by 
an increase in heterogeneity that has an opposing effect to vascularity on f and may explain 
the lack of change observed. Studies of IVIM in cervical cancer found significant differences 
in ADC and D, but not D* or f, between responders and non-responders (Wang et al., 2016). 
Understanding the exact meaning of f and the factors that influence it requires further 
research.  
 
It was not possible to characterise chronological changes in ADC or IVIM parameters in this 
study as patients were imaged for a second time after an average of 71 days of treatment. It 
has been reported that ADC and D increase throughout chemo-radiotherapy, whereas f and 
D* increase initially before a later decrease at around 4 weeks into treatment (Zhu et al., 
2017). It is possible that an early increase in f occurred in patients in this study and was 
negated by a later decrease. As patients were scanned as part of routine management 
additional early imaging to observe trends was not feasible, but further research including 
serial imaging could be conducted to investigate this further.  
 
Novel imaging biomarkers provide additional information to change in tumour size which 
could be helpful clinically in terms of monitoring treatment response and adjusting treatment 
accordingly (Therasse et al., 2000). Absence of correlation with volume change suggests 
ADC and IVIM histogram parameters reflect different underlying tumour properties and 
could potentially be used in a multivariate model as independent markers of treatment 
response. Size reduction has limitations as a surrogate response marker (Olsen, 2015). 
Measurement of tumour size is relatively crude and error prone (Husband et al., 2004) and 
shrinkage does not always translate to improved survival. Change in tumour volume in 
patients in this study did not differ between survivors and non-survivors, although it must be 
noted that nor did any DWI histogram parameters. Tumour shrinkage generally occurs late 
and is relatively insensitive to early treatment effects (Miller et al., 1981). ADC, either 
assessed through visual interpretation of histograms or as quantitative measurements, may be 
a valuable early response marker as increases precede change in size (Kocaoglu and 
Bulakbasi, 2016). As some tumours respond to chemotherapy through differentiation rather 
than shrinkage, size reduction does not always equate to treatment response. Additionally, 
novel agents developed to target specific metabolic pathways rather than resulting in size 
reduction require different measures of efficacy (Harry et al., 2010).  
 
There was no correlation between changes in ADC and IVIM histogram parameters and 
reduction in tumour volume. This substantiates earlier research demonstrating no correlation 
between volume reduction and ADC increase in neuroblastic tumours (Demir et al., 2015). 
The tumour properties reflected by DWI and tumour volume may be different, with potential 
for development of a multivariate model incorporating quantitative DWI in combination with 
size and tumour-specific markers to provide an accurate overall reflection of response.  
 
A reduction in the highly malignant component of a tumour could occur with treatment while 
overall volume remains unchanged. Tumours are heterogeneous masses comprised of highly 
malignant tissue interspersed with other components such as stroma, necrotic tissue and 
cystic regions. Tumour response apparent through change in cellular composition would not 
be reflected through size measurement. Following review of the literature (Gahr et al., 2011; 
Kocaoglu and Bulakbasi, 2016; Gawande et al., 2013) and work previously described in this 
thesis differentiating benign from malignant tumours, an ADC cut-off of 1.01 x10-3mm2/s 
was selected to calculate the volume of highly malignant tissue within a tumour. ADC 
histogram analysis demonstrated a reduction in highly malignant tumour volume in all 
patients in this cohort. Interestingly, the volume of highly malignant tumour decreased in 
both patients who demonstrated an overall increase in tumour size on treatment, with both 
ADC histograms demonstrating a characteristic shift to the right and morphological change in 
shape following chemotherapy. Both children did well clinically, suggesting treatment was 
effective despite this initial tumour growth. This suggests a potential role for ADC histogram 
analysis in the further investigation of patients with apparent tumour progression according to 
size criteria prior to treatment intensification.  
 
This small single centre study has demonstrated promising results for ADC and IVIM 
histogram analysis as potential imaging biomarkers of chemotherapeutic response in 
paediatric solid tumours. There are, however, limitations and larger, prospective, well-
powered studies with longer follow-up times are necessary to provide outcome data and 
information about clinical utility (McShane et al., 2005). The sample size in this study was 
small and the cohort consisted of a wide mix of tumour types. Survival could not be used as 
an outcome measure as treatment was generally effective with few deaths and longitudinal 
data available is insufficient.  It is very possible that early changes in ADC and IVIM 
parameters were missed given the long time interval between diagnostic and follow-up 
imaging: further work incorporating serial scans would be helpful to explore chronological 
changes more fully. It was not possible to explore correlations between post-treatment 
histopathology and histogram parameters or volume change. There is no standardised way of 
reporting histopathological response across several tumour types, and although histological 
interpretation was attempted data procured were unfortunately insufficient for meaningful 
analysis. Further research including robust measures of histopathological response should be 
performed.  
 
This study has demonstrated that visual ADC histogram interpretation and quantitative ADC 
and IVIM histogram analysis are promising non-invasive biomarkers of chemotherapeutic 
response of childhood solid tumours, conferring additional information to that obtained 
through measuring change in size to facilitate clinical decision-making. The imaging 
parameters analysed show similar properties across a range of paediatric tumour types. This 
technique can easily be applied in a clinical setting as most important information can be 
obtained through short image acquisition. The CDSS MIROR allowed clinicians to interpret, 
analyse and compare MR images and complex ADC and IVIM histogram data in an 







The optimum method for determining a Region of Interest (ROI) for quantitative ADC 
histogram analysis has not yet been established in the literature. Some studies have included 
the entire tumour volume with and without cystic (Kocaoglu et al., 2010; Abdel Razek et al., 
2009; Humphries et al., 2007) and necrotic (Littooij et al., 2015; McDonald et al., 2011) 
areas, others have drawn several small ROIs in the solid component of a tumour (Gawande et 
al., 2013; Oka et al., 2010), and drawing a single ROI around the largest axial slice has also 
been proposed. It is important to determine a robust methodology of ROI construction that is 
clinically applicable, reproducible and that provides representative information about tissue 
characteristics of a lesion.  
 
The previous chapters have used whole tumour (WT) ROIs for ADC histogram analysis, 
ensuring maximum sampling of tumour regions.  In theory, histogram analysis from a WT 
ROI should reflect heterogeneity better than selective sampling (Woo et al., 2014a), with 
“fitting” of histogram peaks allowing characterization of the various composite tissue types 
within a lesion. Constructing a WT ROI is, however, labour intensive and time consuming, 
making application difficult in a busy clinical setting. Drawing a single ROI around the 
largest single axial slice (SS) would be more practical and applicable clinically if found to 
yield similar results. Drawing small ROIs drawn in the solid tumour component may be 
influenced by sampling bias and would only convey information about regions demonstrating 
the most restricted diffusion. 
 
Assessment of inter-rater variability is important to ascertain the reproducibility and validity 
of results obtained from different methods of ROI construction. Studies have demonstrated 
excellent intra- and inter-rater reliability of ADC measurement from whole tumour (WT) 
ROIs (Jerome et al., 2016; Littooij et al., 2015), but there is little evidence for reproducibility 
of ADC histogram parameters derived from other methods of ROI construction.  
 
This chapter explores the inter-rater variability of whole tumour (WT) and single slice (SS) 
ROIs, and the variability of ADC histogram parameters obtained by the two different 
construction methods. The aim is to formulate recommendations for the optimum ROI 
methodology for ADC histogram analysis of paediatric solid tumours in clinical practice. 
 
A representative sample of patients with malignant and benign tumours was selected from 
those previously recruited for the study carried out in Chapter 4. 
 
Patients underwent 1.5T MR examination with DWI using the imaging protocol described in 
Methods, Chapter 3.  
 
For each patient, whole tumour (WT) ROIs were drawn around the entire solid tumour on 
high-resolution b0 images using MIROR by two consultant radiologists (KF, 10 years’ 
experience; SA, 1 year experience) and overlaid on matched ADC maps. Single slice (SS) 
ROIs were then drawn around the largest axial tumour slice. Each radiologist was blind to the 
ROIs drawn by the other.  
 
ADC histogram parameters (median, 15th, 25th, 75th and 95th percentile ADC) derived from 
WT and SS ROIs from the two radiologists were compared to assess inter-rater variability. 
These parameters were selected for comparison as they represent the distribution of 
histogram values obtained from an ROI and are widely reported in the literature. Variability 
between methods was determined through comparing ADC histogram parameters obtained 
from WT with those derived from SS ROIs.  
 
To assess significance of variability of histogram parameters produced by the two 
radiologists, comparison of not normally distributed data (median, 15th, 25th, 75th and 95th 
percentile ADC) was performed using the Wilcoxon test. The non-parametric Friedman test 
was used on ADC parameters to compare the WT and SS methods for each radiologist 
separately, and on differences between radiologists’ results to determine any interaction 
between method and inter-rater variability. ADC histogram parameters of benign and 
malignant tumour groups determined from WT and SS ROI construction were compared 
using the Mann–Whitney U test using averages of the two radiologists’ values. Statistical 
significance was taken as p <0.05. 
 
Bland-Altman plots with limits of inter-observer agreement (mean difference +/- 1.96 x 
standard deviation) were constructed to analyse ADC histogram parameter reproducibility 
between radiologists and WT and SS methods of ROI construction. 
A representative sample of 20 patients with malignant and 12 with benign tumours were 
selected for this study. Demographic data is shown in Table 7.1.  
 
Table 7.1. Demographic data of all patients 
Tumour Median age, years 
(range) 
Gender Diagnosis Patients, 
n 
Benign 3.82 (0.03-14.22) F=6; M=6     Liver haemangioma 1 
       Ganglioneuroma 3 
       Mesoblastic nephroma 2 
       Lipoma 1 
       Infantile myofibromatosis 1 
       Haematocolpos 1 
       Vascular malformation 1 
       Ovarian immature teratoma 1 
       Abscess 1 
   Total 12 
     
Malignant 3.19 (0.03-11.82) F= 8; M= 12     Wilms’ tumour 5 
       Neuroblastoma 5 
       Hepatoblastoma 4 
       Rhabdomyosarcoma 3 
       Rhabdoid 2 
       Germ cell 1 
   Total 20 
There were no statistically significant differences between radiologists for any ADC 
parameter for either whole tumour or single slice ROIs (Wilcoxon Signed Rank Test). Table 
7.2 shows the median inter-radiologist difference and 95% confidence intervals for each 
ADC histogram parameter both as an absolute value and as a percentage of the median, 
demonstrating the radiologists differed by at most 2% for any characteristic with no 
significant differences. 
 
Table 7.2. The inter-radiologist difference (+ 95% CI) for each ADC histogram parameter, both as an 
absolute value and as a percentage of the median (n=32) 
Sample Absolute difference Percentage difference p-value 
Whole Tumour    

























Single Slice    

























The unit for ADC value is x 10-3 mm2/s. 
The ADC histograms for individual tumours obtained using either a WT or a SS ROI 
appeared visually identical (Figure 7.1). The Friedman test revealed no significant differences 
between any ADC parameters obtained using single slice and whole tumour methods for 
either radiologist (p>0.05). There was no interaction between inter-rater difference and 
method (p >0.05). 
Figure 7.1. ADC histograms obtained using WT (a) and SS (b) ROIs for an individual tumour (Wilms 
tumour), demonstrating almost identical appearance of the two histograms. 
The average time taken to draw a WT ROI was 10.6 minutes (range 2.3 to 15.9 minutes), 
whereas SS ROIs were drawn in an average time of 34 seconds (range 24 seconds to 1.3 
minutes). Constructing ROIs around small, discrete, homogeneous lesions (e.g. lipoma) was 
less time consuming than constructing ROIs around large, diffuse, heterogeneous masses 
(e.g. neuroblastoma) 
 
The different ADC parameters obtained using WT and SS ROIs between Benign and 
Malignant tumour groups were compared (Mann-Whitney Test), using averages of the values 
obtained by the two radiologists. For both methods of ROI construction, there were strongly 
significant differences in all ADC parameters between benign and malignant tumours, other 
than 95% ADC.  
Table 7.4. The difference between ADC parameters obtained using WT and SS ROIs for Benign and 
Malignant tumour groups (n = 64) 
 ADC Median ADC 15% ADC 25% ADC 75% ADC 95% 
 WT SS WT SS WT SS WT SS WT SS 
Benign 1.55 1.56 1.13 1.17 1.27 1.36 1.67 1.67 1.90 1.98 
Malignant 1.03 1.02 0.74 0.72 0.83 0.81 1.33 1.36 1.98 1.97 
P-value 0.009 0.004 0.024 0.043 0.011 0.014 0.039 0.02 0.48 0.755 
The unit for ADC value is x 10-3 mm2/s. 
Bland-Altman analysis showed that inter-rater reproducibility and reproducibility of the two 
different methods of ROI construction were acceptable for all ADC histogram parameters. 
This is demonstrated in Figure 7.2 using the representative example of Median ADC. 
Figure 7.2. Bland-Altman plot of inter-rater difference versus average median ADC of the two 
radiologists for WT and SS ROIs 
Inter-rater agreement and agreement between methods of ROI construction were good, with 
all but four cases falling within the limits of agreement. There was no significant correlation 
between Mean Difference and Median ADC of raters 1 and 2 (Pearson correlation -0.217, p = 
0.085).  
 
The four cases that fell outside the limits of inter-rater agreement (mean difference +/- 1.96 x 
standard deviation) were a SS and WT vascular malformation, a SS mesoblastic nephroma, 
and a WT ganglioneuroma. The vascular malformation and ganglioneuroma were very small 
lesions (26 mls and 3.4 mls respectively, compared with a mean overall tumour volume of 
378 mls). The two radiologists drew the SS mesoblastic nephroma differently, as one 
included an area the other did not feel was representative of tumour within the ROI. 
 
This study suggests ADC histogram parameters obtained using quantitative DWI are 
reproducible, user-independent, robust to methodology of ROI construction, and provide 
information about tissue characteristics of the imaged lesion. Inter-rater reproducibility of 
both WT and SS ROIs was excellent, with no significant difference in any ADC histogram 
parameter between radiologists using either method. The virtually identical visual appearance 
in ADC histograms, and lack of observed significant difference between histogram 
parameters obtained using WT and SS ROIs, suggest these two methods provide essentially 
equivalent results and may be interchangeable. ADC histogram parameters of benign and 
malignant tumours obtained by both radiologists were significantly different using both WT 
and SS ROIs, suggesting tumour classification as benign or malignant would be unaffected 
by radiologist or method of ROI construction. 
 
It is important to formulate recommendations for the optimum method of ROI construction 
for clinical use of quantitative DWI given the heterogeneity of methodology described in the 
literature. The high inter-rater reproducibility of ADC histogram parameters concurs with 
reports of WT ROI reproducibility (Jerome et al., 2016; Littooij et al., 2015), and provides 
reassuring evidence that accurate results may be obtained from different raters. Constructing 
WT ROIs is labour-intensive, taking our radiologists on average 10.6 minutes but up to 15.9 
minutes to draw, which could be a barrier to implementation in a busy clinical setting. 
Employing simpler methods of ROI construction, such as single slice axial (SS) ROIS, which 
are easier and less time-consuming to construct (taking 34 seconds on average), would 
improve practical applicability. Our finding that SS ROIs are reproducible and provide 
similar information to WT ROIs has important implications for clinical practice. 
 
The only histogram parameter that was not significantly different between benign and 
malignant tumours was 95th percentile ADC, obtained by both WT and SS ROIs. This reflects 
findings described in Chapter 4, and makes biological sense as ADC parameters reflecting 
the extreme right of the histogram represent more cystic tumour components, whereas the 
lower ADC percentile values at the left of the histogram reflect the more highly malignant 
tumour component. 
 
It is important to consider cases for which ADC histogram parameters were not reproducible 
to understand the limitations of these techniques. Of the four cases that fell outside the Bland-
Altman defined limits of inter-rater agreement, two were WT ROIs and two SS, suggesting 
that one method of ROI construction is not inherently less reproducible than the other. The 
three tumours involved were a vascular malformation (WT and SS), mesoblastic nephroma 
(SS) and ganglioneuroma (WT). The comparatively small size of the vascular malformation 
and ganglioneuroma may have contributed to the variability in parameters produced. The 
mesoblastic nephroma was complex and difficult to characterise, with the two radiologists 
interpreting the tumour margins differently when constructing the SS ROI. This indicates that 
caution should be exercised when reviewing results from small or complex tumours, and the 
limitations of ROI construction in these scenarios should be reviewed further. 
 
Inter-rater reproducibility of both WT and SS ROIs is excellent, and ADC histogram 
parameters derived from SS or WT ROIs do not differ significantly. The significant 
differences between ADC histogram parameters of benign and malignant lesions were 
apparent across raters and methods. In view of these findings, we recommend construction of 
a single ROI around the largest axial tumour slice to obtain a preliminary ADC histogram and 
quantitative ADC histogram parameters for clinical use. As this technique is relatively quick, 
user-independent and clinically applicable, use of SS ROIs may facilitate integration of 













Magnetic Resonance Imaging (MRI) is the standard imaging investigation for children with a 
suspected brain tumour, but there is paucity of evidence for its diagnostic accuracy 
(Orphanidou-Vlachou et al., 2013; Panigrahy et al., 2006). Conventional MRI cannot always 
allow accurate identification of tumour type or grade (Panigrahy et al., 2010; Arle et al., 
1997; Panigrahy et al., 2006; Law et al., 2003; Orphanidou-Vlachou et al., 2013; Shiroishi et 
al., 2015) or conclusive differentiation of neoplastic from indolent lesions (Panigrahy and 
Bluml, 2009; Panigrahy et al., 2010; Moller-Hartmann et al., 2002). Definitive diagnosis is 
currently made by histopathology following biopsy or surgical resection (Louis et al., 2007). 
Accurate early non-invasive diagnosis could improve patient care through guiding surgical 
decision-making, allowing timely treatment planning and informing family discussions. 
 
Magnetic Resonance Spectroscopy (MRS) has potential to improve diagnosis and 
characterisation of brain tumours through non-invasive measurement of metabolite profiles 
(Panigrahy et al., 2006; Davies et al., 2008; 2010b). Pathologically different tumour types 
that appear morphologically similar on MRI display different key metabolic features on MRS 
(Hollingworth et al., 2006; Preul et al., 1996; Panigrahy et al., 2010). MRS is not currently 
used routinely in all paediatric centres, partly as there has been little formal evaluation of 
diagnostic utility, and few radiologists are trained in its quantitative evaluation. 
 
Despite evidence for technical feasibility and diagnostic accuracy (Davies et al., 2008; Wang 
et al., 1995; Vicente et al., 2013; Arle et al., 1997), few studies have evaluated how MRS can 
add value to conventional paediatric radiological reporting (Shiroishi et al., 2015). 
Prospective studies of the added diagnostic value of MRS in paediatric oncology are lacking, 
with little systematic comparison with conventional MRI. Research is needed to evaluate the 
diagnostic impact and added value of MRS over MRI alone in this patient population and 
integrate the technique into the diagnostic pathway. Exploring methods of MRS 
interpretation that may be adopted by radiologists without complicated quantitative 
interpretation or sophisticated computer software could facilitate incorporation into clinical 
practice.  
 
The aim of this chapter was to evaluate prospectively the added diagnostic value of MRS in 
combination with conventional radiological reporting in children’s brain tumour diagnosis in 
routine clinical practice.  A further objective was to determine whether MRS is equally 
helpful for all brain tumour types and identify clinical scenarios with potential to improve 
patient care.  
 
Children <16 years of age presenting to Birmingham Children’s Hospital between December 
2015 and 2017 with radiological features suggestive of a brain tumour were eligible for 
inclusion. Participants formed a consecutive series with data collected prospectively and 
recruitment prior to MRS and Paediatric Neuro-Oncology Multidisciplinary Team (MDT) 
consensus diagnosis. All 52 cases with MRI and MRS available prior to histopathological 
diagnosis were included. Ethical approval was granted and written informed parental consent 
obtained. Cases without diagnosis confidently established by the MDT were excluded. 
 
The index test was single-voxel MRS, acquired as standard diagnostic imaging prior to 
treatment or surgical intervention. MRS was performed at 1.5T or 3T following conventional 
MRI, which confirmed voxel placement entirely within solid tumour. The imaging protocol is 
as described in the Methods, Chapter 3. Spectroscopy processing provided a graphical 
magnetic resonance spectrum and tissue metabolite profile using standard scanner software, 
with the majority of raw data also processed using TARQUIN v3.2.2 (Wilson et al., 2011) 
prior to export to hospital clinical PACS (Agfa IMPAX 6.5.2.2016). 
 
The reference standard was Paediatric Neuro-Oncology Multidisciplinary Team (MDT) 
consensus diagnosis, incorporating clinical information, MRI, MRS, histopathology, second 
opinion, genetics and follow-up information about treatment response and tumour behaviour. 
Consensus diagnosis was confirmed once clinical course had been established at study end.  
 
Sub-analysis was performed using histopathology as an alternative reference standard, 
excluding cases without conclusive histopathology. Histopathology is an accepted but 
imperfect diagnostic gold standard: sampling error may occur, particularly in heterogeneous 
tumours, and rare or atypical lesions may be misdiagnosed. Some tumours remain unbiopsied 
or exhibit characteristic clinical or radiological features precluding need for tissue diagnosis.  
 
Three consultant paediatric radiologists who form part of the Neuro-Oncology MDT reported 
conventional and advanced imaging. Radiologist 1 (LM) had over 15 years’ experience in 
paediatric neuroradiology and local and national brain tumour research, Radiologist 2 (AO) 
was an established member of the MDT (6 years) and Radiologist 3 (BP) a newly appointed 
consultant (3 years). Reporting was undertaken blind to final histopathological and reference 
diagnoses, independent from the other two radiologists.  
 
For each case, information was provided about age, gender and clinical presentation. 
Radiologists sequentially viewed conventional imaging followed by MRS processed using 
scanner software or TARQUIN where available. Index case spectra were visually compared 
with mean spectra for common paediatric brain tumours presented in a booklet provided 
(Appendix 3). Each radiologist gave up to four differential diagnoses based on MRI alone, 
rating their certainty of being correct on a scale 1-10. This was repeated after visually 
interpreting MRS. Principal MRI / MRI+MRS diagnosis was taken as that with highest 
certainty. 
An expert spectroscopist and paediatric oncologist (AP, 15 years’ experience), blind to 
radiological, histopathological and reference diagnoses, independently sequentially 
interpreted MRS with no information other than voxel location images, followed by adding 
radiologists’ differential diagnoses. Up to four diagnoses with certainty ratings were given at 
each stage.  All interpreters recorded whether MRS was suitable for analysis. 
 
Histopathology was interpreted by an independent histopathologist (IN, 10 years’ experience) 
as routine clinical practice prior to documentation on an official hospital reporting system 
(Sunquest ICE Desktop Live, v.541).  
Semi-structured interviews (10-15 minutes duration) were performed at study end to 
determine radiologists’ perceptions of the added value of MRS in the diagnostic pathway. 
Interviews included open questions regarding radiologists’ use of MRS in clinical practice, 
their perceptions of the added value of MRS as a diagnostic tool, clinical scenarios for which 
it was most and least helpful, disadvantages and problems encountered, and how information 
available could be improved through provision of additional tools or training. Interviews 
were recorded, transcribed and coded, and thematic analysis performed. 
 
Comparison of post-MRI and post-MRS diagnosis with MDT consensus diagnosis 
determined how many cases were correctly diagnosed in accordance with reference standard 
at each stage. Accuracy of MRI +/- MRS for each category of brain tumour (all locations, 
supratentorial and infratentorial) was made through estimates of sensitivity. Results of 
individual radiologists were analyzed, with inter-observer variability calculated (Chi-squared 
test). McNemar’s test determined if MRS significantly improved individual radiologists’ 
proportion of correct diagnoses. Significance of direction of change towards improvement 
with MRS (McNemar Ordered Category test of Directional Change) and increase in 
radiologists’ agreement on correct diagnoses (Bhapkar Chi-squared test) were assessed 
(Bhapkar, 1966). 
  
Cases were reviewed individually to determine the proportion where MRS added value 
through radiologists changing an incorrect to a correct diagnosis, increasing subjective 
certainty of a correct diagnosis, or reducing the number of differentials considered. Added 
value of expert spectroscopist interpretation was ascertained through reviewing cases with 
correct diagnoses confirmed and those correctly re-diagnosed following spectroscopist 
review. Incorrectly diagnosed cases were evaluated and reasons documented. 
 
The study protocol and workflow is illustrated in Figure 8.1.  
Figure 8.1. Study protocol and workflow 
 
MRS was interpreted independently by 1) radiologists and 2) an expert spectroscopist. All 
readers were blinded to the reference standard of MDT consensus diagnosis and final 
histopathology.  
 
Radiologists determined diagnosis in two stages: 
1. MRI interpretation in combination with clinical information 
2. MRS interpretation in combination with MRI results and clinical information (index 
test)  
The spectroscopist performed a similar process: 
1. MRS interpretation blind to clinical and radiological information (but knowing 
tumour location and voxel position) 
2. MRS interpretation with the differential diagnosis made by radiologists 
Diagnostic MRS was performed on 52 patients following initial imaging. One case was 
excluded for lack of MDT consensus diagnosis. Ages ranged from a fetus at an antenatal age 
of 36 weeks gestation to 15 years (median 6.9 years), 27 were male. Tumours were located in 
the posterior fossa (PF) (27), supratentorially (22) and in the brainstem (2). Breakdown of 
cases by reference diagnosis is described in Table 8.1 with detailed clinical information in 
Table 8.2.  Participant flow is depicted in Figure 8.2. 
 
Of our patient cohort, 35 (69%) individuals had undergone previous imaging that had 
detected a CNS lesion prior to routine reimaging including MRS using the standard 
diagnostic tumor protocol described. Of these 35, 24 (47%) were performed externally, of 
which 7 were CTs, 16 MRIs, and 1 an antenatal ultrasound. Of the 11 (22%) 
previouslyimaged at Birmingham Children’s Hospital, 6 were for epilepsy, 1 requested by 
endocrinology, and 2 emergency scans performed after hours. 
 
Table 8.1. Tumour types and patient demographics 
Tumour Type (TB Consensus Diagnosis) Number 
Medulloblastoma 9 
Ependymoma 4 
Pilocytic Astrocytoma  13 
ATRT  3 
Pineoblastoma 1 
Germinoma  2 
NGGCT  1 
Craniopharyngioma  1 
Atypical Choroid Plexus Papilloma  1 
Diffuse Astrocytoma  2 
Central neurocytoma 1 
Pituitary adenoma  1 
Low grade glioma  1 
Tectal plate glioma 3 
Ganglioglioma 1 
Ewing Sarcoma of occiput 1 
Rhabdomyosarcoma skull base 1 
Non-tumour  5 
Total 51 
Age, years (median, range) 6.9 (36/40-15y) 
Male: female 27:24 
Tumour Location PF = 27; ST = 22; BS = 2 
PF, posterior fossa; ST, supratentorial; BS, brainstem 
 
Figure 8.2. Flow of participants (all cases)  
Table 8.2. Tumour types and clinical and demographic characteristics of study population (n=51) 
Sex Age Presenting Symptoms Tumour Location Diagnosis Method Consensus Diagnosis 
Histopathology available n = 38 
M 2 Vomiting and ataxia 
(2 weeks) 
ST, Third ventricular 
primary, metastases 
EB (endoscopic) ATRT 
F 13 Ataxia (2 months) PF OS Pilocytic Astrocytoma 
M 2 Left sided torticollis and ataxia PF OS Pilocytic Astrocytoma 
M 2 Ataxia (1 month) PF OS Medulloblastoma 
F 7 Unsteadiness PF OS Medulloblastoma 
F 2 Deteriorating gait ST, Pineal region OB Pineoblastoma 
F 2 Unwell, off feeds, lethargic PF, leptomeningeal  OB ATRT 
M 3 New onset squint PF OS Medulloblastoma 
M 10 Headaches and vomiting ST, Suprasellar OB Germinoma 
M 3 Headaches PF, Superior cerebellum OB Pilocytic Astrocytoma 
M 36wk(AN) Antenatal USS finding PF OS (post-mortem) Medulloblastoma 
M 9 Headaches and vomiting PF OS Medulloblastoma 
M 1.8 Nausea and vomiting PF OS ATRT 
M 12 Unsteadiness (2 months) PF, Left cerebellum OS Pilocytic Astrocytoma 
F 10 Recurrent headaches PF, IVth ventricle OS Medulloblastoma 
F 12 Headaches ST, Pituitary fossa OS Pituitary adenoma 
F 9 Vomiting PF, floor IVth ventricle OS Medulloblastoma 
M 1 Haemophilia A, SOL PF PF OS Pilocytic Astrocytoma 
F 8 Headaches and vomiting PF OS Pilocytic Astrocytoma 
M 2 Unsteadiness and falls PF OB Ewing Sarcoma of occiput 
F 7 Headaches and vomiting PF OS Pilocytic Astrocytoma 
M 9 Headaches and vomiting PF OS Pilocytic Astrocytoma 
M 19 Headaches and vomiting PF OS Medulloblastoma 
F 7 Headaches and vomiting PF OS Pilocytic Astrocytoma 
F 11 Headaches and diplopia ST, right basal ganglia OS Pilocytic Astrocytoma 
M 8 Right sided weakness ST, right parietal OS Anaplastic Ependymoma 
F 15 Generalized tonic clonic 
seizure 
ST, parietal lobe OS Grade II partial diffuse 
astrocytoma 
M 7 Focal seizure ST, occipital lobe OS Gangliocytoma 
M 4 Not documented ST, infratemporal fossa OS Rhabdomyosarcoma skull 
base 
M 10 Headaches, papilloedema ST, medial aspect left 
trigone 
OS Atypical choroid plexus 
carcinoma 
F 2 Cough, swallowing problem PF OS Ependymoma 
M 9 Vomiting (6 weeks) PF OS Ependymoma 
M 5 Headaches and vomiting PF OS Pilocytic Astrocytoma 
M 5 Visual impairment ST, suprasellar OB Craniopharyngioma 
F 3 Headaches  PF OS Ependymoma 
M 0.5 Failure to thrive ST, hypothalamus OB Pilocytic astrocytoma 
F 13 Headaches, visual disturbance ST, intraventricular OS Central neurocytoma 
M 5 Headaches and vomiting PF OS Medulloblastoma 
Unbiopsied n = 10 
M 9 Epilepsy ST, Thalamus C Non-tumour 
F 2 Unsteadiness (10 days) PF, Left inferior 
cerebellar peduncle 
C Demyelination 
F 11 New onset focal epilepsy ST, Left parietal lobe C Tectal Plate Glioma 
M 3 Autism and bedwetting ST, Tectal plate C Tectal Plate Glioma 
F 8 Incidental finding BS C Pontine Pilocytic 
Astrocytoma 
M 11 Left sided eye pain PF C Diffuse Astrocytoma 
F 8 Headaches and vomiting  ST, left superior temporal  C Focal cortical dysplasia 
F 6 Endocrine referral: 
polyuria/polydipsia 
ST, suprasellar C Non-germinomatous germ 
cell tumour 
M 13 Epilepsy tumor protocol ST, right para-
hippocampal gyrus 
C Low Grade Glioma 
M 10 Developmental delay ST, tectal plate C Tectal Plate Glioma 
Inconclusive histopathology n = 3 
F 5 Clumsy and ataxic BS OB: C – 2nd histopath 
inconclusive 
Ganglioglioma 
M 14 Vomiting and occipital 
headache 
ST, pineal OB: C – 2nd histopath 
inconclusive 
Germinoma 
F 2 Right hemiparesis and facial 
droop 
ST, left thalamus OB: C - 2nd histopath 
inconclusive  
Infarction 
PF, posterior fossa; ST, supratentorial; BS, brainstem 
C, clinical; F, female; M, male; OB, open biopsy; OS, open surgery; SB, stereotactic biopsy 
Table 8.3 shows radiologists’ combined and individual sequential diagnostic accuracy of 
principal diagnosis, followed by accuracy of spectroscopist interpretation.  
 
Table 8.3. Diagnostic accuracy of radiologists following MRI alone and MRS+MRS, and 
spectroscopist interpretation of MRS alone and MRS+differentials  
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 ST 22  
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All 
Tumours 




PF Posterior Fossa; ST Supratentorial/; BS Brainstem 
aAnalyzable MRS = Passed or borderline QC, or interpretable despite failing QC (n=47) 
 
There was no significant inter-observer difference between radiologists’ diagnostic accuracy 
using conventional MRI (p=0.67, Chi-squared test). Principal MRI diagnosis was correct in 
69% of cases, increasing to 77% with MRS.  
 
MRI+MRS resulted in significantly more additional correct diagnoses than MRI alone 
(p=0.03, McNemar Ordered Category Test of Directional Change). Median changes in 
accuracy and 95% confidence intervals for Radiologist 1 (most experienced), 2 and 3 
respectively following addition of MRS were +5.8% (-0.03-0.14; p=0.25) +5.8% (-0.06-0.18; 
p=0.45) and +11.8% (0.01-0.26; p=0.03) (McNemar’s Test). Direction of change was 
towards improvement for all radiologists, reaching significance for Radiologist 3. There was 
significant increase in radiologists’ agreement on correct diagnosis with addition of MRS 
(p=0.046, Bhapkar chi-squared test) (Bhapkar, 1966). There was no increase in radiologists’ 
agreement when diagnosis was incorrect  
 
Four cases were excluded from independent spectroscopy analysis as MRS failed QC. 
Spectroscopist interpretation was correct in 69% all cases (75% of 47 suitable for analysis) 
increasing to 75% (81% with analyzable MRS) following provision of radiologists’ 
differentials. 
 
Radiologists’ review of MRS added value in 73% cases (37/51) through replacing incorrect 
with correct diagnosis, increasing certainty of diagnosis when correct, or reducing the 
number of differentials considered. Spectroscopist review accurately diagnosed a further 
10%, with a total of 83% of patients (42/51) incurring added value through a combination of 
radiologist and spectroscopist interpretation of MRS. 
 
The 27% (14/51) for which MRS did not benefit radiologists had either failed QC, or were 
rare or atypical tumours without comparator mean MRS or conclusive local histopathology. 
Spectroscopist review correctly diagnosed five of these difficult cases.  
 
Spectroscopist review confirmed correct radiological diagnosis in 70% (36/51) of all cases, or 
77% of the 47 spectra suitable for analysis. Diagnosis was not attempted in four cases (8%) 
where MRS failed QC. Of 11 cases (22%) where the spectroscopist was incorrect, five had 
inconclusive histopathology and were diagnosed following central histopathological review, 
two had inconclusive histopathology post central review and one was unbiopsied. Reasons 
for misdiagnosis of the remaining three were unclear, although each MRS was atypical for 
tumour type. Radiologists diagnosed these three tumours correctly on MRI, suggesting 
clinical management would not have been adversely altered and highlighting the importance 
of integrating all forms of information prior to formulating a conclusive diagnosis.  
 
Review of tumours incorrectly diagnosed on MRI subsequently re-diagnosed correctly 
following MRS suggests where added value may be incurred in the clinical pathway. In the 
posterior fossa, visual MRS interpretation improved radiologists’ diagnostic accuracy of 
medulloblastoma (89% to 96%), pilocytic astrocytoma (72% to 82%), ATRT (50% to 100%), 
and diffuse astrocytoma (67% to 100%), with further improvement in ependymoma (89% to 
100%) following spectroscopist review. Supratentorially, radiologists’ diagnosis of 
ependymoma (0 to 33%) and tectal plate glioma (89% to 100%) improved after MRS, with 
spectroscopist review improving ATRT (0 to 100%) and diffuse astrocytoma (0 to 100%). 
Spectroscopist review also increased diagnostic accuracy of lesions that were not primary 
CNS tumours and non-tumours (67% to 100%) in all locations.  
 
Tumour types with improvement in accuracy of principal diagnosis following radiologist or 
spectroscopist review of MRS are shown in Table 8.4. 
Table 8.4. Tumour types with improvement in accuracy of principal diagnosis following MRS 






Posterior Fossa    
Medulloblastoma 89% 96% 67% 
Ependymoma 89% 89% 100% 
Pilocytic Astrocytoma 72% 82% 82% 
ATRT 50% 100% 100% 
Diffuse Astrocytoma 67% 100% 0% 
Non-Tumour 67% 67% 100% 
Ewing Sarcoma of occiputa 33% 33% 100% 
Supratentorial    
ATRT 0% 0% 100% 
Diffuse Astrocytoma 0% 0% 100% 
Tectal plate glioma 89% 100% 100% 
Ependymoma 0% 33% 0% 
Rhabdomyosarcoma skull basea 67% 67% 100% 
Non-Tumour 67% 67% 100% 
R = Radiologists; S = Spectroscopist; dd = differential diagnosis 
aCorrect diagnosis = not primary CNS lesion 
Of 51 MRS, 36 (71%) met quality control (QC) standards. Nine (17.5%) were borderline for 
reasons of inclusion of normal brain within the voxel, poor voxel placement, poor shimming, 
phasing or line-width, unacceptable baseline, or low signal-to-noise ratio. Six (11.5%) failed 
QC (voxel placement over bone, poor phasing), of which two still provided sufficient 
information for spectroscopist analysis. Interpretation was not attempted in the remaining 
four.  
 
Of 45 spectra obtained at 1.5T, 32 (71%) passed QC, compared to four of six (67%) 3T 
spectra. TARQUIN processing was available in 47, leading to four additional MRS being of 
acceptable quality. One of four MRS processed by scanner software only failed QC. 
Comparison between MRS processed using scanner software and using TARQUIN may be 
seen in Figure 8.3. 
a)                                                                             b) 
Figure 8.3. MRS processed using scanner software (a) and using TARQUIN (b) 
MRS from a patient with medulloblastoma processed using scanner software (a) and using TARQUIN 
(b). Metabolite concentrations and their Crammer Rao lower bounds are listed in the box on the right 
of the TARQUIN output. 
 
The spectroscopist correctly diagnosed eight of nine borderline quality spectra. Of six failing 
QC, two were correctly diagnosed with a third identified as hemorrhagic tumor. Tumours 
with uninterpretable MRS were diagnosed subsequently as germinoma, NGGCT and pituitary 
adenoma. All radiologists correctly diagnosed the germinoma and NGGCT on conventional 
imaging, and two identified pituitary adenoma. 
 
One case, a supratentorial central neurocytoma, was correctly diagnosed by one radiologist 
on MRI but subsequently misdiagnosed following MRS. No other tumours correctly 
diagnosed with conventional imaging were misdiagnosed. 
 
Availability of histopathology is shown in Figure 8.4. 
 
Of 51 patients, 80% (41/51) underwent surgical intervention. Histopathological diagnosis 
was achieved in 75% (38/51); the remaining 25% lack tissue diagnosis. Intraoperative 
histopathology accorded with MDT consensus diagnosis in 42% biopsied (33% all) cases. 
First histopathology was correct in 78% of those biopsied (63% all), incorrect in 7% and 
inconclusive in 15%. Central review was requested in 27%, resulting in change of diagnosis 
in 20% with 7% remaining inconclusive.  
 
First histopathology was available a median of 9.5 days (range 1-611) following MRI, or 6 
days (0-30) post-surgery. Second histological opinion yielded results a median 25 (14-625) 
days following imaging, with treatment commencing after a median of 31 (11-78) days.  
Subgroup analysis was performed in 38 patients with histopathological diagnosis using this 
alternative reference standard (see Table 8.2. for patient demographics). Radiologists 
correctly diagnosed 74% of this subgroup using MRI alone, increasing to 81% with MRS 
(Table 8.3). The 7% increase in accuracy was comparable to 8% observed overall. 
Spectroscopist MRS interpretation was accurate in 74%, or 78% excluding 2 uninterpretable 
spectra. 
 
Examples of cases in which diagnostic accuracy and management were improved following 
MRS are presented in Figures 8.5. and 8.6. 
 
Case 1. ATRT 
An 8 week-old baby presented with a 48-hour history of decreased feeding and lethargy on a 
background of a 2-week history of increasing head circumference and left eye deviation. CT 
revealed a posterior fossa mass, and MRI confirmed the presence of a large, lobulated, 
heterogenous tumour occupying and expanding the fourth ventricle. The lesion included both 
solid and cystic components, demonstrating patchy enhancement, intermediate to low signal 
on FLAIR and restricted diffusion. There was evidence of hydrocephalus with grossly dilated 
ventricles bilaterally. Enhancement along the cord suggested disseminated spinal disease.  
 
Initial differential radiological diagnoses included ependymoma, medulloblastoma and 
ATRT. Spectroscopy favoured ATRT with low N-acetyl aspartate, high choline and lipid. 
The chance of cure was very small in the context of metastatic disease in such a young child. 
Although intensive chemotherapy could have been an option, the baby was too small to 
harvest stem cells and would most likely not tolerate treatment. The Paediatric Neuro-
Oncology MDT discussed offering palliative treatment from the outset, but the decision was 
made to perform a biopsy to confirm histological diagnosis prior to formulating a definitive 
management plan. Pathology reported INI-1 negative undifferentiated embryonal tumour, 
confirming ATRT. A palliative course was followed, and the baby died 2 weeks later. 
 
This case is an example in which a confident non-invasive diagnosis could have spared an 
invasive diagnostic procedure in a patient for whom palliative care and maintaining quality of 
life was appropriate. Using conventional MR imaging alone, radiologists 1 and 2 
misdiagnosed this case as ependymoma with certainties of 50% and 60% respectively. 
Radiologist 3 correctly diagnosed ATRT with certainty of 60%. Incorporation of MRS 
information resulted in a change in the list of differential diagnoses to ATRT alone with 
increases in certainties to 80%, 90% and 90%.  
Figure 8.5. ATRT. T2-weighted sagittal and axial (a) MR images of an 8 week old baby with a 
metastatic posterior fossa lesion. Initial differential radiological diagnoses included ependymoma, 
medulloblastoma and ATRT. MRS (b) favoured ATRT with low NAA, high tCho and LMM, 
subsequently confirmed following open biopsy. 
tCo Total choline, NAA N-acetyl aspartate, LMM Lipids and Macromolecules 
 
Case 2. Medulloblastoma 
Antenatal ultrasound revealed a large congenital posterior fossa tumour in a fetus at 36 weeks 
gestation. Antenatal MRI with MR spectroscopy was performed to further characterize the 
lesion and guide management. Conventional MRI revealed a large posterior fossa mass 
containing a 26mm cyst along the superior aspect, with dilatation of the third and lateral 
ventricles.  
 
Visual inspection of the MRS available on hospital PACS processed by Siemens software 
revealed a spectrum dominated by total choline and lipids (particularly the lipid peak at 
1.3ppm) consistent with a malignant brain tumour. Other metabolite features included a peak 
around 3.6ppm and a broad feature between 2.0 and 2.5ppm. Overall, the spectrum was 
consistent with a medulloblastoma. The mother was counselled accordingly, and a 
management plan was put in place for transfer to Birmingham Children’s Hospital for 
definitive care post-delivery. The baby sadly died following appropriate palliation. Post-
mortem histological review confirmed medulloblastoma. 
 
This case is an example in which accurate non-invasive diagnosis was used to guide timely 
management planning and inform antenatal discussions at a time of considerable distress. 
Reviewing MRI alone, our radiologists misdiagnosed this tumour as teratoma, ATRT and 
germ cell tumour, with certainties of 60%, 60% and 50% respectively. Following review of 
MRS, all three correctly diagnosed medulloblastoma with certainties of 60%, 60% and 80%. 
Figure 8.6. Medulloblastoma. Antenatal MR images (a) of a 36 week gestation fetus with a large 
congenital posterior fossa tumor. Initial MR appearances were suggestive of teratoma, ATRT or germ 
cell tumor. MRS (b), dominated by choline and lipids with a glycine peak at 3.6ppm, was consistent 
with medulloblastoma confirmed following post-mortem histopathology.  
tCo Total choline, NAA N-acetyl aspartate, LMM Lipids and Macromolecules 
Radiologists found MRS a supportive tool to refine diagnoses reached through conventional 
imaging, particularly in differentiating posterior fossa tumours with overlapping imaging 
characteristics such as ependymoma and medulloblastoma. Review of choline facilitated 
classification of ambiguous lesions as malignant or indolent. Aggressive features in 
conservatively managed lesions were identified using choline, lipids and lactate, with usual 
MRS suggesting atypia. In addition to facilitating definitive diagnosis of new tumour types, 
radiologists described using MRS to diagnose recurrence through comparing spectra at 
follow up with those obtained at diagnosis. Radiologists found MRS increasingly helpful as 
they gained experience with its interpretation, and reported being confident to visually 
interpret spectra in 5-10 minutes.  
 
The main difficulty reported with using MRS in clinical practice was quality control (QC) 
issues due to poor voxel placement, inclusion of normal brain, calcification and artefact. 
MRS did not allow definitive diagnosis of rare supratentorial tumours, particularly those 
lacking comparator mean spectra. Despite this, one radiologist reported finding unusual MRS 
features useful in alerting to the possibility of a rare or atypical tumour.  
 
Radiologists considered the provision of additional decision support tools, such as a booklet 
containing mean or example spectra for a wide range of possible tumour types, or a 
computer-based programme, would be helpful to integrate MRS into clinical practice. They 
felt improving their own ability to interpret and verify the quality of MRS was more 
important than reliance on a computer output. MRS was described as “an important tool in 
the radiology toolbox”, used to supplement conventional imaging and support clinical 
decisions based on a range of sources of information, rather than a modality to be used in 
isolation. 
 
The main comments from the spectroscopist were that TARQUIN processing led to 
additional MRS being of acceptable quality in cases where scanner processing did not pass 
QC standards, and that formal discussion with radiologists (rather than just being provided 
with a differential diagnosis and MRS) would provide optimal diagnostic accuracy. 
 
Visual interpretation of MRS improved accuracy of pre-therapeutic diagnosis for all 
participating radiologists, adding further value through confirmation of correct MRI 
diagnoses, narrowing broad differentials and increasing inter-rater agreement. Expert 
spectroscopist review verified correct diagnoses and allowed characterisation of more 
difficult cases. These are clinically important outcomes given the challenge in formulating 
therapeutic decisions based on uncertainty and the potential of accurate early diagnosis of 
childhood brain tumours to improve patient care.  
 
Non-invasive diagnosis of posterior fossa tumours may be sufficiently robust to recommend 
treatment planning prior to histopathological confirmation. Radiologists correctly identified 
88% of all posterior fossa tumours using MRS, similar to earlier reports from our institution 
(Davies et al., 2008) with the majority of misdiagnosed tumours in this location being rare 
lesions. This has important implications for clinical practice. Identification of 
medulloblastomas from diagnostic imaging would allow early radiotherapy referral, and non-
invasive diagnosis of ependymomas could guide surgical planning given the importance of 
complete resection of this tumour type. Correct diagnosis of all indolent lesions after 
spectroscopist review suggests avoidance of biopsy may be reasonable if MRS is typical of 
non-tumour.  
 
All tumours irrespective of location, diagnosis or quality of MRS were included in this study 
to reflect the diversity usually seen in clinical practice. Increased diagnostic accuracy was 
more marked in posterior fossa than supratentorial lesions. The former consist of a limited 
number of tumour types that can be accurately discriminated using computer-based classifiers 
(Wang et al., 1995; Arle et al., 1997; Davies et al., 2008; Vicente et al., 2013), whereas the 
latter are histologically diverse, including rare tumour subtypes without comparator mean 
spectra. Reflecting the proportion of rare tumours in the paediatric population accounts for 
the lower diagnostic accuracy seen in this study than in those of common posterior fossa 
lesions (Wang et al., 1995; Arle et al., 1997; Davies et al., 2008; 2010b; Vicente et al., 2013). 
Although quality control (QC) issues limit implementation of MRS, it was interesting to note 
that our spectroscopist could derive useful diagnostic information from even poorer quality 
spectra. Spectroscopist visual interpretation of MRS passing QC was 81% accurate, 
comparable with reports in the literature of an increase in diagnostic accuracy following 
spectroscopist review of MRS from 63% to 87% (Shiroishi et al., 2015). 
 
The potential role of MRS in the diagnostic pathway can be demonstrated through the 
sequence of imaging interpretation described in this study. Radiologists at Birmingham 
Children’s Hospital review conventional MR imaging and formulate a list of differential 
diagnoses, and then use MRS as a supportive and confirmatory tool seeking expert 
spectroscopist opinion if diagnosis remains uncertain. Conventional imaging is sufficient to 
diagnose lesions with distinct radiological features (e.g. craniopharyngioma). Radiologists’ 
review of MRS adds value in the diagnosis of common tumours with overlapping imaging 
characteristics, such as posterior fossa medulloblastoma and ATRT. Expert spectroscopist 
opinion can further improve diagnosis of difficult cases, with atypical lesions including 
misdiagnosed ependymoma, pontine pilocytic astrocytoma, supratentorial ATRT and non-
primary CNS tumours accurately diagnosed at this stage.  
 
Although MRS is intended to complement rather than replace tissue diagnosis, 
histopathology is an imperfect diagnostic gold standard with several limitations. Many 
paediatric tumours are located in central vital structures and providing representative tissue 
samples through biopsy of such lesions is difficult. Awaiting histopathological confirmation 
of diagnosis can result in treatment delay, which is important to avoid in this vulnerable 
patient group as outcomes may be affected. Advanced imaging would be particularly 
valuable in tumours not amenable to biopsy or those with inconclusive histopathology. Over 
25% of this cohort lacked tissue diagnosis, with management of these patients determined on 
radiological and clinical features alone. Although MRS may influence consensus diagnosis, 
with potential incorporation bias using this as a reference standard, subgroup analysis against 
histopathology including only cases with histopathological confirmation revealed similar net 
improvement in accuracy. MDT diagnoses were verified through clinical course rather than 
simply accepted as correct following MRI and MRS. 
 
It is important to consider potential adverse effects of MRS on diagnosis and clinical 
decision-making. A central neurocytoma diagnosed correctly by MRI was subsequently 
misdiagnosed as a diffuse astrocytoma. Although this is a rare tumour type that did not have 
comparator mean spectra, it was correctly identified following spectroscopist review. 
Spectroscopist analysis was incorrect in three tumours correctly diagnosed by radiologists on 
conventional imaging (medulloblastoma, pilocytic astrocytoma and craniopharyngioma). 
MRS of all these lesions was atypical of tumour type, highlighting the importance of 
interpretation in the context of all available information. Other misdiagnosed lesions were 
rare and difficult to diagnose on histology. 
 
Making MRS widely clinically available is an important objective to improve patient care. 
The techniques described in this chapter are readily applicable without additional 
infrastructure. The MRS protocol used involves single-voxel acquisition and visual 
interpretation, each adding around 5 minutes to examination and reporting times. It is 
generally accepted that optimal analysis of MRS data requires fitting to a linear combination 
of metabolite basis functions, which was not available through scanner software used in this 
study. One barrier to using platform independent software has been the difficulty of handling 
MRS raw data. This is, however, becoming easier as demonstrated by the use of a PACS 
linked to a server running TARQUIN software, making results available to users in real time. 
In this study, TARQUIN analysis was more robust to clinical data of variable quality than 
scanner processed MRS, increasing the number of cases providing useful information. 
Clinicians also appreciated clarification regarding metabolite assignment available through 
TARQUIN. Complex spectroscopy methods with longer acquisition times (e.g. MRSI/CSI), 
sophisticated decision support software and automated classifiers may improve accuracy 
(Wang et al., 1995; Arle et al., 1997; Davies et al., 2008; Vicente et al., 2013), but are not 
routinely available and are challenging to implement clinically.  
 
As radiologists are not formally trained to quantitatively evaluate MRS, it is important to 
present easily interpretable information for clinical use taking into account working practices. 
Radiologists at Birmingham Children’s Hospital incorporate visual MRS interpretation into 
routine practice, comparing the MRS profile from an index case with a repository of mean 
spectra from common tumour types, and report finding MRS a helpful tool to confirm or 
refute diagnoses made through conventional imaging. This is encouraging as it suggests 
widespread implementation of the technique is a realistic objective. Expert spectroscopist 
support for difficult cases and centers with less experience could potentially be provided 
through central radiological review. Developing usable classifiers and decision support 
systems for radiologists may improve MRS interpretation and is a key aim for the future.  
 
It is important to acknowledge limitations of this study design. It is difficult in a single centre 
to ensure complete blindness of radiologists to patients’ clinical course. Bias may have been 
introduced as not all cases were reported contemporaneously, although final histopathological 
and consensus diagnoses were not revealed until study end. Results of this single-centre study 
may not be generalizable to institutions with less spectroscopic or more paediatric 
neuroradiological expertise and robust prospective multi-centre evaluation is required. 
Although Birmingham Children’s Hospital is one of the largest centres in the UK with an 
established neuro-oncology MDT and imaging research programme, participating 
radiologists were not all experienced in MRS interpretation. Our least experienced radiologist 
demonstrated greatest improvement, indicating visual MRS interpretation may benefit those 
with less expertise with modest training requirements. 
 
In conclusion, this study demonstrates MRS can add diagnostic value in clinical practice, 
both through visual interpretation by radiologists and expert spectroscopy review. Further 
prospective multi-centre studies are needed to validate these findings in a range of clinical 
settings and formulate recommendations to incorporate MRS into the diagnostic pathway to 
improve patient care. Work is also needed to evaluate the therapeutic impact of MRS and 
determine its added value in clinical decision-making in paediatric neuro-oncology to 










MRS has been shown to add diagnostic value in a clinical setting. As shown in Chapter 8, 
visual interpretation of MRS by radiologists and expert spectroscopist review can improve 
the accuracy of non-invasive diagnosis of childhood brain tumours compared with that 
obtained through conventional MRI. Although there is evidence that MRS can enhance 
conventional radiological reporting at diagnosis (Murphy et al., 2002; Julia-Sape et al., 2012; 
Galanaud et al., 2006; Shiroishi et al., 2015), there has been little work assessing its impact 
on other forms of management decisions or its therapeutic impact in clinical practice (Lin et 
al., 1999; Moller-Hartmann et al., 2002). 
 
There are a number of additional potential clinical roles for MRS in paediatric neuro-
oncology. MRS could be used to guide biopsy to target the highly malignant component of 
heterogeneous lesions, identify unusual or aggressive high grade tumours through 
characteristic features such as high lipids (Wilson et al., 2013; Vicente et al., 2013; Astrakas 
et al., 2004) and choline (Marcus et al., 2007) and facilitate surgical planning through 
accurate pre-operative diagnosis. Confident non-invasive diagnosis of indolent lesions could 
negate the need for biopsy. It could also be possible to diagnose relapse or metastases that 
display similar metabolic features to the primary lesion (Gill et al., 2013) and differentiate 
progression from pseudoprogression or treatment induced changes. Studies are needed to 
quantify the extent to which MRS enhances clinical decision-making for children with brain 
tumours to facilitate optimal integration into diagnostic and management pathways.  
 
The aim of this chapter was to review clinical use of MRS in a single centre, establish added 
value in non-invasive diagnosis and clinical decision-making and investigate potential impact 
on patient care. 
All 69 children referred to the Paediatric Neuro-Oncology Multidisciplinary Team (MDT) at 
Birmingham Children’s Hospital with a suspected brain tumour following imaging with MRI 
and MRS between January 2014 and 2016 were included in this observational study.  
 
Single-voxel MRS was performed as diagnostic imaging prior to surgical intervention or 
treatment. MRS was acquired on one of three MR scanners (1.5T GE Signa Excite, 1.5T 
Siemens Avanto 3T Philips Interna Achieva) after conventional MRI using the protocol 
described in the Methods Chapter 3. Spectroscopy was processed using standard scanner 
software exported to hospital PACS (Agfa IMPAX 6.5.2.2016), with raw spectroscopy data 
processed using TARQUIN v3.2.2 (Wilson et al., 2011) for research use.  
 
The Paediatric Neuro-Oncology MDT reviewed all patients. Decisions regarding diagnosis 
and management were made following review of clinical information, conventional imaging, 
MRS and histopathology. MDT discussions, clinical questions and decisions were 
contemporaneously documented in detail in real time by an experienced medical secretarial 
team and reviewed by clinicians prior to storage. Diagnostic reference standard was the 
diagnosis agreed by the MDT at study end, verified through clinical course. Tumours with 
diagnoses confirmed on histopathology were classified according to the WHO Classification 
of Tumours of the Central Nervous System 2007 (Louis et al., 2007). Those lacking 
histopathological diagnosis were assigned a diagnosis from a predefined list (see Table 8.1.). 
The radiologists reporting imaging in this study were consultant paediatric radiologists 
(n = 10), seven of whom had a special interest in neuroradiology through involvement in a 
relevant clinical study board, with 3 responsible for reporting images at Neuro-Oncology 
MDT meetings. Radiologists commonly discuss cases with colleagues prior to issuing formal 
reports which are uploaded onto the hospital PACS. The majority of diagnostic imaging in 
children presenting with suspected brain tumours was reported by paediatric radiologists with 
an interest in paediatric neuroradiology. MRI scans from patients presenting out of hours 
were preliminarily reported by the consultant paediatric radiologist on duty, but usually 
reviewed by a radiologist with an interest in neuroradiology prior to release of the official 
imaging report. All MRI and MRS included in this study were reviewed by a paediatric 
radiologist with an interest in neuroradiology as part of the MDT. 
 
Conventional MRI scans were reported by a consultant paediatric radiologist prior to 
availability of histopathology. Official imaging reports were retrospectively reviewed to 
obtain the primary contemporaneous radiological diagnosis. Radiological diagnosis was 
defined as ‘correct’ (certain) if the only documented diagnosis on the imaging report exactly 
corresponded to that determined by the MDT at study end, and ‘partially correct’ (uncertain) 
if this was first in a list of differentials or reported as a query.  An ‘incorrect’ MRI diagnosis 
was where the MDT diagnosis was in a list of differentials but not first, or not listed. Cases 
with no documented radiological diagnosis were excluded. 
Contemporaneous MRS interpretation prior to availability of histopathology was taken from 
imaging and MDT reports, inter-clinician correspondence and medical records. Documented 
MDT discussions and clinical correspondence were reviewed to identify clinical questions 
answered using information from spectroscopy. Cases in which MRS facilitated diagnosis, 
helped answer a specific clinical question, or influenced management or outcome were 
examined in detail and recorded.  
 
MRS data processed using scanner software and uploaded to the hospital PACS were 
available at the time of initial MRI reporting. The accepted system for radiological reporting 
at Birmingham Children’s Hospital is to view and interpret conventional MRI first, then 
follow this by adding information from visual interpretation of MRS. Diagnostic 
considerations are documented at each stage and included in the radiology report, making it 
possible to form a clear distinction of the contribution made by MRS to the diagnostic 
process. The interpretation of MRS used clinically was made through visualization of the 
spectra in the great majority of cases. Spectroscopy processing was undertaken using 
standard scanner software and exported to hospital PACS in all cases described. Raw 
spectroscopy data processed using TARQUIN were available in a subset of patients as part of 
a research study. Contemporaneous MRS interpretation in clinical practice was mainly via 
visual interpretation by radiologists of the scanner-processed spectra via PACS, with some 
support provided by visual inspection of the TARQUIN processed spectra. Although 
radiologists did not tend to use TARQUIN for metabolite quantitation they anecdotally found 
individual metabolite fits provided by TARQUIN useful. Detailed interpretation of MRS by 
expert clinicians and researchers from the hospital Children’s Brain Tumour Research Team 
was requested on a subset of 14 patients. 
Histopathology reports were obtained from the official hospital results reporting system 
(Sunquest ICE Desktop Live, version 541).  
 
‘Correct’ and ‘partially correct’ MRI reports were combined to determine the percentage of 
patients with accurate radiological diagnosis made on conventional imaging alone.  ‘Correct’ 
MRI reports were interpreted as implying diagnostic certainty, whereas ‘partially correct’ 
reports implied uncertainty. Non-invasive diagnoses corresponding to those determined by 
the MDT following addition of MRS were totalled to determine the accuracy of MRI 
combined with MRS. The number of ‘partially correct’ radiology reports confirmed by MRS 
reflected the increase in diagnostic certainty.  
 
Comparison of post-MRI and post-MRS diagnosis with the reference diagnosis determined 
how many more cases were diagnosed correctly. Proportions were reported with 95% 
confidence intervals calculated from the Binomial distribution. McNemar's test determined if 
MRS had a statistically significant effect on correct diagnosis compared with MRI alone. 
Accuracy of MRI +/- MRS for each tumour category (all locations, supratentorial, 
infratentorial and brainstem) was made through estimates of sensitivity.  
Five cases were excluded for lack of documented MRI diagnosis, with 64 patients included in 
the analysis. The patients’ ages ranged from 1 month to 16 years (median 9 years), 40 were 
male and 24 female. All cases had their diagnosis reviewed by the local MDT. The 
breakdown of cases by MDT diagnosis with corresponding histopathological confirmation 
can be seen in Table 9.1. 
 
Table 9.1. Multidisciplinary Team (MDT) Diagnoses  











40 24 8 4 
Anaplastic Astrocytoma 1 1 0 0 
ATRT 3 3 0 0 
Diffuse astrocytoma 1 1 1 0 
DNET 3 2 1 0 
Germinoma 1 0 0 0 
Glioblastoma multiforme 1 1 0 0 
Mixed germ cell tumour 1 1 0 0 
Meningioma  1 0 0 0 
Teratoma  2 2 0 0 
Optic pathway glioma 2 0 0 0 
Pilocytic astrocytoma 4 4 0 0 
Pilomyxoid astrocytoma 1 1 1 0 
Pituitary macroadenoma 1 1 1 0 
Supratentorial PNET 2 2 2 0 
Supratentorial ependymoma 1 1 0 0 
Non-malignant: 2=cortical dysplasia, 
1=pineal cyst, 1=epidermoid cyst, 6= 
incidental lesions 
10 2 0 0 
 Diagnosis Uncertain: 1= 
?astroblastoma, 2=?tectal plate 
glioma, 2=?LGG 
5 0 0 4  
(1 unbiopsied) 
Posterior Fossa 17 14 0 0 
Medulloblastoma 6 6 0 0 
Ependymoma 1 1 0 0 
Pilocytic Astrocytoma 7 7 0 0 
Non-malignant (incidental lesions) 3 0 0 0 
Brainstem 
 
7 1 0 0 
DIPG 5 1 0 0 








8   (8/39= 21%) 
 
4 (4/39 = 10%) 
 
Of 64 patients, biopsy or surgical resection was performed in 43 (67%). Conclusive 
histopathological diagnosis was available in 39 (61% of all patients, 91% biopsied patients) a 
median of 12 (4–40) days following imaging or nine (0-16) days post-biopsy. Central 
histopathology review was requested and undertaken in eight samples (19%) in which there 
was diagnostic uncertainty, leading to minor change in diagnoses in seven (16%). 
Histopathology was inconclusive in four biopsied patients (15%), one due to sampling error 
and three due to atypical histopathological appearance. Of all patients, 25 (39%) were 
managed without histopathological diagnosis. Availability of histopathological diagnosis for 
brain lesions is shown in Figure 9.1. 
Figure 9.1. Consort chart. Availability of histopathology diagnosis for CNS lesions 
Of the 64 MRS studies performed, 11 (17%) failed quality control (QC). Of these, 5 did not 
meet standards for voxel placement and contained predominantly normal brain or necrotic 
tumour, 2 were incorrectly configured, 2 had poor signal:noise ratio, 1 had poor line-width 
secondary to intratumoral calcification and 1 was uninterpretable due to presence of blood 
products. 
The principal MRI diagnosis was accurate in terms of exact accordance with the reference 
standard of diagnosis agreed by the MDT at study end in 38 of 64 patients (59% sensitivity), 
increasing to 47 (73% sensitivity) with addition of MRS (Table 9.2.). Nine of these 47 cases 
(19.1%: 95%CI (9.1%, 33.3%)) had been incorrectly diagnosed with MRI alone. MRS had a 
statistically significant effect on correct diagnosis for all tumour types (p = 0.012) 
(McNemar’s Test). None of the 17 cases incorrectly diagnosed after MRS and MRI had been 
correctly diagnosed after MRI alone. 
 
Of 40 supratentorial tumours, 17 (43% sensitivity) were correctly diagnosed with MRI alone 
with 24 (60% sensitivity) correctly diagnosed after MRS and MRI. Seven of the 24 (30.4%: 
95%CI (13.2%, 52.9%)) were incorrectly diagnosed with MRI alone. None of 16 cases 
incorrectly diagnosed after MRS and MRI had previously been diagnosed correctly using 
MRI alone. McNemar's test shows a significant MRS effect on correct diagnosis (p = 0.016). 
The other tumour types in the posterior fossa and brainstem are too small in number for 
separate statistical consideration. Radiological diagnosis using MRI alone was accurate in 15 
of 17 posterior fossa (88%) and six of seven brainstem (86%) tumours increasing to 16 (94%) 
and 17 (100%) respectively with addition of information from MRS.  
Of the 38 accurate diagnoses made using MRI alone, 18 (28%) were certain (‘correct’) and 
20 (31%) uncertain (‘partially correct’). Following addition of MRS, confidence increased in 
14 (37%) accurate MRI diagnoses with none incorrectly re-diagnosed. Addition of MRS 
resulted in an increase in confidence in correct MRI diagnosis in 41%, 27% and 50% of 
supratentorial, posterior fossa and brainstem lesions respectively. MRS identified both 
ependymomas preoperatively, neither of which were diagnosed on conventional MRI. Table 
9.3. provides detailed analysis of diagnosis at each stage of the diagnostic pathway. 
Table 9.2. Diagnosis of CNS lesions by location using MRI alone, MRI+MRS and histopathology 
 Supratentorial Posterior Fossa Brainstem Total 
N 40 17 7 64 
Accurate MRI diagnosisa 17 (43%) 15 (88%) 6 (86%) 38 (59%) 
MRI diagnosis ‘correct’  
(certain) 
6 (15%) 9 (53%) 3 (43%) 18 (28%) 
Accurate MRI+MRS 
diagnosis  
24 (60%) 16 (94%) 7 (100%) 47 (73%) 
Accurate MRI diagnoses 
with increased certainty 
following MRS 
7/17 (41%) 4/15 (27%) 3/6 (50%) 14 (37%) 
MRI diagnosis ‘incorrect’ 
or ’inconclusive’ correctly 
diagnosed by MRS 
8/23 (35%) 1/2 (50%) 1/1 (100%) 10/26 (38%) 
MRS diagnosis ‘incorrect’ 2 (5%) 0 0 2 (3%) 
Appropriate change in 
management after MRS 
17 (43%) 2 (12%) 4 (57%) 23 (36%) 
Biopsy/resection 26 (65%) 16 (94%) 1 (14%) 43 (67%) 
Histopathological diagnosis 
available 
24 (60%) 14 (82%) 1 (14%) 39 (61%) 
Central histopathology 
review requested 
8  (31% 
samples) 





0 0 4 (9%) 
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9.3.4. Lesions without histopathological diagnosis 
Of all patients, 25 (39%) lacked histopathological diagnosis. Of these, 21 (84%; 33% all 
patients) were unbiopsied and four (16%) reported as inconclusive (one due to sampling 
error, three due to atypical histopathological appearance). MDT consensus diagnosis was 
reached in 21 (84%) of these patients, with diagnostic uncertainty remaining in four (16%). 
MRS contributed to diagnosis in 17 (68%) of this group, modifying it in three (12%). 
Management was influenced by MRS in 13 (52%) of these patients through avoiding biopsy 
(n=10), revision of diagnosis with subsequent appropriate management (n=1), and alerting to 
high-grade behaviour of lesions initially thought to be low grade (n=2). For diagnosis of CNS 
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Table 9.5. Diagnosis of CNS lesions managed without histopathology  
  Percentage (number) Notes 
Number of patients 
without histopathology 
39% (25)  
MDT consensus 
diagnosis reached 
84% (21) Diagnostic uncertainty: 16% (4) 
MRS contributed to 
MDT diagnosis  
68% (17) MRS modified diagnosis: 12% (3) 
MRS influenced 
management 
52% (13) -Avoiding biopsy (10) 
-Revision of diagnosis with subsequent 
appropriate management (1) 
-Alerting to high-grade behaviour of lesions 
initially thought low grade (2).  
 
Indolent lesions were diagnosed in 13 patients (20%), all of which were subsequently 
verified on clinical course. Non-invasive diagnosis of incidental tumours and cortical 
dysplasia was made in 11 patients (85%), with MRS making a major contribution to 
10 (91%) of these diagnoses. A major contribution describes a case in which 
diagnosis was unclear prior to addition of MRS interpretation, but information from 
MRS allowed formulation of a clear diagnosis and management plan. The diagnosis 
of whether the tumour was indolent in these 11 cases was not clear from MRI 
interpretation alone, but review of MRS allowed the diagnosis to be made with 
confidence. MRI alone suggested a diagnosis of non-malignant lesion in 6 cases 
(46%), none of which were certain (all “partially correct”). There was no 
misclassification of malignant lesions as indolent using MRS.  
 
Histopathology was available in 2 of these 13 patients, confirming an arteriovenous 
malformation in one and a pigmented epidermoid cyst in the other. The arterioveous 
malformation was seen on imaging as a hyperdense lesion on the dorsal aspect of the 
pons with a ring of T1 enhancement and visible patchy hemosiderin. Imaging features 
were suggestive of pontine cavernoma, but concerns regarding possible underlying 
pathology led to national multidisciplinary review with the recommendation for 
biopsy. The epidermoid cyst was confirmed histopathologically following surgical 
resection of a posterior fossa lesion with associated gross symptomatic 
hydropcephalus. Table 9.6. provides details of diagnosis of indolent lesions. 
 Number Percentage 





Indolent lesions diagnosed non-
invasively  
11 85% 
Indolent lesions diagnosed following 
MRI alone 
6 (all “partially 
correct”) 
46% 
Indolent lesions diagnosed following 
MRI+MRS 
10 77% 
Malignant lesions misclassified as 
indolent using MRS 
0 0 




Management changed by MRS 10 (avoided 
biopsy) 
10/11 unbiopsied  
= 91% non-invasive diagnoses 
confirmed using MRS 
Treatment was initiated a median of 28 (1–364) days following initial imaging. In 10 
patients (seven medulloblastomas; two diffuse intrinsic pontine gliomas (DIPG); one 
glioblastoma multiforme) first line treatment with radiotherapy commenced a median 
of 45.5 (13-53) days after imaging, or 43.5 (31-49) days after surgery. In 
medulloblastoma, the median time from surgery to radiotherapy was 45 days (31-49), 
longer than the recommended standard of 28-41 days recommended to confer good 
prognosis. 
MRS influenced clinical management in 36% of cases (23 patients) through avoiding 
and guiding biopsy, aiding tumour characterisation, facilitating diagnosis in cases 
without histopathology, surgical planning, and identifying unusual tumour types.  
 
The following cases are examples of patients in which MRS influenced or improved 
clinical management. Conventional MR images and corresponding MRS profiles are 
demonstrated to illustrate the information conveyed through the two complementary 
imaging modalities, and the role of MRS in guiding clinical decision-making. 
 
Case 1. Determining biopsy site in a heterogeneous lesion  (Figure 9.2.) 
Figure 9.2. Determining biopsy site in a heterogeneous lesion           
A) Right thalamus and trigone    
B) Medial temporal lobe 
 
MRI of a 2-year old girl revealed a diffuse, heterogeneous CNS lesion affecting the 
right thalamus and trigone (A) and medial temporal lobe (B). Although the right 
trigone was a more surgically accessible biopsy site it was unclear if this contained 
representative tumour, or very diffuse infiltrating tumour and oedema unlikely to 
provide positive histopathology. Accessing the medial temporal lobe, which looked 
more typical of tumour on conventional imaging, necessitated a more invasive 
procedure with higher risk of morbidity. To aid decision-making repeat MRI with 
spectroscopy was performed over potential biopsy sites, revealing increased 
choline:creatine ratio over the right thalamus and trigone suggestive of representative 
tumour tissue. The overall MRS in this region was suggestive of a childhood low-
grade glioma. Successful biopsy of this area with minimal morbidity yielded 
histopathological diagnosis of low-grade glioma.  
 
Case 2. Exclusion of metastatic disease: bifocal, mixed germ cell tumour (Figure 9.3.) 
 
Figure 9.3. Exclusion of metastatic disease in a bifocal, mixed germ cell tumour 
A) Pineal component  
B) Suprasellar component 
MRI of a 9-year old boy revealed a bifocal midline tumour radiologically consistent 
with a mixed germ cell tumour with possible metastatic disease. MRS profiles of two 
components this tumour appeared very different. The homogeneous pineal component 
(A) had a spectrum typical of germinoma, whereas the heterogeneous suprasellar 
component (B) had a profile suggestive of the secreting component of a germ cell 
tumour. MRS thus facilitated exclusion of metastatic disease in favour of bifocal germ 
cell tumour without the need for biopsy of the pineal lesion. Metastatic germ cell 
tumour would have required cranio-spinal irradiation (CSI) whereas the diagnosis of 
bifocal germ cell tumour allowed monitoring of the suprasellar lesion without CSI 
initially. Rapid life-threatening suprasellar tumour progression subsequently 
necessitated surgical resection. The patient was later referred for focal proton beam 
radiotherapy instead of CSI. 
 
Case 3. Pre-operative diagnosis facilitating surgical planning (Figure 9.4.) 
Figure 9.4. Pre-operative diagnosis facilitating surgical planning 
MRI of a 9-year old boy with an underlying diagnosis of neurofibromatosis type 2 
(NF2) revealed an infratentorial lesion radiologically consistent with pilocytic 
astrocytoma or ependymoma. The tumour was diagnosed pre-operatively as an 
ependymoma using information from MRS, allowing surgical planning for complete 
resection. Interestingly, although high myo-inositol on MRS of this case supported a 
diagnosis of ependymoma, intraoperative histopathology did not support this. The 
final histopathological diagnosis confirmed ependymoma.
 
Case 4. Identification of high-grade, unusual tumour types in cases with inconclusive 
histopathology (Figure 9.5.) 
 
Figure 9.5. Identification of high-grade, unusual tumour types in a case with inconclusive 
histopathology  
MRI of a 13-year old girl revealed a supratentorial tumour of uncertain diagnosis. 
Although a definitive diagnosis was not made following biopsy, the lesion 
demonstrated histological features consistent with a low-grade tumour. MRS 
demonstrated high-grade features of high choline, low N-acetyl aspartate and high 
lipids. This unusual MRS profile alerted clinicians to the possibility of rare tumour 
type and possible sampling error on biopsy, which was later confirmed. Close 
monitoring allowed early detection of rapid growth and metastatic spread. This 
tumour followed an aggressive course and was diagnosed as a probable astroblastoma 
following central review.  
 
Two incorrect diagnoses were made using MRS (ATRT and supratentorial PNET 
both misdiagnosed as ependymoma). Neither was correctly diagnosed on MRI and 
management was not altered. MRS diagnosis was not documented in 18 cases (28%), 
and unsuitable for analysis in two (3%) due to tumour calcification and poor line-
width.  
 
This study indicates that MRS can guide clinical decision-making in paediatric neuro-
oncology through provision of information unavailable from conventional imaging. 
Visual interpretation of MRS resulted in improved accuracy and confidence in non-
invasive diagnosis of paediatric brain tumours in real time in clinical practice. In 
addition to facilitating diagnosis of tumour type, MRS allowed confident 
identification of indolent lesions with avoidance of biopsy and its associated 
comorbidities. The additional information provided also influenced patient 
management through guiding biopsy of heterogeneous tumours, aiding tumour 
characterisation, allowing diagnosis in cases without histopathological confirmation 
and identifying unusual and aggressive tumour types. 
  
This is the first study evaluating the impact of MRS on clinical decision-making in 
paediatric neuro-oncology. The degree of improvement in diagnostic accuracy from 
that obtained with MRI alone (59%) to that following MRS (73%) is similar to other 
reports (Arle et al., 1997; Shiroishi et al., 2015). Work described in chapter 7 found 
addition of MRS improved non-invasive diagnostic accuracy for paediatric brain 
tumours at all locations from 69% to 77%. The slightly higher accuracies in this 
earlier work may be explained by the higher level of neuroradiological expertise of 
the three participating radiologists, all of whom formed part of the Neuro-Oncology 
MDT, compared to radiologists in this study who were not pre-selected and had more 
varied neuroradiology experience. The work described in this chapter investigated the 
impact of MRS on clinical practice in real time, capturing the complexities and 
limitations of radiological reporting and decision-making in a clinical setting.  
 
This study aimed to reflect clinical practice through describing added value of MRS 
in unselected CNS lesions, incorporating challenges of variable neuroradiology 
experience and data quality. Radiologists in Birmingham Children’s Hospital perform 
visual interpretation of MRS profiles generated through scanner software prior to 
availability of TARQUIN analysis. This is advantageous as information is available to 
clinicians in real time, but is a limitation in terms of optimising diagnostic accuracy. 
Studies have shown improved accuracy using sophisticated data analysis techniques 
and automated classifiers (Vicente et al., 2013; Wang et al., 1995; Arle et al., 1997; 
Davies et al., 2008), but these are currently unavailable for clinical use. Making 
classifiers and decision support systems widely available may improve MRS 
interpretation and allow its use in centres with less expertise. Supporting clinical 
practice is a key objective to allow routine implementation of MRS to improve patient 
care and is an important aim for the future. Indeed the incorporation of MRS into 
MIROR is currently being undertaken. 
 
The limitations of histopathology as gold standard for brain tumour diagnosis have 
previously been described. In this cohort, 15% histopathology samples were reported 
as inconclusive and 19% required central review, and the delay of a median of 12 
days from imaging to histopathological confirmation potentially translated into delay 
in initiating treatment. Median time from surgery to radiotherapy in medulloblastoma 
was 45 days, longer than the recommendation of 28-41 days to confer good prognosis 
in standard risk patients. It is important to consider the potential for reducing time-to-
treatment conferred through accurate non-invasive diagnosis with MRS, particularly 
with emergence of proton therapy where times from decision to treatment initiation 
may be longer due to the centralisation of services. 
 
This retrospective study was limited by completeness of contemporaneous 
documentation of both MRI and MRS interpretation and the clinical decisions that 
ensued. This may have resulted in under-reporting of both diagnostic accuracy and the 
impact of MRS on management decisions. There is, unfortunately, no current 
standardization in either radiological reporting or recording the decisions of the MDT. 
As there is an inevitable lack of precision in information documented in a 
retrospective study where recording standards were not predetermined, future 
prospective studies should use specific recording standards to overcome this 
limitation. It is not uncommon for a radiologist to give a broad differential even in 
light of a more certain suspicion, possibly resulting in a greater number of “partially 
correct” outcomes. As it is difficult to make management decisions based on broad 
differentials, it could be argued that MRS added value to the clinical decision-making 
process through narrowing the long list of possibilities made from conventional 
imaging and confirming the correct diagnosis. Follow-up time is relatively short, the 
longest being 2 years post-diagnosis, and it is possible that MDT diagnosis may be 
reviewed in some cases at a later date.  
 
A further limitation is that this study included a small number of cases managed at a 
single centre, cautioning against generalization of results to centres with different 
levels of expertise and processes. The results described reflect practice in 
Birmingham Children’s Hospital, one of the largest institutions in the United 
Kingdom with a well-established, specific Neuro-Oncology MDT, an active imaging 
research program, and well established interest in advanced MRI techniques such as 
MRS. Clinicians also have the opportunity for support with MRS interpretation from 
an active research team and expert clinicians. This may limit the ease with which 
these results can be replicated by institutions with less spectroscopy experience. This 
study should be repeated in other institutions, preferably in a prospective manner, 
where definitions and recoding standards can be agreed prior to acquiring data. A 
number of patients in this study lacked histopathological diagnosis, reflecting clinical 
practice. Although it is more challenging to make a definitive diagnosis on cases 
without histology, MDT diagnoses were verified through clinical course rather than 
simply being accepted as correct following MRI and MRS. Clinical course on follow-
up is an important element of confirming the diagnosis for unbiopsied lesions: no 
lesion diagnosed as indolent by the MDT, for example, subsequently demonstrated 
aggressive behaviour.  
 
Benefits of MRS in this patient cohort included guidance for management for lesions 
lacking histopathology, and support of decisions for observation rather than biopsy 
following MRS suggestive of indolence. A limitation of an observational study is that 
it cannot be certain that patients would not have been managed in the same way 
without MRS. Contemporaneous documentation did, however, reveal MRS to provide 
additional useful clinical information contributing to the clinical decisions made, and 
it could be argued that inclusion of a modality providing reassurance adds value to 
clinical decision-making regarding observation of benign lesions. Multi-parametric 
imaging will not replace tumour tissue analysis in the majority of cases, but having a 
more accurate diagnosis early in the patient pathway can have some major 
advantages. Surgical strategies can be influenced, plans can be made in a more timely 
manner even if they need refining at a later date, and discussions with the family can 
proceed.  
 
There is a paucity of research into the optimum way to implement MRS into 
diagnostic and management pathways. Added value of MRS over conventional 
imaging in therapeutic decision-making has not been evaluated prospectively in the 
paediatric population in a multicentre setting and studies are needed in this area. 
Further work with longer follow up times and clear outcome measures is needed to 
evaluate the impact of MRS on patient management and clinical outcomes. 
 
MRS provides information to facilitate clinical decision-making additional to that 
available through conventional radiological methods. There is potential to improve 
patient outcomes through accurate early non-invasive diagnosis, avoiding biopsy of 
indolent lesions, aiding tumour characterisation and facilitating early treatment 
planning. There has been considerable progress in development and evaluation of 
MRS in paediatric oncology. Integration into clinical practice could help guide 
important management decisions and individualise treatment. Further multicentre 
research is needed to define the optimum use of MRS in a clinical setting and 











This thesis has demonstrated that functional imaging has potential to add value to 
diagnosis and treatment monitoring in paediatric oncology compared with 
conventional MRI alone. Presentation of complex information derived from DWI and 
ADC histogram analysis through a clinical decision support system (CDSS), MIROR, 
and provision of visually interpretable comparator mean MR spectra, were well 
received by radiologists and applicable in a clinical setting. Incorporating these 
techniques into clinical practice has potential to facilitate clinical decision-making 
and ultimately improve patient care. 
 
Quantitative DWI and ADC histogram analysis could facilitate non-invasive 
diagnosis of paediatric solid body tumours as histograms of benign and malignant 
tumours are morphologically and quantifiably different. Histograms of malignant 
tumours appear shifted to the left, more positively skewed and peaked than those of 
benign lesions, reflected numerically by significantly lower ADC percentile values 
and higher skewness and kurtosis. Parameters obtained from more complex IVIM 
analysis did not perform as well as ADC. The information described could be made 
accessible and comprehensible for clinicians through MIROR, a CDSS developed as 
an integral part of this research. Calculating mean ADC histograms for benign and 
malignant tumours from data stored within a continually updated repository could 
facilitate diagnosis of new cases through allowing visual comparison of index and 
mean histograms.  
 
Visual interpretation of ADC histograms significantly improved prospective non-
invasive radiological discrimination of benign from malignant body tumours over 
conventional MRI alone. Following morphological comparison of the ADC histogram 
of an index case with mean histograms derived from the MIROR repository, the 
percentage of benign tumours correctly diagnosed improved from 45% to 73%, with 
no malignant tumours incorrectly diagnosed. The technique was well received by 
radiologists, who considered ADC histogram analysis using MIROR a clinically 
applicable and potentially valuable additional diagnostic tool to confirm or refute a 
provisional diagnosis of malignancy.  
 
Quantitative ADC and IVIM histogram analysis are promising non-invasive 
biomarkers of chemotherapeutic response of childhood solid tumours, conferring 
additional information to measuring change in size. Visual interpretation of ADC 
histograms revealed a shift to the right and marked morphological changes in shape 
following treatment, reflected through significant quantitative differences in 
parameters including increases in ADC and D. Imaging biomarkers analysed show 
similar properties across a range of paediatric tumour types. MIROR allowed 
clinicians to interpret, analyse and compare MR images and complex ADC and IVIM 
histogram data through superimposition of pre- and post-treatment histograms and 
provision of comparator quantitative parameters.  
 
ADC histogram analysis provides reproducible, user-independent data that is robust to 
methodology of ROI construction and accurately reflects tissue characteristics of the 
imaged lesion. Inter-rater reproducibility of both whole-tumour (WT) and single-slice 
(SS) ROIs is excellent, and histogram-derived parameters from SS ROIs enable 
classification of benign and malignant tumours as well as those derived from WT 
ROIs. As WT ROI construction is labour-intensive and time-consuming, construction 
of a single ROI around the largest axial tumour slice can be recommended to obtain 
an ADC histogram for clinical use. This technique is time-efficient, user-independent 
and clinically applicable, which may facilitate integration of quantitative ADC 
histogram analysis into clinical practice.  
 
Qualitative radiological review of single voxel 1H-MRS can improve accuracy of non-
invasive diagnosis of paediatric brain tumours and add value in the diagnostic 
pathway. Radiologists’ principal MRI diagnosis was correct in 69% of an unselected 
cohort of childhood CNS lesions, increasing to 77% with MRS with significantly 
improved inter-rater agreement. Non-invasive diagnosis of posterior fossa tumours 
with MRS may be sufficiently accurate (88%) to recommend treatment planning prior 
to histopathological confirmation. MRS added further value through radiologists’ 
increased certainty of correct diagnosis and reduced number of differentials, with 
additional expert spectroscopist review proving helpful in characterisation of difficult 
cases.  
 
In addition to improving non-invasive diagnosis, MRS can add therapeutic value to 
conventional imaging and facilitate clinical decision-making in paediatric neuro-
oncology. MRS has potential to enhance patient care through avoiding biopsy of 
indolent lesions, aiding tumour characterisation and facilitating earlier family 
discussions and treatment planning. Integration into clinical practice can help guide 
important management decisions and individualise treatment.  
 
This research has contributed to the development, refinement and evaluation of 
MIROR as a CDSS suitable for integration into clinical practice. This involved 
working closely with radiologists to determine clinical usability, with feedback 
incorporated into the on-going design process to develop a tool based on the needs of 
those intended to utilise it. Although work to date has predominantly involved 
analysis of advanced DWI data, there is potential to incorporate modules for analysis 
of other imaging information, such as MR spectroscopy. Availability of a user-
friendly and flexible CDSS that encompasses a variety of medical image analysis 
techniques and post-processing methods could facilitate uptake of advanced MRI in a 
real-time clinical setting.  
 
MIROR has potential to guide clinicians through the implementation and analysis of 
advanced imaging techniques in real-time and engender clinical acceptance through 
translational applications. The current version has a user-friendly graphical user 
interface that allows clinicians to draw a region of interest (ROI) around a tumour and 
measure morphologic properties such as size, shape and volume. Statistical data 
analysis of the ROI overlaid on advanced ADC parametric maps allows derivation of 
an ADC histogram, from which parameters such as median, entropy, skewness, 
kurtosis and various centile values are extracted and stored. The self-archiving 
repository allows continual expansion with acquisition of new tumour cases, and on-
going improvement of prediction accuracy of available biomarkers in the database. 
MIROR provides decision support to aid diagnosis through allowing visual 
comparison of a case histogram with mean histograms of benign and malignant 
tumours stored within the repository, and can also be used to compare sequentially 
acquired histograms from an individual case to monitor changes with treatment and 
ascertain degree of chemotherapeutic response.  
 
The work in this thesis has highlighted several areas for future research. 
Establishment of quantitative reference values for descriptive parameters of ADC 
histogram shape, such as skewness, kurtosis and entropy, may provide useful 
additional information for diagnosis of malignancy in body tumours. Sophisticated 
multi-variate analysis techniques could facilitate discrimination between benign and 
malignant lesions, and more cases are needed to build adequate predictive models and 
determine cut-off values, which should be validated for clinical use. Further research 
with larger tumour cohorts and prospective testing is needed to determine robust 
quantitative measures that may be employed in a fully automated CDSS, the 
development of which is an important aim for the future.  
 
The potential for mean ADC histograms of individual types of malignant tumours to 
facilitate tumour-specific non-invasive diagnosis should be evaluated. Acquisition of 
sufficient cases from which to determine robust representative examples and calculate 
reference histogram parameters will be possible through continuing growth of the 
MIROR tumour repository. Research is needed to determine whether histogram 
analysis may identify high-risk tumours and provide prognostic information. The role 
in determining chemotherapeutic response requires further study, including 
prospective validation in a larger patient cohort through links to clinical trials with 
well-specified treatment protocols, exploring changes early in the course of treatment, 
and correlating histogram parameters with histopathology. Longer follow-up times 
are required to determine outcome and survival associations with identified 
biomarkers. Exploration of the role of IVIM in diagnosis and treatment monitoring is 
another aim, particularly additional value of the perfusion factor f. It is also important 
to evaluate MIROR and the ROI techniques recommended in a multicentre setting to 
establish whether results obtained in our single centre are reproducible and widely 
applicable. 
 
Despite the growing body of evidence for the added diagnostic and therapeutic value 
of MRS, further work is needed to define its optimum use in clinical practice and 
make clear recommendations for incorporation into diagnostic and therapeutic 
pathways. Prospective multi-centre studies with standardised acquisition and analysis 
protocols are needed to validate findings for the added value of MRS in a range of 
clinical settings. The acquisition of mean, location-specific MR spectra for rare 
tumour types and providing example spectra at higher field strengths is important on-
going work. Developing usable classifiers and CDSSs for radiologists is a key future 
aim to improve MRS interpretation and clinical integration. Expansion of the 
functionality of MIROR will include addition of more embedded advanced 
quantitative analysis options for MRS, with addition of real-time interactive machine 
learning to optimise use of available information. 
 
The studies described in this thesis are an important base for further larger multicentre 
prospective studies allowing subgroup analysis and collection of outcome-related 
data. Further work is needed to continue integration of these promising new 
techniques into clinical practice, evaluate their applicability and reproducibility in a 
multicentre setting, and formulate recommendations for incorporation into diagnostic 
and therapeutic pathways. 
 
This thesis demonstrates that diffusion weighted imaging with quantitative ADC 
histogram analysis is a valuable adjunct to conventional imaging in diagnosis and 
treatment monitoring of solid childhood body tumours. Single voxel magnetic 
resonance spectroscopy adds value to information provided through MRI in non-
invasive diagnosis and therapeutic management of paediatric CNS lesions. 
Presentation of information derived from these advanced imaging techniques in a 
visual manner through a CDSS (MIROR) improves accessibility and clinical 
applicability, potentially allowing use in real-time in a clinical setting to improve care 









































































































































Core Multimodal Protocol (Brain) 













































Abstracts submitted to conferences and accepted as either first author oral 
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International Society of Paediatric Neuro-Oncology (ISPNO) Meeting, Denver, June 
2018 (poster) 
Diagnostic accuracy and added value of qualitative radiological review of 1H-
MRS in evaluation of childhood brain tumors 
Manias KA1,2, Gill SK1,2, MacPherson L2, Oates A2, Pinkey B2, Davies P2, Zarinabad 
N1,2, Davies NP1,2,3, Zarinabad N1,2, Babourina-Brooks B1,2, Wilson M1,3, Peet AC1,2 
1Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, 
UK 2Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, UK 
3Department of Imaging and Medical Physics, University Hospitals Birmingham NHS 
Foundation Trust, Birmingham, UK 
 
Background: 1H-Magnetic Resonance Spectroscopy (MRS) facilitates non-invasive 
diagnosis of pediatric brain tumors through providing metabolite profiles. Prospective 
studies of diagnostic accuracy and comparisons with conventional Magnetic 
Resonance Imaging (MRI) are lacking.  
Aim: To evaluate diagnostic accuracy of qualitative radiological review of MRS for 
childhood brain tumors, and determine added clinical value compared with 
conventional MRI.  
Methods: Children presenting to a Tertiary Pediatric Centre with brain lesions from 
December 2015-17 were eligible for inclusion. MRI and single-voxel MRS were 
acquired on 52 tumors and sequentially interpreted by three radiologists, blind to 
histopathology. Proportions of correct diagnoses and inter-rater agreement at each 
stage were compared. Cases were reviewed to determine added value through 
increased certainty of correct diagnosis, reduced number of differentials, or diagnosis 
following spectroscopist evaluation. Final diagnosis was agreed by the Tumor Board 
(TB) at study end.  
Results: Radiologists’ principal MRI diagnosis was correct in 69%, increasing to 
77% with MRS. MRI+MRS resulted in significantly more additional correct 
diagnoses than MRI alone (p=0.035). There was significant increase in inter-rater 
agreement when correct with MRS (p=0.046). Added value following radiologist 
interpretation of MRS occurred in 73% of cases, increasing to 83% with additional 
spectroscopist review. First histopathological diagnosis was available a median 9.5 
days following imaging, with 25% of all patients managed without conclusive 
histopathology.  
Conclusion: MRS can improve accuracy of non-invasive diagnosis of pediatric brain 
tumors and add value in the diagnostic pathway. Incorporation into practice has 







SIOPe, Prague, September 2017 (oral) 
Functional Imaging in CNS Germ Cell Tumors. 
Manias KA1,2, Rose HEL1, Withey S1, Peet AC1,2 
1Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, 
UK 2Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, UK 
 
Background: Functional imaging provides quantitative information to complement 
more traditional imaging techniques. Accurate non-invasive diagnosis of Intracranial 
Germ Cell Tumours would be clinically important as treatment differs according to 
histological subtype.    AIM: To describe functional imaging characteristics of 
different histological subtypes of IGCTS, and to identify imaging characteristics 
likely to facilitate their differentiation.     
Methods:  This was a multicentre study using data from the CCLG functional 
imaging database, evaluating diagnostic scans of patients imaged at 5 recruiting 
centres between 2005 and 2017. Our cohort included 46 patients comprised of 21 
germinomas and 25 NGGCTs (including 12 teraomas, 6 unbiopsied secreting germ 
cell tumurs, 4 yolk sac tumours and 3 mixed GCTs)     
Results: Comparison of ADC histogram parameters of different histological subtypes 
of IGCTs revealed significant differences in ADC median, 25th and 75th percentiles. 
Median ADC was significantly lower in germinomas than NGGCTs, reflecting their 
increased cellularity. The mean ADC histograms of germinomas and NCCGTS were 
also distinct, with germinomas shifted to the left reflecting.  All germ cell tumours 
had a low FA on DTI, which may be attributed to the highly cellular nature of the 
tumours leading to isotropic restriction of diffusion. MR spectra of all IGCTs revealed 
high levels of lipids, with germinomas characterised by the presence of taurine and 
higher levels of choline and creatine than other histological subtypes. DSC showed 
Germinomas to have a higher rCBV than NGGCTs.     
Conclusion: Functional imaging reflects the histological characteristics of IGCTs. 
Germinomas are characterised by a low ADC with little heterogeneity on DWI, low 
FA on DTI, high lipids, tcho, cr and taurine on MRS, and high rCBV on DSC. 
NGGCTs are characterised by higher ADC and more heterogeneity on DWI, low FA 
on DTI, high lipids on MRS with less tcho and taurine, and lower rCBV on DSC. In 
general, secreting GCT lie between germinomas and teratomas. These encouraging 

















SIOPe, Prague, September 2017 (oral) 
Added value of 1H-MRS for the diagnosis of paediatric brain tumors. 
Manias KA1,2, English M2, Gill SK1,2, MacPherson L2, Nicklaus-Wollenteit I2, 
Rodrigues D2, Peet AC1,2 
1Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, 
UK 2Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, UK  
 
 
Background. Magnetic resonance spectroscopy (MRS) aids non-invasive diagnosis 
of pediatric brain tumors, but use in clinical practice is not well documented. We 
aimed to review clinical use of MRS, establish added value in non-invasive diagnosis 
and investigate potential impact on patient care. 
Methods. 69 children with lesions imaged using MRS and reviewed by the Tumor 
Board (TB) from January 2014-2016 met inclusion criteria. Contemporaneous MRI 
diagnosis, spectroscopy analysis, histopathology and clinical information were 
reviewed. Final diagnosis was agreed by the TB at study end. 
Results. Five cases were excluded for lack of documented MRI diagnosis. The 
principal MRI diagnosis by general pediatric radiologists was correct in 59%, 
increasing to 73% with addition of MRS. Of the 73%, 19.1% (95%CI (9.1%, 33.3%)) 
were incorrectly diagnosed with MRI alone. MRS led to a significant improvement 
correct diagnosis over all tumor types (p=0.012). Of MRI correct diagnoses, 
confidence increased in 37% by adding MRS with none incorrectly re-diagnosed. 
Indolent lesions were diagnosed non-invasively in 85% with MRS a major contributor 
to 91% of these. Of all patients, 39% were managed without histopathological 
diagnosis.  MRS contributed to diagnosis in 68% of this group, modifying it in 12%. 
MRS influenced management in 33% of cases, mainly through avoiding and guiding 
biopsy and aiding tumor characterisation. 
Conclusion. MRS can improve accuracy and confidence in non-invasive diagnosis of 
pediatric brain lesions in clinical practice. There is potential to improve outcomes 
through avoiding biopsy of indolent lesions, aiding tumor characterisation and 



















Childhood Cancer and Leukaemia Group (CCLG) Annual Summer Meeting, London, 
July 2017 (oral and poster) 
Differentiating between benign and malignant solid paediatric tumours and 
identifying tumour type using diffusion-weighted MRI and quantitative 
Apparent Diffusion Coefficient (ADC) 
Karen Manias1,2, Katharine Foster3, Niloufar Zarinbad1,2, Andrew Peet1,2 
1 Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, 
UK, 2 Department of Paediatric Oncology, Birmingham Children’s Hospital, 
Birmingham, UK, 3 Department of Radiology, Birmingham Children’s Hospital, 
Birmingham, UK 
 
Background: Apparent diffusion coefficient (ADC) reflects tissue cellularity. As 
solid malignant tumours are highly cellular, ADC could potentially be used to non-
invasively discriminate between benign and malignant paediatric tumours or 
differentiate tumour type. 
Aim: The aim of this feasibility study was to determine whether ADC values could be 
used to differentiate benign from malignant solid tumours in children or distinguish 
tumour type. 
Methods: Thirty-eight children, with 32 malignant and 6 benign tumours, were 
included in this prospective observational study. Malignancies included 
neuroblastoma, wilms, rhabdoid, rhobdomyosarcoma, hepatoblastoma and germ cell 
tumours, and benign lesions consisted of vascular malformations, abscesses, 
haemangiomas and ganglioneuromas.  All children were imaged using multi-b value 
diffusion-weighted MRI at diagnosis. Analysis was performed by drawing regions-of-
interest around the whole tumour from which ADC histograms were constructed.  
Median, 25th and 75th percentile ADC values and entropy were calculated for all 
benign and malignant tumours and compared using the Kruskal-Wallace test. 
Results: Although ADC values were higher in benign than malignant tumours, this 
did not reach significance (ADC median p = 0.496; 25th centile = 0.066; 75th centile 
0.447). Entropy was higher in malignant lesions, but not significantly so (p = 0.066). 
It was not possible to differentiate between individual malignant tumour types in this 
small cohort using the ADC values evaluated. 
Conclusion:  Conducing and interpreting diffusion-weighted MRI at diagnosis of 
childhood solid tumours using quantitative ADC and histogram analysis is feasible. 
Our study did not identify significant differences between ADC values of different 
paediatric tumours, although a trend towards higher ADC in benign lesions was 
observed. This finding deserves further evaluation with a larger cohort of children 












International Society of Magnetic Resonance in Medicine (ISMRM) 17th Annual 
Meeting, 2017(poster) 
The role of ADC histogram analysis in discriminating between benign and 
malignant tumours in children  
Karen Maniasa,b, Niloufar Zarinabada, Emma Meeusa, Katharine Fosterc, Paul Daviesa, 
Jan Novaka, Andrew C. Peet a,b a. Institute of Cancer and Genomic Sciences, 
University of Birmingham, Edgbaston, Birmingham, UK, B15 2TT b. Department of 
Paediatric Oncology, Birmingham Children’s Hospital, Steelhouse Lane, 
Birmingham, UK, B4 6NH c. Department of Radiology, Birmingham Children’s 
Hospital, Steelhouse Lane, Birmingham, UK, B4 6NH 
 
Synopsis. 
We evaluated histogram analysis of ADC maps to differentiate benign from malignant 
solid paediatric tumours in children and distinguish tumour type. Fifty children (38 
malignant, 12 benign tumours) were imaged using multi-b value diffusion-weighted 
MRI at diagnosis. Whole tumour regions-of-interest (ROIs) were drawn, ADC 
histograms constructed, and median, 2nd-98th percentile ADC values, skewness, 
kurtosis and entropy calculated. ADC histogram parameters are significantly different 
between malignant and benign lesions, with skewness and kurtosis predictive of 
malignancy. These findings deserve further evaluation with a larger cohort of 
children. 
Purpose. Definitive diagnosis of solid tumours in children is not possible using 
conventional imaging alone. Diffusion-Weighted MR Imaging (DWI) provides 
information about tissue cellularity through measuring the microscopic rate of water 
diffusion. Images acquired with high and low-diffusion weighting (b-values) are used 
to calculate the Apparent Diffusion Coefficient (ADC), a quantitative measure with 
an inverse relationship with cellularity 1-5. Constructing ADC histograms may provide 
information about tumour heterogeneity to non-invasively discriminate benign from 
malignant tumours or differentiate tumour type. 
This study aimed to evaluate the value of histogram analysis of ADC maps in 
differentiating benign from malignant solid tumours in children or distinguishing 
tumour type, and identify histogram parameters predictive of malignancy. 
Methods. Fifty children (38 malignant, 12 benign tumours) were included. 
Malignancies included neuroblastoma, wilms, rhabdoid, rhabdomyosarcoma and 
hepatoblastoma. Benign lesions consisted of vascular malformations, lipomas, 
mesoblastic nephromas and ganglioneuromas.  
All patients underwent 1.5T MR examination (Siemens Avanto, Siemens Healthcare, 
Erlangen, Germany). The imaging protocol consists of fat-suppressed axial pre- and 
post-gadolinium T1-W turbo spin echo, axial and coronal T2-W short tau inversion 
recovery. DW-MRI was acquired using an echo-planar imaging (EPI) sequence in an 
axial acquisition plane with a field of view (FOV) 187 x 250 mm2, matrix size 144 x 
192, slice thickness 5.0mm, gap 5mm.  For each subject 6 b-values (0, 50, 100, 150, 
600, 1000 s/mm2) were acquired in three orthogonal directions with TR/TE = 5700/92 
m/s. 
ADC maps were automatically generated by scanner software MIROI. An in-house 
developed medical image analysis toolbox was used for data extraction and regions of 
interest (ROI) analysis.  ROIs were drawn in MIROI around the entire solid tumour 
on high resolution B0 images by an experienced radiologist prior to overlay on 
matched ADC maps. Conventional MR guided definition of the outline of the tumour 
at each consecutive tumour-containing slice, excluding peritumoural oedema. Median, 
2nd, 5th, 10th, 15th, 25th, 75th, 85th, 90th, 95th and 98th percentile ADC, skewness, 
kurtosis and entropy were extracted and their discriminatory potential evaluated. 
Groups were compared using the Kruskal-Wallice test and p values reported. 
Multivariate discriminant analysis determined the combination of histogram 
parameters most predictive of malignancy, and ROC curve analysis the diagnostic 
value for malignancy of each significant parameter.  
Results. ADC values were significantly lower in malignant than benign tumours 
(median, 2nd, 5th, 10th, 15th, 25th, and 75th percentile ADC; p=0.004 to p=0.035). 
Higher percentile values (85th, 95th and 98th) did not reach statistical significance. 
Malignant lesions had more positively skewed histograms (p<0.0001), and 
significantly higher kurtosis (p<0.0001) and entropy (p=0.031) (Table 1, Figure 1).  
Discriminant analysis revealed skewness and kurtosis as highly predictive of 
malignancy (accuracy 90%). In ROC analysis, skewness yielded the best Area Under 
Curve, AUC (0.84, p=0.001, 95%CI 0.653-1.00, sensitivity 92%, specificity 67%) 
with cut-off 0.0159. It was not possible to differentiate individual malignant tumour 
types in this small cohort. 
Of clinical relevance, malignant neuroblastoma could be distinguished from benign 
ganaglioneuroma through the former demonstrating significantly lower median, 2nd, 
5th, 10th, 15th, 25th, 75th and 85th centile (p=0.004) ADC values, more positive 
skewness (p=0.004) and higher kurtosis (p=0.009). These lesions cannot be 
differentiated on conventional MR imaging. 
Discussion. Histogram analysis of ADC maps using a whole-tumour ROI approach 
could facilitate non-invasive differentiation of malignant from benign body tumours 
in children with 2nd, 5th, 10th, 15th, 25th, 50th and 75th percentile ADC significantly 
lower and skewness and kurtosis significantly higher in malignancy. Our finding of 
low ADC of malignant lesions corresponds to other paediatric studies 1,6,7.  
This is the first study of ADC histogram analysis to differentiate between childhood 
tumours. Previous paediatric studies evaluating mean or median ADC 6-9 do not 
account for tumour heterogeneity. A histogram-based evaluation provides information 
about skewness, kurtosis and entropy, reflecting histological characteristics.  
Skewness and kurtosis were significant predictors of malignancy. Similar findings 
have been reported in adult studies 10-12. High skewness could equate to high 
cellularity reflected by dense population of the left end of the histogram 
corresponding to low ADC values.  
Although histograms of different tumour types appear morphologically different 
(Figures 3-5), we were unable to identify parameters predictive of individual 
malignant tumour type. More sophisticated multi-variate analysis may help in this 
discrimination, but more cases are needed. 
Conclusion.  Conducting and interpreting diffusion-weighted MRI of childhood solid 
tumours using quantitative ADC and histogram analysis is feasible. ADC histogram 
parameters are significantly different between malignant and benign lesions. 
Skewness and kurtosis are highly predictive of malignancy and potentially useful non-
invasive biomarkers. These findings deserve further evaluation with a larger cohort of 
children. 
 
Figure Captions. (all figures are included in Chapter 4 of the body of the thesis) 
Figure 1. 
Table 1. Comparison of median ADC histogram parameters between malignant and 
benign childhood tumours  
Figure 2. a-d.  
Box plots show comparison of ADC histogram parameters (ADC median (a), 
skewness (b), kurtosis (c) and entropy (d) for benign and malignant paediatric 
tumours. Line in box represents the median, height of the box represents the 
interquartile range, whiskers are the lowest and highest data points within 1.5 
interquartile range, and asterixes indicate outliers. 
Figure 3. a-c.  
A 2 year old girl with a left sided neuroblastoma. Axial T2-weighted image (a) shows 
a large abdominal mass lying anterior to the left kidney. ADC map was obtained and 
a whole-tumour ROI selected (b). The corresponding histogram of the neuroblastoma 
(c) shows ADC median 0.996x10-3 mm2/s, kurtosis 2.25150, skewness 0.0216472 and 
entropy 7.466. 
Figure 4. a-c.  
A 3 year old boy with a right sided wilms tumour. Axial T2-weighted image (a) 
shows a large, lobulated, heterogeneous tumour arising from the right kidney. The 
mass is prediminantly solid, but contains minor haemorrhage and small cystic lesions. 
Solid components restrict diffusion. ADC map was obtained and a whole-tumour ROI 
selected (b). The corresponding histogram of the wilms tumour (c) shows ADC 
median 0.738x10-3 mm2/s, kurtosis 2.17527, skewness 0.0238226 and entropy 
6.82697.  
Figure 5. a-c.  
A 6 year old boy with a left-sided ganglioneuroma. Axial T2-weighted image (a) 
shows a well-defined round mass in the left side of the abdomen. The mass enhances 
heterogeneously and does not restrict diffusion.  ADC map was obtained and a whole-
tumour ROI selected (b). The corresponding histogram of the ganglioneuroma (c) 
shows ADC median 1.576x10-3 mm2/s, kurtosis 2.02974, skewness -0.0195563 and 
entropy 6.50132. 
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Background: Assessment of the response of paediatric solid tumours to 
chemotherapy is predominantly based on size reduction, which may be unreliable in 
the presence of necrosis. As apparent diffusion coefficient (ADC) reflects tissue 
cellularity, measuring changes in ADC obtained by diffusion-weighted MRI could 
potentially reflect early oncological response to treatment.  
Aim: The aim of this study was to determine whether measuring changes in ADC 
values and distribution could be used to assess chemotherapeutic response in 
childhood solid tumours. 
Methods: Thirteen children were included in this prospective observational study. A 
mixed group of tumours including wilms, neuroblastoma, hepatoblastoma and 
rhabdomyosarcoma were evaluated.  All children were imaged using multi-b value 
diffusion-weighted MRI at diagnosis and after chemotherapy. Analysis was 
performed by drawing regions-of-interest around the whole tumour from which ADC 
histograms were constructed. Pre- and post-chemotherapy median, 25th and 75th 
percentile ADC and entropy were calculated and compared using the Wilcoxon 
signed rank test. 
Results:  Post-chemotherapy ADC values were significantly higher than those 
obtained at diagnosis. Tumours demonstrated a significant increase in 25th centile (p = 
0.005) and median (p = 0.043) ADC and a significant decrease in entropy (p = 0.005). 
Increase in 75th centile ADC did not reach significance (p = 0.255). 
Conclusion: Diffusion-weighted imaging and quantitative ADC analysis is a 
promising non-invasive biomarker of chemotherapeutic response of childhood solid 
tumours. Further work is needed to validate these preliminary results in a larger 
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Background. Magnetic resonance spectroscopy (MRS) aids non-invasive diagnosis 
of paediatric brain tumours, but use in clinical practice is not well documented. We 
aimed to review clinical use of MRS, establish added value in non-invasive diagnosis 
and investigate potential impact on patient care. 
Methods. 69 children with lesions imaged using MRS and reviewed by the Tumour 
Board (TB) from January 2014-2016 met inclusion criteria. Contemporaneous MRI 
diagnosis, spectroscopy analysis, histopathology and clinical information were 
reviewed. Final diagnosis was agreed by the TB at study end. 
Results. Five cases were excluded for lack of documented MRI diagnosis. The 
principal MRI diagnosis by general pediatric radiologists was correct in 59%, 
increasing to 73% with addition of MRS. Of the 73%, 19.1% (95%CI (9.1%, 33.3%)) 
were incorrectly diagnosed with MRI alone. MRS led to a significant improvement 
correct diagnosis over all tumor types (p=0.012). Of MRI correct diagnoses, 
confidence increased in 37% by adding MRS with none incorrectly re-diagnosed. 
Indolent lesions were diagnosed non-invasively in 85% with MRS a major contributor 
to 91% of these. Of all patients, 39% were managed without histopathological 
diagnosis.  MRS contributed to diagnosis in 68% of this group, modifying it in 12%. 
MRS influenced management in 33% of cases, mainly through avoiding and guiding 
biopsy and aiding tumor characterisation. 
Conclusion. MRS can improve accuracy and confidence in non-invasive diagnosis of 
pediatric brain lesions in clinical practice. There is potential to improve outcomes 
through avoiding biopsy of indolent lesions, aiding tumor characterisation and 
facilitating earlier family discussions and treatment planning. 
 
 
 
